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Tripartite motif (TRIM) proteins are numerous in the human proteome, and a 
number of these molecules are known to restrict retroviral replication. 
   
TRIM5α (T5α) is one such factor.  It targets the viral capsid and imposes a block to 
infection between entry and reverse transcription.  Capsid recognition is mediated 
by the C-terminal B30.2 domain, which contains surface-exposed loops of high 
amino acid variability.  Restriction is then effected via proteasome recruitment and 
the induction of innate immune cascades.  Although T5α is well-characterised in 
this respect, other factors – such as the highly divergent TRIM1 (T1) – remain 
poorly understood.   
 
To further characterise the T1 restriction phenotype, chimeras of this protein and its 
non-restricting paralogue, T18, were generated by overlapping PCR.  The 
restriction activities of the resulting molecules were then measured using an 
established flow cytometry assay.  These experiments revealed that T1 also binds 
capsid via the B30.2 domain, although the majority of this region can be 
functionally replaced.  Other aspects of T1 biology addressed in this work include 
the contribution of N-terminal components to restriction potency, and the 
relationship between protein expression level and restriction activity. 
 
Following a number of attempts to generate a functional chimera of T1 and 5α, the 
latter half of this thesis explores how the spacing between capsid-binding and 
effector domains can influence restriction activity.  To this end, a panel of mutations 
were made in the linker 2 (L2) region of T5α, and their effects on restriction 
measured.  These experiments revealed that even small changes in interdomain 
spacing can have profound phenotypic consequences. 
 
Collectively, this work reinforces the notion that TRIM family members share a 
common overall design, allowing individual components to be shuffled between 
them.  At the same time, each molecule has been shaped by unique evolutionary 
pressures, which can render them sensitive even to relatively minor modifications. 
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1.1 Retroviruses 
1.1.1 Classification of retroviruses 
The retroviruses (Retroviridae) are a large family of enveloped, positive-sense RNA 
viruses.  They are characterised by a lifecycle involving reverse transcription of 
their genome into dsDNA, and the subsequent integration of this molecule into host 
chromatin.  The Retroviridae were classically assigned to one of four groups – A, B, 
C or D – according to their particle morphology as observed by electron microscopy 
(Vogt, 1997).  However, this system has since been displaced by a two-subfamily 
system, in which all retroviruses are divided between the Orthoretrovirinae and 
Spumaretrovirinae (Stoye et al., 2011) (Figure 1.1). The former can be further 
divided into 6 genera – the α, β, γ, δ and ε-retroviruses and the lentiviruses – while 
the latter comprises a single grouping, owing to unique aspects in their morphology 
and replication (Lochelt and Flugel, 1996; Yu et al., 1996b).   
 
 
Figure 1.1: Phylogeny of the Retroviridae  
The tree was derived by alignment of reverse transcriptase coding sequences. 
Simple retroviral genomes encode only the basic structural and catalytic proteins, 
while complex genomes contain additional, overlapping ORFs that encode various 
regulatory and accessory proteins (see Section 1.1.3). Genera from the 
Orthoretrovirinae are written in black font, and those from the Spumaretrovirinae in 
blue. Viruses of relevance to this work are highlighted in red. Adapted from Weiss 
(2006). 
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1.1.2 Retroviral particles 
Mature retroviral particles typically span 80–120 nm in diameter.  They are diploid, 
possessing two copies of genomic RNA (gRNA) that dimerise via a ‘kissing loop’ 
structure and are packaged with nucleocapsid (NC) proteins (Skripkin et al., 1994; 
Clever et al., 1996).  This complex, along with multiple viral enzymes, is contained 
within a hexameric lattice of capsid (CA) monomers to form the viral core.  Different 
retroviruses exhibit distinct core morphologies: for example, while N-MLV and most 
other orthoretroviruses possess spherical cores, in the lentiviruses this structure is 
conical, and in epsilonretroviruses, cylindrical (Figure 1.2). 
 
In a mature virion, the viral core is encased in matrix (MA) proteins, and the entire 
structure surrounded by a lipid envelope.  The envelope is studded with Env 
glycoproteins, which comprise a surface subunit (SU) that binds to the target cell, 
and a transmembrane subunit (TM) that mediates fusion between the viral and 
cellular membranes.   
 
 
 
 
Figure 1.2: Cross-sections of a mature retrovirus with (A) spherical and (B) 
conical core morphology 
gRNA is depicted in red; NC, blue; PR, pink; RT, red; IN, yellow; CA, green; MA, 
purple and Env, grey. 
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1.1.3 Retroviral genome organisation 
The retroviral genome is a single-stranded, non-segmented, positive-sense RNA 
molecule, ranging from 7–12 kb in length.  It exists within the virion as a homodimer, 
which is maintained through hydrogen bonding between 5’ loop structures called 
dimer linkage sequences (Jones et al., 1993).      
 
Like a eukaryotic transcript, the viral genomic RNA (gRNA) possesses a 5’ 
methylguanosine cap and a 3’ polyadenylated tail in order to support translation.  
Each end of the RNA has a repeat sequence (R) and a sequence unique to that 
terminus (U5 or U3).  These sequences are duplicated during reverse transcription, 
resulting in a double-stranded cDNA that is flanked by long terminal repeats (LTRs) 
with U3-R-U5 architecture (Figure 1.3).  After integration, the 5’ LTR directs 
transcription of the proviral DNA. 
 
Immediately downstream of the U5 region in gRNA is a primer-binding site (pbs).  
This binds the tRNA responsible for priming minus-strand DNA synthesis during 
reverse transcription.  Following the pbs, all retroviruses possess the gag, pol and 
env genes, in that order.  Gag encodes the structural proteins of the virus; pol, the 
replicative enzymes, and env, the glycoproteins that stud the outer surface of the 
virion.  Towards the 3’ end of this molecule is a polypurine tract (PPT), which 
primes plus-strand DNA synthesis.  Some retroviruses, including HIV-1, possess 
an additional PPT in the centre of the genome (cPPT) to permit dual initiation of 
plus-strand synthesis.  All retroviral gRNAs also contain a packaging signal (ψ) to 
promote their specific encapsidation during virion assembly. 
 
Complex retroviruses – such as HIV-1 – have a more elaborate genomic structure, 
containing additional genes encoded in overlapping reading frames (Figure 1.4).  
The proteins that they encode perform diverse functions, including transcriptional 
trans-activation and immune evasion (Emerman and Malim, 1998).   
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Figure 1.3: Retroviral nucleic acid metabolism 
Ψ indicates the location of the packaging signal. 
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Figure 1.4: A comparison of the proviral genomes of (A) simple and (B) complex 
retroviruses 
RRE: Rev-response element (described in Section 1.2.5). 
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1.1.4 Retroviral proteins 
Orthoretroviruses encode all of their structural and catalytic proteins within three 
open reading frames: gag, pol and env.  Each of these is translated as a 
polyprotein (Gag, Gag-Pol or Env), which is cleaved into its constituent parts during 
virion maturation (see Section 1.2.8).  Spumaviruses also encode Gag, Pol and 
Env, although their post-translational cleavage is comparatively limited.  This 
section will focus broadly on the structure and function of the orthoretroviral 
molecules; their spumaviral counterparts will be discussed in Section 1.1.6.  
Gag 
The group-specific antigen (Gag) polyprotein contains most of the structural 
proteins of the virus.  From the N-terminus, these are matrix (MA), capsid (CA) and 
nucleocapsid (NC).  Each of these components is integral to viral function; however, 
Gag itself plays a number of roles in the viral lifecycle prior to cleavage, including 
the recruitment of gRNA, trafficking of viral components to the plasma membrane, 
and the assembly and budding of nascent virions.  A detailed review of the role of 
Gag in these processes can be found in Freed (2015); the remainder of this section 
will deal with each of its cleavage products in turn.   
 
MA targets Gag to the plasma membrane during the assembly of both HIV and 
MLV virions (Ono et al., 2000; Li et al., 2013a).  To facilitate this process, the MA 
proteins of many retroviruses are myristoylated at their N-termini to permit 
hydrophobic interactions with the lipid bilayer (Rein et al., 1986; Bryant and Ratner, 
1990; Liu et al., 2011b).  It has been postulated that a patch of surface-exposed 
basic residues in the MA N-terminus might also contribute to this process, via 
electrostatic interactions with the acidic phospholipid head groups (Murray et al., 
2005).   
 
Although there is little sequence identity in the MA proteins of different retroviruses, 
there is strong conservation in their structural arrangement.  This consists of four 
α-helices that come together to form a globular core, which is then capped by a 
three-stranded β-sheet.  In the immature Gag polyprotein, a fifth helix links MA to 
the adjacent CA domain (Massiah et al., 1994; Conte and Matthews, 1998).  
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Crystal structures are available for MA from both HIV-1 and Moloney MLV 
(Momany et al., 1996; Riffel et al., 2002). 
 
CA forms a hexameric lattice that both protects the viral genome and interacts with 
numerous cellular co-factors necessary for replication.  For example, HIV-1 CA 
interacts with a host of factors involved in the nuclear import and trafficking of the 
viral pre-integration complex (PIC) (Price et al., 2012b; Chen et al., 2016).  The 
structure and function of CA are particularly pertinent to this project and will 
therefore be treated separately in Section 1.1.5. 
 
NC is a highly basic protein that co-ordinates Zn2+ ions and engages in various 
critical protein-nucleic acid interactions.  HIV-1 NC contains two zinc fingers with 
the canonical sequence CX4CX4HX4C, separated by a short, basic linker (Darlix et 
al., 1995), while that of MLV contains only a single zinc finger.  NC is required for a 
number of stages in the retroviral lifecycle, including genome dimerisation (Darlix et 
al., 1990); packaging of viral gRNA (Berkowitz et al., 1995); reverse transcription 
(Tsuchihashi and Brown, 1994; Cristofari and Darlix, 2002) and the integration of 
proviral DNA (Carteau et al., 1999).  All of these functions hinge on the ability of NC 
to function as a nucleic acid chaperone, facilitating structural rearrangements within 
these molecules to maintain them in thermodynamically stable conformations (Rein 
et al., 1998; Levin et al., 2005).    
 
Some retroviruses encode additional proteins within the gag reading frame.  For 
example, HIV-1 encodes an unstructured peptide called p6 at the extreme 
C-terminus of Gag, as well as spacer peptides 1 and 2 (SP1/2) at the junctions 
between CA and NC, and NC and p6, respectively.  SP1 and 2 contain cleavage 
sites that are important for proper maturation of the retroviral core (Accola et al., 
1998; de Marco et al., 2012), while p6 recruits ESCRT proteins during budding 
(Pornillos et al., 2002; Sette et al., 2010) and interacts with the viral accessory 
protein, Vpr (Salgado et al., 2009).  Meanwhile, MLV encodes p12 between MA 
and CA, which contributes to functions such as core stability and chromatin 
tethering (Wight et al., 2012). 
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Pol 
The polymerase (Pol) polyprotein encodes the viral enzymes necessary for 
replication.  From the N-terminus, these are protease (PR), reverse transcriptase 
(RT) and integrase (IN).  In orthoretroviruses, Pol is invariably translated as part of 
a Gag-Pol polyprotein (160 kDa).  Stepwise proteolytic cleavage then liberates 
each of the subunits during maturation of the virion (Section 1.2.8).   
 
PR is an aspartyl protease that functions as a homodimer.  It first auto-catalytically 
cleaves itself from the Pol polyprotein, and then mediates a series of 
carefully-timed, high-fidelity proteolytic events necessary for the maturation of 
nascent virions (Wiegers et al., 1998; Goodenow et al., 2002).  Each PR monomer 
consists of a β-hairpin followed by a wide loop, an α-helix and a second β-hairpin, 
all of which are present in duplicate; the active site of the enzyme lies in a cleft at 
the interface between monomers (Wlodawer and Erickson, 1993).  PR structures 
are available for HIV-1, HIV-2, feline immunodeficiency virus (FIV) and simian 
immunodeficiency virus (SIV), among others (Wlodawer et al., 1989; Mulichak et al., 
1993; Rose et al., 1993; Wlodawer et al., 1995).  Furthermore, crystal structures 
snapshotting the mechanism of proteolysis by HIV-1 PR have been captured to 
about 1.3 Å resolution (Shen et al., 2012).   
 
RT is the enzyme responsible for reverse-transcribing viral gRNA into an 
integration-competent cDNA.  It harbours multiple functions to this end, including 
RNA- and DNA-dependent DNA polymerase activities, and an RNaseH activity for 
degradation of the template.  HIV-1 RT forms an asymmetric heterodimer, with one 
subunit that comprises both polymerase and RNaseH domains (p66), and another 
that lacks the RNaseH component (p51).  Interestingly, despite identical amino acid 
sequences, the polymerase domains of each subunit exhibit distinct tertiary 
structures.  High-resolution crystal structures are available for the heterodimeric RT 
of HIV-1 and -2, and the monomeric RT of Moloney MLV (Jacobo-Molina et al., 
1993; Das et al., 2008; Ren et al., 2002). 
 
IN catalyses the steps necessary for the insertion of viral cDNA into host chromatin.  
It comprises three structural domains for this purpose: an N-terminal zinc-binding 
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domain, a catalytic core domain, and a C-terminal DNA-binding domain (Johnson 
et al., 1986; Engelman and Craigie, 1992).  Following reverse transcription, IN 
forms a complex with the viral cDNA known as an intasome.  Within this structure, 
the DNA undergoes a series of reactions in order to become integration-competent 
(Section 1.2.4).   
 
The structure of the PFV intasome was solved some time ago, revealing a 
homotetramer (a dimer of dimers) that tightly associates with two ends of the viral 
DNA (Hare et al., 2010; Maertens et al., 2010).  Until earlier this year, it was 
believed that orthoretroviral IN also functions as a tetramer; however, recent 
characterisation of the intasome from mouse mammary tumour virus (MMTV), a 
β-retrovirus, has instead revealed an octameric architecture (Ballandras-Colas et 
al., 2016).  This structure comprises a central tetramer with two flanking dimers, 
which associate with the core via their C-terminal domains (CTDs).  These dimers 
are functionally important because they supply the target-DNA-binding activity of 
the intasome.  This function cannot be provided in cis by the central tetramer due to 
a structurally restrictive linker region between the catalytic core and CTD of MMTV 
IN (compared to its longer, more flexible counterpart in PFV). The recent 
characterisation of the intasome of rous sarcoma virus (RSV), an α-retrovirus, 
revealed that this structure is also octameric, with one pair of integrase dimers 
engaging either end of the viral DNA for catalysis, while the other pair capture the 
target DNA ready for strand transfer. (Yin et al., 2016) 
 
Env 
Env encodes the envelope glycoproteins that stud the surface of the virion.  These 
are required both for adsorption to cell surface receptors, and for the subsequent 
fusion of viral and host membranes.   
 
The Env precursor of HIV-1 (gp160) is a heterodimer of surface (SU; gp120) and 
transmembrane (TM; gp41) subunits.  This polyprotein is translated directly into the 
endoplasmic reticulum (ER), where it undergoes co-translational glycosylation of 
several key residues, before assembling into trimers in the ER lumen.  The 
homotrimer then migrates to the Golgi apparatus, where each monomer is cleaved 
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into its constituent parts by subtilisin-like endoproteases (Hallenberger et al., 
1997a).  Crystal structures are available for HIV-1 Env in its native, trimeric form 
(Julien et al., 2013; Do Kwon et al., 2015). 
 
HIV-1 regulatory and accessory proteins 
Complex retroviruses such as HIV-1 possess a number of ORFs in addition to gag, 
pol and env (see Table 1.1).  These ORFs encode regulatory proteins, which are 
essential for replication, and accessory proteins, which are broadly dispensable in 
vitro, but may be required in vivo. 
 
  
 
 
Gene 
 
Protein Function(s) 
Regulatory 
tat Tat 
 
 Transcriptional trans-activation1 
 
rev Rev 
 
 Nuclear export of viral mRNA2 
 Temporal regulation of transcription3 
 
Accessory 
nef Nef 
 
 Downregulation of CD4 receptors4 
 Inhibition of T-cell activation5 
 Counteraction of SERINC3/5 (Section 1.3.2) 
 
vpr Vpr 
 
 Nuclear localisation of the PIC6 
 Cell cycle modulation7 
 Counteraction of SAMHD1 (Section 1.3.4) 
 
vif Vif 
 
 Counteraction of A3G (Section 1.3.3) 
 
vpu Vpu 
 
 Downregulation of CD4 receptors8 
 Counteraction of tetherin (Section 1.3.8) 
 
Table 1.1 Functions of the regulatory and accessory proteins encoded by HIV-1 
References: (1) Ruben et al., (1989); (2) Zapp and Green (1989); (3) Kim et al. 
(1989); (4) Garcia and Miller (1991); (5) Luria et al. (1991); (6) Heinzinger et al., 
1994); (7) Jowett et al. (1995); (8) Chen et al. (1993). 
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1.1.5 Structure of the retroviral capsid 
The retroviral capsid monomer (CA) is one of three structural proteins encoded 
within the gag reading frame.  The structure of this protein is particularly pertinent 
to this thesis as it is the target of numerous retroviral restriction factors. 
 
CA lies between MA and NC in the immature Gag polyprotein.  During maturation, 
it is proteolytically liberated from this precursor and condenses into a core structure 
that is conical in HIV-1 and spherical in MLV (Ganser-Pornillos et al., 2004).  
Although retroviruses differ tremendously in the primary sequence of CA, the 
secondary and tertiary structures of this protein are remarkably well-conserved (de 
Marco et al., 2010a). 
 
The HIV-1 CA monomer is split between a 150-residue N-terminal domain (NTD) 
and an 80-residue C-terminal domain (CTD) (Figure 1.5).  The former consists of a 
β-hairpin followed by seven α-helices, with a proline-rich loop between helices 4 
and 5 that binds the peptidyl prolyl isomerase, cyclophilin A (CypA) (Gamble et al., 
1996; Gitti et al., 1996; Du et al., 2011).  Meanwhile, the latter comprises 4 α-
helices, an unstructured region, and a core of highly conserved hydrophobic 
residues known as the major homology region (MHR), which coordinates 
conformational changes in CA during maturation (Gamble et al., 1997).  
Unsurprisingly, mutational inactivation of the MHR can have profound effects on 
virion morphology and infectivity (Purdy et al., 2008).  The NTD and CTD are joined 
in the middle by a flexible linker, which is required for their correct orientation in 
higher-order capsid structures (Arvidson et al., 2003).  
 
MLV CA is, in many ways, structurally reminiscent of its lentiviral counterpart.  The 
NTD comprises a β-hairpin followed by six α-helices, the first three of which 
superimpose almost perfectly on the HIV structure (Mortuza et al., 2004); however, 
unlike HIV, MLV CA does not bind CypA.  A crystal structure for the CTD of this 
protein is presently unavailable. 
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Figure 1.5: HIV-1 CA monomer 
The monomeric structure of HIV-1 CA. The N-terminal β-hairpin is indicated in 
green, and α helices in blue. PDB accession code: 2M8N (Deshmukh et al., 2013) 
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The mature retroviral core is a lattice of CA hexamers, punctuated by occasional 
pentamers that offer curvature at the top and bottom of the structure.  The mature 
core of HIV-1 consists of approximately 1500 CA monomers arranged in a 
hexameric lattice, with 12 pentamers that close the lattice into a fullerene cone: five 
at the apex and seven at the base (Briggs et al., 2004; Zhao et al., 2013).  Recent 
work has highlighted the importance of water molecules in the capsid structure, 
both for stabilising inter-hexamer interactions and permitting conformational 
changes that are requisite at different stages of the lifecycle (Gres et al., 2015). 
 
In the assembled lattice, each CA monomer is oriented such that the NTD is 
located on the outer surface and the CTD buried underneath.  Thus, the majority of 
residues in CA that govern restriction factor sensitivity map to the NTD.  Multiple 
interactions between CA monomers are responsible for preserving the integrity of 
this structure, including sixfold NTD-NTD interfaces within a hexamer (Ganser-
Pornillos et al., 2007); two- and threefold CTD-CTD interfaces between hexamers 
(Ivanov et al., 2007; Byeon et al., 2009); and individual NTD-CTD interfaces within 
hexamers (Pornillos et al., 2009; Yufenyuy and Aiken, 2013).  The latter interface 
also forms a binding pocket, which is necessary for interactions with numerous 
cellular cofactors, and is the target for various antiretroviral compounds 
(Bhattacharya et al., 2014; Price et al., 2014). 
 
Recent data has revealed that HIV-1 CA is the most genetically fragile of any 
protein for which this property has been quantified (Rihn et al., 2013).  In other 
words, it is highly intolerant of non-synonymous substitutions, with approximately 
70% of amino acid changes yielding non-viable mutants.  This low mutational 
robustness reflects the need for CA to form a diverse range of contacts in the 
mature core.  For example, an identical monomer must engage in different sets of 
interactions depending on whether it contributes to a hexamer or a pentamer.  In 
addition to these spatial restrictions, CA must also form contacts that are 
temporally conducive to the processes of uncoating and maturation, while 
interacting with a host of cellular co-factors that are critical for replication, including 
CPSF6, CypA, and components of the nuclear pore complex (Luban et al., 1993; 
Price et al., 2012a; De Iaco et al., 2013).  The MLV capsid is also relatively 
intolerant of mutation (Auerbach et al., 2006; Auerbach et al., 2007).   
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In summary, CA is subject to strong purifying selection in order to preserve both 
structure and function.  This renders it susceptible to immune recognition because 
it lacks the scope for diversification, perhaps explaining why nature has selected 
the capsid as an opportune antiretroviral target. 
 
1.1.6 The Spumaretrovirinae 
The Spumaretrovirinae (also known as foamy viruses; FVs herein) are a genus of 
retrovirus that were first described in the 1950s and isolated about twenty years 
later (Enders, 1954; Achong et al., 1971).  While these viruses induce cytopathic 
effects in vitro, there is currently no evidence of pathogenicity in humans or other 
animals (Linial, 2000). 
 
FVs are widespread among mammalian hosts, with isolates available from 
baboons, chimpanzees, gorillas, cats and cows, among others (Linial, 1999); 
(Meiering and Linial, 2001).  The first to be discovered – prototypic foamy virus 
(PFV) – was isolated from a human nasopharyngeal cell line in the seventies 
(Achong et al., 1971) and was the first member of the genus to be cloned and 
sequenced (Flügel et al., 1987; Maurer et al., 1988).  Eventual sequencing of other 
FV genomes revealed that these viruses are genetically distinct from all other 
retroviral genera – their closest known relatives being endogenous retroviruses of 
human and murine origin (Cordonnier et al., 1995).  In fact, given certain aspects of 
their lifecycle and the fact that infectious particles carry DNA rather than RNA, FVs 
are often regarded as ‘bridging the gap’ between retroviruses and the 
Hepadnaviridae, the only other family of reverse-transcribing viruses. 
 
Like all retroviruses, FV genomes possess the gag, pol and env ORFs.  These 
genes encode proteins with the same basic functions as those already described.  
However, there are marked differences that distinguish the FV molecules from their 
counterparts in other retroviral genera. 
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Gag 
 
In contrast to the orthoretroviral protein, FV Gag does not comprise individual MA, 
CA and NC subunits that are liberated during maturation.  Instead, it undergoes a 
single, PR-dependent cleavage at the C-terminus to yield full-length (p71) and 
truncated (p68) species that appear in the viral capsid at a ratio between 1:1 and 
1:4 (Enssle et al., 1997; Cartellieri et al., 2005).  The presence of both molecules is 
critical for optimal infectivity, though not for particle release (Enssle et al., 1997).  
FV Gag is also distinctive in its low abundance of lysine residues, with the majority 
of the protein’s basic content coming from arginines.  Interestingly, however, R-K 
substitutions do not appear to have a deleterious effect on FV replication in culture 
(Matthes et al., 2011).   
 
In place of the MA-CA-NC subdomain structure of orthoretroviral Gag, the FV 
protein possesses four coiled-coil (CC) domains that perform analogous functions 
(Matthes et al., 2011) (Figure 1.6).  At the N-terminus, CC1 appears to be involved 
in interactions between Gag and Env that are required for particle release, while 
CC2 mediates the homotypic Gag-Gag interactions that are necessary for capsid 
assembly (Tobaly-Tapiero et al., 2001).  Definitive functions have not been 
assigned to CC3 and 4, although there are indications that the former mediates an 
interaction between FV Gag and the light chain of dynein motor protein complexes, 
which is necessary for the trafficking of incoming virions to the 
microtubule-organising centre (MTOC) (Petit et al., 2003).  Like its orthoretroviral 
counterpart, FV Gag also harbours an L-domain for the recruitment of ESCRT 
proteins during egress. 
 
FV Gag is distinct from that of orthoretroviruses in that it lacks zinc finger motifs for 
genome packaging.  These are instead replaced with glycine-arginine-rich domains 
known as GR boxes, which reside at the C-terminus of Gag and bind DNA and 
RNA with equal affinity (Schliephake and Rethwilm, 1994; Yu et al., 1996c).  The 
primate variants possess three GR boxes, which contribute to genome binding, 
reverse transcription and chromatin tethering (Tobaly-Tapiero et al., 2008; Müllers 
et al., 2011).  A putative nuclear export signal (NES) has also been identified at the 
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N-terminus of FV Gag, indicating a role in the nuclear export of unspliced and 
singly spliced viral transcripts (Renault et al., 2011). 
 
 
 
Figure 1.6: A typical FV Gag molecule 
The Gag polyprotein of PFV compared to the MA-CA-NC subdomain architecture 
of orthoretroviral Gag. CC: coiled coil; L: late domain; GR: glycine-arginine box. 
Adapted from Müllers (2013).  
 
 
A crystal structure of the N-terminal domain of PFV Gag (PFV-Gag-NTD) is 
available at 2.4 Å resolution (Goldstone et al., 2013).  This revealed distinct 
structural divergence when compared to the orthoretroviral MA domain, despite 
conservation of function.  While the MAs of other retroviruses possess a highly 
basic region – and often a myristate moiety – at their N-termini, neither of these 
components are present in PFV-Gag-NTD.  Additionally, the tertiary structure of the 
latter comprises a mixed αβ topology with head and stalk domains.  This stands in 
stark contrast to the predominantly α-helical, globular structure of orthoretroviral 
MA (Conte and Matthews, 1998).  Despite these differences, however, the 
capsid-binding restriction factor, T5α (see Section 1.4.5) appears to bind both 
PFV-Gag-NTD and the NTD of orthoretroviral CA (Yap et al., 2008; Goldstone et 
al., 2013). 
 
Pol 
 
In the orthoretroviruses, either frameshift or readthrough of the gag stop codon 
enables the neighbouring pol ORF to be translated as part of a Gag-Pol 
polyprotein; it is then liberated by PR during virion maturation.  In FVs, however, no 
such fusion is detectable in infected cells, even when the active site of PR is 
mutated (Konvalinka et al., 1995b).   
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Instead, FV Pol is translated from a separate, singly spliced mRNA (Yu et al., 
1996a), and its expression is regulated post-transcriptionally by way of a 
suboptimal splice acceptor site upstream of its start codon (Lee et al., 2008).  While 
orthoretroviruses incorporate Pol into virions via covalent linkage to Gag, in FVs 
this is instead mediated by an interaction between Pol and the viral gRNA 
(Heinkelein et al., 2002).  FV Pol is also peculiar in that undergoes only a single 
internal cleavage during maturation, yielding free IN and a PR-RT fusion (Pfrepper 
et al., 1998).  Both molecules adopt a nuclear localisation (Imrich et al., 2000). 
 
Env 
 
Like the orthoretroviral protein, FV Env is translated from a spliced mRNA directly 
into the endoplasmic reticulum (ER), where it undergoes co-translational 
glycosylation of several key residues.  However, FV Env is distinct from the 
orthoretroviral glycoprotein in that it retains the signal peptide that directs 
translation to the ER.  This results in an Env precursor comprising an N-terminal 
signal peptide (termed the leader peptide, LP, from this point forward) in addition to 
the usual surface (SU) and transmembrane (TM) subunits.  The LP is 
proteolytically liberated by furin or furin-like proteases as the protein translocates 
through the secretory pathway (Duda et al., 2004; Geiselhart et al., 2004). 
 
FVs are largely intolerant of pseudotyping with heterologous Env glycoproteins, 
including those from MLV and VSVg (Lindemann et al., 1997; Pietschmann et al., 
1999).  This is attributable to an interaction between FV Gag and its cognate Env, 
which involves the N-termini of both partners and is essential for virion release 
(Wilk et al., 2001; Lindemann et al., 2001).  A crystal structure is available for PFV 
Gag in complex with the Env leader peptide (Goldstone et al., 2013). 
 
Accessory proteins 
 
Like other complex retroviruses, FVs encode genes in addition to the gag, pol and 
env ORFs.  FVs possess two such genes, both of which lie towards the 3’ end of 
the genome. 
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Tas (formerly bel-1) encodes a 36 kDa transcriptional trans-activator with 
analogous function to the Tat protein of HIV-1.  It harbours a C-terminal 
transcription activation domain and a centrally located DNA-binding domain (Blair 
et al., 1994; He et al., 1996), and binds to DNA sequences that contain conserved 
purine residues, but little other sequence identity (Kang et al., 1998).  PFV Tas is 
indispensable for replication, and may also control the transcription of specific 
cellular genes (Baunach et al., 1993; Wagner et al., 2000). 
 
Bet is an accessory protein found in all known foamy viruses.  It has numerous 
functions, including conferring resistance to superinfection (Bock et al., 1998); 
negative regulation of proviral transcription (Meiering and Linial, 2002); and 
inhibition of restriction by the APOBEC (A3) family of enzymes (Löchelt et al., 
2005).  The latter function is analogous to that of HIV-1 Vif; however, unlike Vif, Bet 
acts by preventing the incorporation of A3 into virions (Lukic et al., 2013; Jaguva 
Vasudevan et al., 2013). 
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1.2 Retroviral replication 
The retroviral lifecycle is complex and has been extensively described in a number 
of reviews (Perez and Nolan, 2001); (Amara and Littman, 2003); (Nisole and Saib, 
2004).  It can broadly be divided into an early phase, where virions enter the cell 
and travel to their site of genomic integration, and a late phase, where viral genes 
are expressed and progeny virions are synthesised, assembled and released.  The 
entirety of this process is detailed in Figure 1.7 (below).  Each stage is individually 
described in the sections that follow. 
 
 
 
 
Figure 1.7: The retroviral lifecycle 
(1) Adsorption; (2) cell entry; (3) uncoating; (4) reverse transcription; (5) nuclear 
trafficking and entry; (6) integration; (7) proviral transcription; (8) splicing and 
nuclear export; (9) translation; (10) assembly; (11) budding; (12) maturation.  
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1.2.1 Adsorption and entry 
The initial encounter between a retrovirus and its target cell is mediated by weak 
interactions between the viral envelope glycoprotein, Env (or cellular proteins that 
have been incorporated into the virion membrane) and cell surface receptors: 
typically heparin for MLV (Walker et al., 2002), and heparin sulphate for HIV-1 
(Saphire et al., 2001; Vivès et al., 2005).  This provisional interaction is not 
essential for infection, although it does improve the efficiency of viral entry by 
bringing virions into close proximity with their primary receptor (Ugolini et al., 1999).  
Once a virion is adsorbed to the cell surface, a stronger interaction between Env 
and the viral receptor can proceed.  This is sometimes supplemented by a 
secondary interaction with a co-receptor.   
 
In the case of MLV, the receptor utilised determines the tropism of the strain.  
MLVs can be classified into ecotropic, xenotropic, polytropic and amphotropic 
subgroups depending on their host range.  Ecotropic MLVs infect only mouse or rat 
cells using the mouse cationic amino acid transporter, mCAT-1 (Albritton et al., 
1989).  The remaining subgroups infect a broader range of mammalian hosts: 
amphotropic MLVs utilise the sodium-dependent phosphate transporter, Pit-2, to 
accomplish this (Kavanaugh et al., 1994), while poly- and xenotropic MLVs use 
different alleles of the Xpr1 cell-surface receptor (Kozak, 2010). 
 
In the case of primate lentiviruses, entry involves engagement with the CD4 
receptor, which is present on T-cells, macrophages, monocytes and dendritic cells 
– all of which are susceptible to infection by these viruses.  Briefly, the gp120 
subunit of Env binds to a membrane-distal region of CD4, thereby inducing a 
number of conformational changes in the former, first in the V1/V2 loops and 
subsequently in V3 (Kwong et al., 1998).  CD4 binding also induces the formation 
of two double-stranded β-sheets (Chen et al., 2005) which, in combination with the 
reconfigured V3 loop, facilitate the engagement of a co-receptor.   
 
Co-receptor binding by the V3 loop of gp120 is broadly considered the catalyst that 
triggers fusion of the viral and cellular membranes, specifically by externalising the 
hydrophobic gp41 fusion peptide of Env.  The only co-receptors known to be 
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important for HIV-1 infection in vivo are the chemokine receptors CXCR4 (for 
X4-tropic viruses) or CCR5 (R5-tropic viruses); viruses that can engage either 
co-receptor are dubbed R5X4 viruses (Berger et al., 1998).  With few exceptions, 
only R5 and R5X4 viruses are able to transmit between individuals (Keele et al., 
2008).  However, progression from R5 to X4 tropism in vivo is typically associated 
with rapid T-cell depletion and the onset of AIDS (Tersmette et al., 1989; Scarlatti 
et al., 1997). 
 
Once receptor and co-receptor are engaged, HIV-1 co-opts underlying cytoskeletal 
components to ‘surf’ across the membrane to a site where membrane fusion can 
occur (Lehmann et al., 2005).  Once a suitable region has been located, the 
exposed gp41 fusion peptide inserts into the host membrane, tethering the virion to 
the cell.  This anchoring induces the three gp41 subunits of each Env trimer to fold 
at a hinge region, bringing their N- and C-termini together to form a six-helix bundle 
(6HB) (Chan et al., 1997).  Because the N-termini are proximal to the cell 
membrane and the C-termini to the viral membrane, the formation of the 6HB 
brings the two partners together to create, and then stabilise, a fusion pore 
(Melikyan, 2008).  This is the portal through which the viral core enters the 
cytoplasm. 
 
1.2.2 Reverse transcription and uncoating 
Following internalisation, the viral core undergoes numerous transformations in 
order to become integration-competent.  These include the conversion of viral RNA 
into dsDNA (reverse transcription), the progressive displacement of capsid proteins 
(uncoating), and the trafficking of this reverse-transcribing structure, known as the 
reverse transcription complex (RTC), towards the nucleus.  The precise order and 
interdependence of these events remains the subject of ongoing research 
(reviewed by (Campbell and Hope, 2015));  however, in the interests of clarity, 
reverse transcription and uncoating will be covered in this section, and nuclear 
trafficking in the subsequent one (Section 1.2.3). 
 
 
 
Chapter 1: Introduction 
 
46 
 
Reverse transcription  
 
Reverse transcription (Figure 1.8) is initiated by the annealing of a partially 
unwound host tRNA to an 18-nt primer binding site (pbs) at the 5’ end of the viral 
genome.  The tRNA species utilised for this purpose differs between retroviral 
genera.  For example, while HIV-1 uses tRNAlys3 (Wain-Hobson et al., 1985), MLV 
uses tRNApro (Peters et al., 1977).   
 
Minus-strand DNA synthesis is then initiated from the 3’ end of the tRNA primer 
and progresses towards the 5’ end of the genomic template, yielding a DNA-RNA 
hybrid.  The RNaseH activity of RT degrades the RNA portion of this structure, 
leaving behind a single-stranded DNA species known as minus-strand strong stop 
DNA.  This molecule possesses a repeat sequence (R) at its 3’ end, which enables 
it to hybridise with the complementary sequence at the 3’ end of the genomic 
template in a process called first-strand transfer.  Following this jump, minus-strand 
DNA synthesis is completed up to the pbs, and RNaseH degrades the majority of 
the remaining template. 
 
A short, purine-rich sequence towards the 3’ end of the viral RNA, known as the 
polypurine tract (PPT), is able to resist degradation by RNaseH and can therefore 
serve as a primer for plus-strand DNA synthesis.  RT proceeds from the 3’ end of 
the PPT towards the 5’ end of the minus-strand DNA, and then 18 nt into the 
unwound tRNA primer (up to and including the pbs) to yield a species called 
plus-strand strong stop DNA.  Further progression along the tRNA template is 
prohibited by a 1-methyladenine (m1A) residue.   
 
Once the 3’ tail of the tRNA has been copied, RT degrades the tRNA primer in its 
entirety, thereby liberating the 5’ end of the minus-strand DNA and enabling the 
plus-strand DNA to detach and reanneal with the opposing pbs.  Following this 
process – known as second-strand transfer – both minus- and plus-strand DNA 
synthesis are completed in full.  The resulting molecule has duplications of the 
U3-R-U5 sequences at either end, known as long terminal repeats, or LTRs.  The 
5’ LTR will ultimately serve as a promoter for transcription of the integrated provirus.   
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Figure 1.8: Reverse transcription 
Viral genomic RNA (gRNA) is depicted in blue and nascent DNA in red.  Dashed 
blue lines represent gRNA that has been degraded by RNase H.  Steps depicted 
include (1) gRNA prior to reverse transcription; (2) synthesis of minus-strand strong 
stop DNA; (3) first-strand transfer; (4) synthesis of plus-strand strong stop DNA; (5) 
second-strand transfer; (6) completion of reverse transcription and the formation of 
LTRs. 
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Uncoating 
 
Uncoating was classically defined as the complete dissociation of CA from the RTC 
shortly after viral entry (Aiken, 2006).  However, the growing appreciation of the 
role that CA plays in later stages of the lifecycle – including reverse transcription 
(Forshey et al., 2002); shielding of viral nucleic acids from cytosolic DNA sensing 
(Gao et al., 2013; Lahaye et al., 2013); translocation across the nuclear membrane 
(Matreyek and Engelman, 2011; Matreyek et al., 2013) and targeting of proviral 
DNA to transcriptionally active sites in the genome (Koh et al., 2013) – has  
warranted a revision of this definition. 
 
Although the exact timing of uncoating remains elusive, the fact that the HIV-1 core 
is about 20 nm too large to pass through a nuclear pore complex (Panté and Kann, 
2002; Ganser-Pornillos et al., 2007), combined with the recent observation that 
some CA remains associated with the viral cDNA after nuclear entry (Peng et al., 
2014; Hulme et al., 2015), indicates that it is likely to occur in two distinct phases: 
an initial loss of core integrity in the cytoplasm, followed by a complete dissociation 
of CA in the nucleus. 
 
The precise mechanism through which this process occurs remains the subject of 
considerable ongoing research.  Nevertheless, numerous hypotheses have been 
put forward in an attempt to reconcile the existing data, including mechanical stress 
imparted by the nascent viral cDNA during reverse transcription (Forshey et al., 
2002), and a tug-of-war-like strain generated by the opposing microtubule motor 
proteins, dynein and kinesin-1 (Lukic et al., 2014; Pawlica and Berthoux, 2014).  
Uncoating within the nucleus is thought to be an active process mediated by 
transportin-3 (TNPO3) (Zhou et al., 2011).  These models are supported by varying 
degrees of evidence and need not be mutually exclusive. 
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1.2.3 Nuclear trafficking and import 
In parallel to reverse transcription and uncoating, the viral RTC must be trafficked 
towards the nucleus.  To accomplish this, the virus exploits actin microfilaments for 
short-range movement near the cell periphery, and then microtubules (MTs) for the 
longer journey from the periphery to the nuclear membrane (Campbell and Hope, 
2005); (Naghavi and Goff, 2007).  Retroviruses specifically utilise stable MTs over 
their dynamic counterparts.  These are typified by post-translational modifications 
such as detyrosination and acetylation, and are recognised by motor proteins as 
specialised tracks for long-range vesicle trafficking.  This specific co-option of 
stable MTs explains the previously conflicting observation that HIV-1 is resistant to 
the pharmacological disruption of MT polymerisation (Sabo et al., 2013). 
 
Upon completion of reverse transcription and partial uncoating, the resulting 
structure is known as the pre-integration complex (PIC).  PICs are defined by their 
capacity for in vitro integration, and have offered a valuable system for the detailed 
characterisation of this process (Hansen et al., 1999).  The HIV-1 PIC is trafficked 
to the nucleus by virtue of a number of viral karyophilic elements, including MA, IN 
and Vpr (Rivière et al., 2010).  These components are central to the ability of HIV-1 
and other lentiviruses to enter the nuclei of non-dividing cells.  Other retroviruses, 
including MLV, depend on mitotic breakdown of the nuclear membrane for this 
process (Roe et al., 1993). 
 
In order to enter the nucleus of a resting cell, the lentiviral PIC must harness 
components of the nuclear pore complex (NPC) (Fassati et al., 2003; Zaitseva et 
al., 2009; Yeung et al., 2009).  In particular, Nup98, Nup153, Nup358 and TNPO3 
are required for both nuclear import and proper trafficking within the nucleus: 
depletion of these factors shifts the distribution of integration sites from gene-dense 
to gene-poor regions (Schaller et al., 2011; Ocwieja et al., 2011; Di Nunzio et al., 
2013).   On the viral side of this interaction, CA is the major determinant for nuclear 
import and trafficking events within the nucleus.  This is evidenced by the 
observation that the N57A and N74D mutations in HIV-1 CA cause a change in 
integration site preference from transcriptionally-active to -inactive regions, 
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phenocopying the knockdown of NPC components (Schaller et al., 2011; Ocwieja 
et al., 2011; Koh et al., 2013).   
 
Nuclear import of the lentiviral PIC is a complex process involving a large 
complement of host proteins.  During the early stages of infection, the viral core 
binds CPSF6 (Lee et al., 2012); this mediates interaction with the nuclear pore 
component, Nup358 (Bichel et al., 2013).  Upon engagement of Nup358, the 
kinesin-1 motor protein KIF5B traffics the Nup358-bound core away from the 
nuclear pore (Dharan et al., 2016).  Precisely how this facilitates nuclear import is 
currently unknown.  Putative mechanisms include the reduction of PIC size by 
Nup358-mediated uncoating, as well as increased permeability of the nuclear 
membrane following the cytoplasmic relocalisation of this protein.  Once the PIC is 
competent to access the nucleus, it is recognised as cargo by TNPO3, a member 
of the karyopherin-β family of nuclear transporters, and shuttled across the nuclear 
membrane (Chook and Süel, 2011).  
 
On the nucleoplasmic side of the NPC, the PIC is recognised by another NPC 
component, Nup153 (Matreyek et al., 2013).  Recent data from the Fassati lab 
suggests that this interaction maintains the integrity of the PIC (Chen et al., 2016), 
while CPSF6 targets it towards transcriptionally active regions of chromatin (Chin et 
al., 2015; Sowd et al., 2016).  Once the PIC arrives at its genomic destination, 
TNPO3 triggers the displacement of any remaining CA (and any bound factors, 
including CPSF6), freeing the viral cDNA to interact with the necessary chromatin-
tethering factors so that integration can ensue. 
 
1.2.4 Integration 
A defining step in the retroviral lifecycle is the integration of viral cDNA into the 
genome of an infected cell.  However, nuclear entry does not guarantee successful 
integration.  Viral DNA can undergo a number of circularisation reactions within the 
nucleoplasm that yield non-productive species and represent dead-ends for the 
virus (Farnet and Haseltine, 1991).  These include 2-LTR circles, which occur when 
the cellular machinery ligates the viral DNA end-to-end (Li et al., 2001); 1-LTR 
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circles, resulting from homologous recombination between LTRs (Kilzer et al., 
2003), and various autointegration products (Shoemaker et al., 1980). 
 
However, the population of PICs that do remain integration-competent must be 
targeted and tethered to host chromatin.  While the HIV-1 PIC associates with 
chromatin via the cellular co-factor LEDGF/p75 (Hombrouck et al., 2007), MLV 
relies on members of the chromatin-bound Bromodomain and Extra-Terminal 
(BET) family of proteins for this process (Gupta et al., 2013; Sharma et al., 2013; 
De Rijck et al., 2013).  Mutagenesis and fluorescence microscopy have revealed 
that the virally-encoded p12 also contributes to the chromatin tethering of MLV 
PICs (Elis et al., 2012; Wight et al., 2012).  These separate chromatin-targeting 
pathways result in distinct integration site preferences: while HIV-1 tends to 
integrate within the bodies of actively transcribed genes (Schroder et al., 2002), 
MLV integration is biased towards transcriptional start sites (Sharma et al., 2013).    
 
Integration is catalysed by the virally-encoded integrase (IN) enzyme.  IN functions 
as either an octamer (in α- and β-retroviruses) or a tetramer (in spumaviruses) and 
forms a complex with linear viral dsDNA known as the intasome.  While chromatin-
tethering factors are required to direct the intasome to the appropriate genomic 
location, the exact site of integration is governed by an interaction between 
residues in the CTD of IN and specific bases in the target DNA (Maertens et al., 
2010; Serrao et al., 2014).  
 
IN catalyses two sequential reactions that are necessary for integration (Figure 1.9).  
First, it processes the 3’ end of each strand of the viral DNA to reveal a conserved 
CA dinucleotide; this probably occurs within the cytoplasm (Fassati and Goff, 1999).  
Once the PIC has reached the site of integration, the second step – known as 
strand transfer – can proceed.  In this step, the newly exposed hydroxyl groups on 
the viral DNA are used in the nucleophilic attack of a pair of phosphodiester bonds 
on the target DNA, and the 3’ end of the viral DNA is simultaneously ligated to the 
5’ end of the host DNA (Vink et al., 1991).  This results in a dinucleotide overhang 
and a single-stranded region of either 4 (MLV) or 5 (HIV-1) nucleotides on either 
side of the attack site, both of which are subsequently repaired by cellular enzymes.  
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Once integration is complete, the viral DNA is referred to as a provirus and the 
early phase of the lifecycle is complete.   
 
 
 
 
 
Figure 1.9: Processing and integration of viral cDNA 
Adapted from Van Maele et al. (2006). 
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1.2.5 Transcription, splicing and nuclear export 
Transcription of the provirus is typically initiated from a promoter sequence at the 
U3-R boundary of the 5’ LTR.  This element is usually sufficient to drive constitutive 
expression of the viral genome, although this is somewhat dependent on factors 
such as cell type and the exact site of integration (Feinstein et al., 1982). Rabson 
(1997) provides a detailed description of retroviral RNA synthesis; this section will 
offer only a brief overview of this process. 
 
Transcription 
 
Shortly following integration, a period of limited transcription from the HIV-1 
provirus yields short, fully spliced mRNAs corresponding to the tat, rev and nef 
reading frames.  Once sufficient Tat has been synthesised, it directs the 
transcription of longer, incompletely spliced mRNAs encoding env, vif, vpr and vpu, 
along with unspliced transcripts that serve both as a template for gag-pol 
translation, and as gRNA for progeny virions (Kim et al., 1989; Pomerantz et al., 
1990). 
 
Tat directs transcriptional transactivation by recruiting the transcription elongation 
factor, P-TEFb, which itself is a complex of cyclin T1 and Cdk9 (Wei et al., 1998).  
Tat binds the cyclin T1 component of this complex, as well as the 
trans-activation-responsive (TAR) region found at the 5’ end of all viral transcripts.  
This brings Cdk9 in close proximity of the transcriptional machinery, enabling it to 
phosphorylate several residues within the C-terminal domain of the large subunit of 
RNA Polymerase II.  These modifications substantially increase the processivity of 
the enzyme (Kim et al., 2002). 
 
Transcription of the MLV provirus is less-well regulated, owing to the absence of a 
transcriptional trans-activator. Nevertheless, the U3 region contains a host of 
cis-regulatory sequences, including an E-box that binds basic helix-loop-helix 
(bHLH) transcription factors (Nielsen et al., 1992; Nielsen et al., 1994; Lawrenz-
Smith and Thomas, 1995). 
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Splicing and nuclear export 
 
Upon dissociation from the proviral template, all viral transcripts are modified with a 
5’ methylguanosine cap and a 3’ polyA tail, and a subset are spliced to remove 
portions of the coding sequence.  While MLV produces only unspliced and singly 
spliced mRNAs, the presence of twelve splice sites in the HIV-1 genome yields 
more than 40 different transcripts of varying abundance (Purcell and Martin, 1993). 
 
As described on the previous page, HIV-1 transcription is temporally regulated.  
During the first wave of transcription, only completely spliced RNAs corresponding 
to tat, rev and nef are maintained, while any unspliced or singly spliced species are 
degraded upon synthesis.   
 
While Tat is crucial for boosting subsequent levels of transcription, Rev serves to 
control the export of mRNAs once they are synthesised.  Thus, as Rev protein 
levels accumulate with successive rounds of early transcription, longer mRNAs are 
eventually recognised and targeted for export.  This occurs by virtue of a 
Rev-response element (RRE), which is only present in singly- and unspliced viral 
transcripts, and a nuclear export signal (NES) found roughly in the middle Rev 
(Fischer et al., 1995).  The NES facilitates an interaction between the Rev-RNA 
complex and the karyopherin, Crm1, permitting the active transport of viral mRNA 
into the cytoplasm.  Rev can then return to the nucleoplasm through an interaction 
between its N-terminal NLS and importin-β (Henderson and Percipalle, 1997). 
 
Again, MLV lacks an equivalent trans-acting accessory protein.  However, it does 
contain a cis-acting cytoplasmic accumulation element (CAE), which is found 
towards the 3’ end of pol and mediates the export of transcripts through association 
with the nuclear export receptor, NXF1 (Sakuma et al., 2014).  Consistent with this 
notion is the observation that inserting a CAE into the genome of HIV-1 facilitates 
the Rev-independent expression of Gag.  Additionally, the 3’ U3 region of the MLV 
genome appears to be required for the export of full-length transcripts (Volkova et 
al., 2014). 
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1.2.6 Translation  
The synthesis of viral proteins is initiated upon recognition of the 5’ 
methylguanosine cap – which is present on all viral transcripts – by the ribosome. 
 
The gag reading frame encodes the structural proteins of the virus.  In 
orthoretroviruses, its translation yields a polyprotein that is ultimately cleaved into 
matrix (MA), capsid (CA) and nucleocapsid (NC) subunits, along with a number of 
smaller peptides.  As discussed in Section 1.1.6, spumaviral Gag has a rather 
different structure and remains largely uncleaved throughout the viral lifecycle.  In 
MLV, a heavily glycosylated form of this protein – glycoGag – is synthesised by 
translational initiation from an upstream CUG codon (Edwards and Fan, 1979); 
(Prats et al., 1989).  This yields a protein with an 88 aa leader sequence appended 
to the N-terminus, which directs it to the Golgi apparatus for the addition of 
carbohydrate moieties.  GlycoGag confers viral resistance to the SERINC3/5 and 
APOBEC restriction factors (see Sections 1.3.2 and 1.3.3, respectively) (Stavrou et 
al., 2013; Rosa et al., 2015, Usami et al., 2015).  Additionally, the Gag polyprotein 
of both MLV and HIV-1 is co-translationally myristoylated to facilitate association 
with the plasma membrane during assembly (Henderson et al., 1983; Bryant and 
Ratner, 1990). 
 
In orthoretroviruses, the pol reading frame – including protease (PR), reverse 
transcriptase (RT) and integrase (IN) – is translated as part of a Gag-Pol 
polyprotein.  This fusion is synthesised by translational readthrough of the gag stop 
codon, which is mediated by a pseudoknot structure in the transcripts of MLV (Wills 
et al., 1994) and by a -1 ribosomal frameshift in HIV-1 (Jacks et al., 1988).  In both 
cases, readthrough occurs with approximately 5% efficiency.  This phenomenon 
maintains a Gag to Gag-Pol ratio of approximately 20:1 in the producer cell, a ratio 
that is conserved among retroviruses and is important for late-phase events such 
as genome dimerisation and proteolytic processing (Shehu-Xhilaga et al., 2001).  In 
spumaviruses, on the other hand, Pol is translated independently of Gag. 
 
In all retroviruses, Env is synthesised from a spliced mRNA that lacks the former 
two reading frames.  Translation of the HIV-1 Env precursor (gp160) occurs on the 
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rough endoplasmic reticulum, where it undergoes co-translational glycosylation of 
several key residues and post-translational cleavage of the N-terminal signal 
peptide that got it there.  Upon entering the oxidising environment of the ER lumen, 
disulphide bonds form between the nascent gp160 monomers, facilitating their 
association into trimers (Earl et al., 1991).  The trimeric precursor is then 
translocated to the Golgi apparatus, where it is cleaved into surface (SU; gp120) 
and transmembrane (TM; gp41) subunits by resident subtilisin-like endoproteases 
(Hallenberger et al., 1997b; Willey et al., 1988).  This cleavage event weakens, but 
maintains, the Env trimer.   
 
In addition to gag, pol and env, complex retroviruses possess additional ORFs 
encoding regulatory and accessory proteins.  In HIV-1, these are vif and vpr, which 
are expressed from singly spliced transcripts; tat, rev and nef, from multiply spliced 
transcripts; and vpu, which is encoded on a bicistronic mRNA upstream of env 
(Schwartz et al., 1990). 
 
1.2.7 Assembly 
Once the full complement of structural and catalytic proteins have been 
synthesised, a complex orchestration of events leads to the assembly of immature 
virions.   
 
Early interactions between the NC domain of Gag and the packaging signal (ψ) of 
unspliced viral transcripts facilitates the specific encapsidation of viral genomes, 
while excluding all cellular and spliced viral RNA species.  MLV ψ consists of four 
stem-loops – two for packaging (SL-C/D) (D’Souza et al., 2001), and two for the 
initiation of genome dimerisation (DIS-1/2) (Ly and Parslow, 2002).  Conversely, ψ 
is poorly defined in HIV-1, with a variety of mutations in the 5’ UTR resulting in a 
reduction in packaging efficiency.  Indeed, it has been postulated that a 
‘conformational switch’ in this region shifts the RNA from a structure that is 
conducive to translation to one that promotes packaging (Lu et al., 2011b). 
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Following this initial encounter between Gag and gRNA, assembly of the viral core 
can proceed.  For both MLV and HIV-1, this requires association with the plasma 
membrane via the myristoylated MA domain of Gag.  Interestingly, this change in 
localisation reconfigures the Gag-RNA interaction from one involving primarily the 
5’ UTR of the latter, to one that spans the entire length of the genome (Kutluay et 
al., 2014). 
 
The MA domain specifically targets the assembling viral complex to lipid rafts:  
domains within the membrane that are enriched for certain classes of lipid, 
including cholesterol, phosphatidyl serine and phosphatidyl inositol (4,5) 
bisphosphate (PIP2) (Chan et al., 2008).  While the incorporation of cholesterol is 
critical for virion infectivity (Liao et al., 2003), acidic phospholipids such as PIP2 are 
required to form electrostatic interactions with basic residues in MA (Ono et al., 
2004), to externalise the covalently attached myristate residue (Saad et al., 2006), 
and to competitively displace any RNA bound to this region (Chukkapalli et al., 
2010).   Collectively, these phenomena ensure tight anchoring of Gag to the 
plasma membrane.  Once the viral complex is properly tethered, Gag 
polymerisation ensues.  This yields an immature hexagonal lattice of 1100-1800 
Gag molecules for MLV (Yeager et al., 1998) and 5000 molecules for HIV-1 (Briggs 
et al., 2004), collectively accounting for about 50% of total virion mass.   
 
The curvature and flexibility of this lattice have posed substantial technical 
obstacles to defining its structure.  However, a combination of electron microscopy 
and cryotomography recently accomplished this for the immature lattice of a 
truncated Gag from Mason-Pfizer monkey virus, a β-retrovirus (Bharat et al., 2012).  
Interestingly, this work revealed contacts between the unprocessed CA domains 
that are distinct from those found in the mature retroviral core.  It is presently 
unclear whether the transition from an immature lattice to a condensed core 
involves an intermediate phase of Gag disassembly (Keller et al., 2013; Frank et 
al., 2015). 
 
Env trimers are targeted to lipid rafts independently of Gag.  Genetic evidence 
suggests that this is mediated by the cytoplasmic TM subunit of Env, which both 
directs it to the plasma membrane and ensures its incorporation into virions through 
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an interaction with MA (Yu et al., 1993; Cosson, 1996; Murakami and Freed, 2000).  
Interestingly, however, neither deletion of the TM subunit (Einfeld, 1996), nor the 
replacement of Env with a heterologous glycoprotein (Briggs et al., 2003), prevent 
the incorporation of Env in virions, indicating that a direct interaction between Env 
and MA is not essential for this process.  Thus, a compensatory pathway must also 
exist, which may involve the recruitment of cellular proteins to act as a bridge 
between Env and MA (Checkley et al., 2011; Tedbury and Freed, 2014).  In any 
case, the trimerisation of MA is probably important for Env incorporation (Tedbury 
et al., 2013). 
 
The overall kinetics of virion assembly – from the initial detection of 
membrane-associated Gag to the formation of an immature lattice – have been 
estimated at 5-9 min on average, with an upper limit of around 20 min (Jouvenet et 
al., 2008; Ivanchenko et al., 2009). 
 
1.2.8 Budding and maturation 
Once all of the viral components have assembled at the plasma membrane, the 
immature virion must egress to the cell surface.  This process is initiated by the 
polymerisation of Gag at the assembly site, which deforms the planar lipid bilayer 
into a spherical, virion-like configuration (Carlson et al., 2008).  The resulting 
structure remains attached to the producer cell through a neck region.  Complete 
membrane fission requires that this region be severed by components of the 
cellular ESCRT machinery.  
 
The ESCRT pathway involves numerous protein complexes whose usual roles 
include cell abscission during cytokinesis and the biogenesis of multivesicular 
bodies (Hurley and Hanson, 2010).  Retroviruses possess late assembly (L-) 
domains for the recruitment of these proteins.  L-domains typically come in three 
flavours: P(T/S)AP, which is found in MLV MA and HIV-1 p6 (Garrus et al., 2001; 
Segura-Morales et al., 2005); LYPxnL, which is found at the MLV MA-p12 junction 
and in HIV-1 p6 (Segura-Morales et al., 2005; Strack et al., 2003), and PPxY, 
which is present in MLV p12, but absent in HIV-1 (Yuan et al., 2000).   
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The viral L-domains recruit either the ESCRT-I heterotetramer or the 
ESCRT-associated protein ALIX, which themselves activate ESCRT-III protein 
complexes, including CHMP2 and 4 (Wollert and Hurley, 2010).  These oligomers 
form long filamentous structures around the bud neck, which coil into a dome 
shape at the base of the virion (Shen et al., 2014).  It is possible that this process is 
completed upon hydrolysis of ATP by the VPS4 complex (Babst et al., 1998; Scott 
et al., 2005), although this remains the subject of ongoing investigation.  
Alternatively, recent data from super-resolution microscopy suggests that ESCRT 
components are recruited within the head of the budding virion, where their 
selective remodelling might act as the driving force for membrane scission (Van 
Engelenburg et al., 2014). 
 
Immediately following its release from the producer cell, the nascent virion 
undergoes a series of tightly regulated morphological changes that are necessary 
for subsequent infectivity.  This is known as maturation (Kohl et al., 1988; 
Konvalinka et al., 1995a).   
 
This process begins with the autocatalytic cleavage of PR from Pol shortly after the 
completion of budding.  Immediately following the autoprocessing of PR, RT and IN 
are cleaved from one another, although it remains unclear whether this 
phenomenon occurs in cis, trans, or some combination thereof (Pettit et al., 2004).  
PR then catalyses sequential cleavage events within Gag, liberating each of its 
constituents in a stepwise manner.  This temporal regulation is achieved by 
different rates of processing at each of the five Gag cleavage sites (Figure 1.10).  
In HIV-1, these sites fall into three categories according to their rate of processing 
by PR: rapid (SP1/NC), intermediate (SP2/p6, MA/CA) and slow (NC/SP2, 
CA/SP1).  By examining mutant virions that are defective for cleavage at each of 
these sites, it has been possible to deduce their respective contributions to 
maturation. 
 
SP1/NC cleavage activates the fusogenic potential of Env (Wyma et al., 2004) and 
promotes the condensation of NC with the viral RNA (de Marco et al., 2010b).  The 
resulting RNP particle is further processed by the SP2/p6 and NC/SP2 cleavages, 
which collectively free NC to act as a chaperone for the genome dimer (Kafaie et 
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al., 2008).  Cleavage at the MA/CA junction liberates CA-SP1 from the membrane 
and causes the immature Gag lattice to disassemble; CA/SP1 cleavage then frees 
CA entirely, enabling it to form the conical structure that typifies the core of HIV-1 
(de Marco et al., 2010b).  
  
In addition to unshackling the individual domains of Gag, these events facilitate 
conformational changes within them that allow new interactions to be established.  
For example, the liberation of CA from MA enables the N-terminal 13 residues of 
the former to fold into a β-hairpin, thereby initiating the formation of mature CA 
hexamers. 
 
The maturation process is less-well characterised for MLV virions, although it is 
known that cleavage between MA and p12 is not required for the formation of 
mature cores (Oshima et al., 2004).  Cleavage at the p12/CA site, however, is 
crucial for the subsequent round of reverse transcription and integration (Rulli Jr et 
al., 2006). 
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Figure 1.10: Retroviral maturation 
(A) A schematic depicting the structural rearrangements that convert an immature 
virion (left) to a mature particle with either spherical (top right) or conical (bottom 
right) core morphology.  Env trimers are shown in grey; MA, purple; CA, green; NC, 
blue; PR, pink; RT, red and IN, yellow.  (B) Sequential, PR-mediated proteolysis of 
the Gag-Pol precursor.  White triangles represent cleavage sites in Pol; red 
triangles, rapid cleavage sites in Gag; orange triangles, intermediate cleavage sites 
in Gag, and green triangles, slow cleavage sites in Gag. 
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1.2.9 Unique aspects of the Spumaretrovirinae lifecycle 
The processes described in this chapter so far apply predominantly to viruses of 
the Orthoretrovirinae subfamily.  The lifecycle of the spumaviruses is distinct in a 
number of ways, some of which unite them more closely with the Hepadnaviridae, 
a family of DNA viruses that includes hepatitis B virus (HBV).  Some of these 
differences are highlighted in Table 1.2. 
 
  
Orthoretrovirinae 
 
Spumaretrovirinae Hepadnaviridae 
Reverse 
transcription 
Occurs during early 
phase of the 
lifecycle; infectious 
particles contain 
RNA. 
Occurs during late 
phase of the 
lifecycle; infectious 
particles contain 
DNA.1  
Occurs during late 
phase of the 
lifecycle; infectious 
particles contain 
DNA. 
 
Nuclear 
entry 
Virions are not 
recycled 
intracellularly. 
  
Intracellular 
‘recycling’ of virions 
yields high 
copy-number in 
nucleus of the 
producer cell.2 
Intracellular 
‘recycling’ of virions 
yields high 
copy-number in 
nucleus of the 
producer cell.3 
 
Integration 
Essential for 
replication. 
Essential for 
replication.4 
 
Does not occur. 
Transcription 
Initiated from a 
single promoter. 
Initiated from 
multiple promoters.5 
 
Initiated from 
multiple promoters.6 
Assembly 
Gag binds RNA via 
NC domain. 
Gag binds DNA and 
RNA with equal 
affinity.7 
HBV core protein 
binds DNA and RNA 
with equal affinity.8  
 
Budding & 
maturation 
Budding occurs at 
the plasma 
membrane and 
maturation occurs 
extracellularly.  
 
Both processes 
occur within 
intracellular 
compartments such 
as the ER.9 
 
Both processes 
occur within 
intracellular 
compartments such 
as the ER.10 
 
Table 1.2: A comparison of orthoretroviruses, FVs and hepadnaviruses 
Orthoretroviral phenotypes are shaded in pink and hepadnaviral ones in blue. 
References: (1) Moebes et al. (1997); (2) Meiering et al. (2000); (3) Tuttleman et al. 
(1986); (4) Enssle et al. (1999); (5) Löchelt et al. (1993); (6) McLachlan (1991); (7) 
Yu et al. (1996c); (8) Nassal (1992); (9) Goepfert et al. (1999); (10) Ganem (1991). 
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1.3 Retroviral restriction factors 
Restriction factors are host-expressed proteins which form the basis of a 
cell-intrinsic antiviral response (Figure 1.11) (Yan and Chen, 2012).  Intrinsic 
immunity is distinct from the innate and adaptive arms in that the proteins 
responsible are usually constitutively expressed, although they may be upregulated 
by interferon (Tanaka et al., 2006; Carthagena et al., 2009; Abdel-Mohsen et al., 
2014).  This chapter will describe each of the major retroviral restriction factors in 
turn, beginning with those that inhibit viral entry. 
 
 
 
 
 
Figure 1.11: The retroviral lifecycle, illustrating the stage-specific blocks 
imposed by restriction factors 
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1.3.1 IFITMs 
The interferon-inducible transmembrane (IFITM) family of proteins comprises five 
members, of which three – IFITM1, 2 and 3 – are induced by both type I and II 
interferon.  These proteins are known to restrict the entry of a number of enveloped 
viruses, including influenza A virus, hepatitis C virus and HIV-1 (Brass et al., 2009; 
Lu et al., 2011a; Narayana et al., 2015). 
 
The IFITMs consist of a cytosolic N-terminus, followed by two hydrophobic 
intramembrane domains separated by a conserved intracellular loop.  IFITM1, 2 
and 3 also undergo post-translational modifications of several residues, some of 
which are imperative for restriction (Perreira et al., 2013).  The IFITMs block viral 
entry by preventing fusion between the host and viral membranes (Li et al., 2013b).  
One model for how they accomplish this is by reducing membrane fluidity, thereby 
preventing the changes in membrane curvature that are requisite for a hemifusion 
event. 
 
1.3.2 SERINC3/5 
Serine incorporator 3 and 5 (SERINC3 & 5) belong to a family of transmembrane 
carrier proteins that facilitate the incorporation of serine into lipids of the plasma 
membrane (Inuzuka et al., 2005).  Their role in the Env-dependent restriction of 
HIV-1 was independently reported by two groups, both of whom were seeking to 
identify the mechanism through which HIV-1 Nef and the structurally distinct MLV 
glycoGag are able to enhance the infectivity of HIV-1 virions (Rosa et al., 2015; 
Usami et al., 2015).  
 
The two groups discovered that Nef and glycoGag function by downregulating 
SERINC3 and 5 from the plasma membrane.  This prevents their incorporation into 
budding virions, where they have an inhibitory effect on replication.  A number of 
mechanisms for the restriction of HIV-1 by SERINCs have been postulated, 
including physical hindrance of Env trimer clustering and increasing the energy 
barrier for membrane fusion (Usami et al., 2015). It is also possible that these 
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proteins compromise infectivity by altering the lipid composition of the envelope 
(Waheed and Freed, 2010). 
 
Although little is presently known about the mechanism through which Nef 
overcomes SERINC-mediated restriction, a preliminary observation suggested that 
it may target the latter to Rab7+ endosomal compartments for eventual degradation 
by the lysosome (Rosa et al., 2015). However, more recent findings have shown 
that the downregulation of SERINC by Nef is dispensable and insufficient for 
antagonism. This indicates that virion exclusion is not the only mechanism through 
which Nef counteracts SERINC-mediated restriction. (Trautz et al., 2016)  
 
1.3.3 APOBEC family members 
The APOBEC family of proteins comprises eleven members, all of which have 
cytosine deaminase activity.  The substrate for these enzymes is typically 
single-stranded DNA, with a requirement for three bases preceding the target 
cytosine and a single one following it (Nabel et al., 2013).  A conserved glutamic 
acid in the catalytic site promotes the hydrolytic deamination of cytosine by 
deprotonating water, thereby providing a hydroxide ion that can be used for 
nucleophilic attack of the pyrimidine ring.  The net result is the replacement of the 
4’ amine with a carbonyl group – i.e. the conversion of cytosine to uracil. 
 
The APOBEC family has a colourful evolutionary history, evidenced by the 
extensive variation in gene copy number among mammals (Conticello et al., 2005).  
Although all mammals possess activation-induced cytidine deaminase (AID) and 
APOBECs 1, 2 and 3, there is evidence of particular gene expansion among the 
primates, where tandem duplications in the APOBEC3 locus have yielded a total of 
seven protein-coding genes (A3A-H).     
 
While it has been known for some time that the APOBEC family member AID 
contributes to adaptive immunity by promoting antibody diversity (Muramatsu et al., 
1999), work over the past decade has uncovered numerous other members that 
contribute to retroviral restriction.  APOBEC3G (A3G herein) was initially 
discovered as a dominant cellular factor that blocks the replication of Vif-deficient 
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HIV-1 in culture (Madani and Kabat, 1998; Sheehy et al., 2002).  Later studies 
revealed that a number of other proteins in the A3 subfamily – including A3D, A3F 
and A3H – harbour similar activities (Hultquist et al., 2011; Ooms et al., 2013).  
 
A3 enzymes are incorporated into budding virions in the producer cell via an 
RNA-bridged interaction with the NC domain of Gag (Apolonia et al., 2015).  
Shortly after budding, a substantial fraction of the incorporated restriction factor 
then becomes encapsidated in the viral core (Donahue et al., 2015).   
 
Restriction itself is manifested in the target cell, specifically during reverse 
transcription.  In the early stages of RT, degradation of the genomic RNA yields a 
single-stranded cDNA that is susceptible to modification by the encapsidated A3 
enzyme.  Deamination of this molecule provides an aberrant template for 
plus-strand synthesis, resulting in a high frequency of G-A mutations in the nascent 
proviral DNA (Harris et al., 2003; Mangeat et al., 2003).   
 
A3 enzymes can also inhibit the elongation of reverse transcripts in a 
deamination-independent manner, by associating with viral ssRNA and imposing a 
physical barrier to the progression of reverse transcriptase along the template 
(Iwatani et al., 2007; Bishop et al., 2008).  This steric hindrance requires a shift in 
the binding kinetics of the enzyme, from a fast off-rate (to permit rapid scanning for 
cytosine residues) to a much slower one (to pose a block to RT).  This transition is 
mediated by a gradual oligomerisation of A3 (Chaurasiya et al., 2014), and is 
utilised to a greater extent by A3F than by A3G (Kobayashi et al., 2014).  
A3-mediated restriction of other retroviruses – including MLV, HTLV-1 and various 
foamy viruses – has also been reported (Delebecque et al., 2006; Rulli et al., 2008; 
Ooms et al., 2012). 
 
Unsurprisingly, retroviruses have evolved various means of counteracting 
restriction by A3 proteins.  The HIV-1 viral infectivity factor (Vif) is an accessory 
protein that renders the virus resistant to restriction by A3.  Specifically, Vif recruits 
the Cullin5-ElonginB-ElonginC complex, which facilitates the polyubiquitination and 
proteasomal degradation of the restriction factor (Conticello et al., 2003).  MLV 
antagonises A3 by way of a heavily glycosylated form of Gag (glycoGag), which 
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confers resistance by excluding the enzyme from incorporation into virions (Boi et 
al., 2014). Meanwhile, foamy viruses counter restriction using the accessory 
protein, Bet, which appears to employ a mechanism that is distinct from both Vif 
and glycoGag (Chareza et al., 2012).  
 
The pressure to evade such viral countermeasures has resulted in numerous 
positively selected residues within genes of the A3 subfamily (Sawyer et al., 2004; 
Duggal et al., 2013).  Interestingly, some of these predate the emergence of 
modern lentiviruses, implying that an ancient – and perhaps still extant – selective 
force has helped to shape the evolution of this protein. 
 
1.3.4 SAMHD1 
Sterile alpha motif (SAM) and histidine/aspartic acid (HD) domain-containing 
protein 1 (SAMHD1) is a restriction factor that inhibits HIV-1 and SIV replication in 
cells of the dendritic and myeloid lineages, and in resting CD4+ T-cells (Laguette et 
al., 2011; Baldauf et al., 2012).  The HD domain of the protein is a deoxynucleoside 
triphosphate triphosphohydrolase (dNTPase), which cleaves its substrate at the 
phosphoester bond between the α-phosphate and the 5’ carbon of the ribose ring, 
thereby liberating the triphosphate moiety from its deoxynucleoside partner 
(Goldstone et al., 2011).  This depletes the cellular pool of dNTPs, thus preventing 
the restricted virus from completing reverse transcription (Lahouassa et al., 2012). 
 
The active form of SAMHD1 is a homotetramer with a total of 4 catalytic and 8 
allosteric sites.  Tetramerisation requires the C-terminal domain (CtD, residues 
584-629) and is dependent on allosteric activation by (d)GTP.  This induces 
conformational changes within the subunits that promote and stabilise their 
interaction with one another (Powell et al., 2011; Amie et al., 2013).  A structure of 
the SAMHD1 tetramer in complex with dGTP has been solved to 1.8 Å resolution 
(Zhu et al., 2013). 
 
While SAMHD1 limits the dNTP pool in differentiated and resting cells, it is inhibited 
in cycling cells to maintain sufficient dNTP concentrations for DNA synthesis.  The 
inactivation of SAMHD1 occurs post-translationally through the phosphorylation of 
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T592 by the cyclin A2/CDK1 complex (Tang et al., 2015).  This modification 
destabilises the tetramer by creating an electrostatic repulsion between the 
subunits, thereby inhibiting dNTPase activity.  This has a knock-on effect on 
restriction, partly explaining why cycling CD4+ T-cells are susceptible to HIV-1 
infection despite sustained expression of SAMHD1 (Baldauf et al., 2012).  
Interestingly, T592 phosphorylation is reduced in response to IFN-I, suggesting that 
viral threat can directly result in the heightened activation of this restriction factor 
(Cribier et al., 2013). 
 
In order to overcome SAMHD1 restriction in non-cycling cells, some retroviruses 
have evolved specialised countermeasures.  The HIV-2/SIVmac accessory protein, 
Vpx is one such example.  Vpx interacts with both the CtD of SAMHD1 and the 
Cullin4A complex (via the adaptor protein DCAF1) in order to promote the 
proteasomal degradation of the former (Schwefel et al., 2015).  The SAMHD1-CtD 
thus exhibits strong signatures of positive selection (Laguette et al., 2012), the 
hallmark of an ongoing evolutionary arms race between a restriction factor and its 
viral antagonist. 
 
1.3.5 REAF 
RNA-associated early-stage antiviral factor (REAF) is a recently discovered 
restriction factor that acts in the early phase of the retroviral lifecycle, either during 
or immediately following the initiation of reverse transcription (Marno et al., 2014).  
The protein was first identified in a genome-wide siRNA screen (Liu et al., 2011a), 
where its knockdown in HeLa cells was found to result in >50-fold rescue of viral 
titres. 
 
REAF has been shown to restrict HIV-1, HIV-2 and a number of SIVs, implying that 
its viral target is conserved at least among the primate lentiviruses. Although the 
mechanism of restriction is presently unclear, one hypothesis suggests that REAF 
associates with viral reverse transcription products and targets them for 
degradation (Marno et al., 2014).  However, whether this interaction occurs directly 
or via an adaptor molecule remains to be seen. 
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Given the general observation that HIV-1 and other retroviruses typically evolve 
means of evading restriction factors, it is likely that such a countermeasure also 
exists for REAF.  Consistent with this notion, REAF protein levels have been shown 
to decrease as soon as 1 h after viral challenge in HeLa cells (Marno et al., 2014), 
a phenotype that is lost with the addition of proteasome inhibitors.  This implies that 
HIV-1 targets REAF for proteasomal degradation in a fashion that mirrors the 
retroviral antagonism of A3G and SAMHD1. 
 
1.3.6 Capsid-targeting restriction factors: Fv1, T5α, TCyp and Mx2 
The history of research on capsid-binding restriction factors can be traced to the 
discovery of the murine restriction factor, Fv1, a dominant gene that confers mice 
with resistance to MLV (Lilly, 1970; Rowe and Hartley, 1972; Odaka, 1975).  More 
than twenty years following its discovery, the Fv1 gene was cloned and sequenced 
by a positional cloning method (Best et al., 1996), and a sequence alignment 
revealed that it is derived from the Gag sequence of an endogenous retrovirus of 
the MERV-L family (Stoye, 1998).   
 
The gene exists in two primary alleles, Fv1n and Fv1b, with the former conferring 
resistance to B-tropic MLV and the latter usually to N-tropic, although it is modestly 
active against B-tropic virus when expressed above endogenous levels (Hartley et 
al., 1970; Bishop et al., 2001).  The determinant responsible for the differential 
sensitivity of MLVs to alleles of Fv1 was later mapped to a single amino acid 
(residue 110) in the MLV capsid (Kozak and Chakraborti, 1996), although 
additional determinants have since been identified (Stevens et al., 2004; Ohkura 
and Stoye, 2013).  
 
Fv1 restricts MLV at a stage after reverse transcription but prior to genomic 
integration (Jolicoeur and Baltimore, 1976; Sveda and Soeiro, 1976).  It does this, 
in part, by binding to the MLV capsid via its C-terminal recognition domain (Bishop 
et al., 2001).  An exact mechanism of restriction is yet to be elucidated, but it is 
known that self-association of Fv1 via an N-terminal dimerisation domain is a 
prerequisite for restriction (Bishop et al., 2006; Yap et al., 2007).  It is also evident 
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that the capsid target must exist in its mature and multimeric form for a successful 
Fv1 interaction to occur (Dodding et al., 2005). 
 
A recent study characterising the restriction profiles of Fv1 orthologues from wild 
mice found that some are able to target non-MLV retroviruses, including lenti- and 
foamy viruses (Yap et al., 2014).  This work revealed several novel determinants of 
restriction in the C-terminus of Fv1, and reinforced the notion that this restriction 
factor has been defending mice against episodes of retroviral challenge since its 
endogenisation, at least 4 million years ago (Yan et al., 2009). 
 
Although Fv1 is a murine-specific factor, an Fv1-like activity became apparent in 
various primate cell lines in the late 1990s.  These cells restricted N-, but not 
B-MLV, and, like Fv1, the factor responsible appeared to be both dominant and 
saturable, although its effects were manifested prior to reverse transcription.  This 
activity was provisionally referred to as Ref1 (Towers et al., 2000, 2002).  Around 
the same time, several primate cell lines had been reported to block the replication 
of lentiviruses such as HIV-1 and SIVmac (Hofmann et al., 1999; Besnier et al., 
2002; Cowan et al., 2002; Hatziioannou et al., 2003).  Again, this phenotype was 
mediated by a factor that was dominant, saturable and acted pre-RT; it was 
denoted Lv1.  
 
It was eventually discovered that a single protein was responsible for both of these 
phenomena.  This was the alpha isoform of the T5 gene (T5α herein).  T5α was 
identified by screening a rhesus macaque cDNA library for genes that conferred 
human cells with resistance to HIV-1 infection (Stremlau et al., 2004).  It has since 
been discovered that T5α is also capable of restricting N-MLV and a panel of lenti- 
and foamy viruses (Perron et al., 2004; Yap et al., 2004; Saenz et al., 2005; Yap et 
al., 2008). 
 
A subsequent screen by the Luban group sought to identify the determinant for 
HIV-1 restriction in owl monkey kidney (OMK) cells (Sayah et al., 2004).  Given 
former evidence that Lv1 activity in OMK cells could be abolished using 
cyclosporine, a competitive inhibitor of CypA, the OMK cDNA library was screened 
for clones with homology to CypA.  This screen yielded an unexpected result: a 
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fusion product combining the T5 and CypA open reading frames, which is believed 
to have arisen via a LINE-I-mediated retrotransposition event that inserted a CypA 
cDNA into intron 7 of the T5 gene.  This fusion protein – TCyp – confers permissive 
human cells with anti-HIV-1 activity (Nisole et al., 2004).  Such fusions have since 
been identified in several primate lineages (Brennan et al., 2008; Newman et al., 
2008; Dietrich et al., 2010; Yu et al., 2013).  A more thorough treatment of both T5α 
and TCyp can be found in Section 1.4.5. 
 
More recently, myxovirus resistance 2 (Mx2) was identified as an 
interferon-inducible factor with restriction activity against HIV-1 (Goujon et al., 
2013; Kane et al., 2013; Liu et al., 2013).  Mx2 interacts directly with the HIV-1 
capsid via its N-terminal domain (Kong et al., 2014), and then effects restriction by 
stabilising the core, thus preventing uncoating (Fricke et al., 2014).  The N-terminal 
domain is both necessary and sufficient for capsid recognition, as is evidenced by 
the observation that fusing the N-terminal 91 amino acids of Mx2 to Fv1b yields a 
chimera with potent anti-HIV-1 activity (Goujon et al., 2015).  The C-terminal 
domain of Mx2 is responsible for dimerisation of the protein, a function that is also 
indispensable for its restriction activity (Fricke et al., 2014; Goujon et al., 2015). 
 
Recent work has uncovered circulating variants of HIV-1 with capsid mutations that 
confer resistance to Mx2 (Wei et al., 2016).  Correspondingly, sites of positive 
selection have been identified within Mx2 (Busnadiego et al., 2014; Sironi et al., 
2014), implying an ongoing evolutionary arms race between the two. 
 
1.3.7 TRIM28 
TRIM28 (T28 herein) is a restriction factor that targets the integrated provirus of 
MLV and induces its transcriptional silencing (Wolf et al., 2008).  T28 is recruited to 
a sequence element within the proviral DNA which closely overlaps with the 
conserved tRNApro primer-binding site of the ecotropic MLV genome.  This is 
mediated by members of the Krüppel-associated box (KRAB) family of zinc finger 
DNA-binding proteins, including ZPF809 (Wolf and Goff, 2009).  Upon recruitment 
to the proviral DNA, T28 itself recruits a complex of chromatin modifiers that serve 
to repress local transcription, including a histone deacetylase complex, a histone 
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H3K9 methyltransferase, and the heterochromatin-associated protein, HP1 
(Schultz et al., 2001, 2002). 
 
T28 has also been shown to repress the transcription of endogenous retroviruses 
in neural progenitor cells (Fasching et al., 2015), a process that may be critical for  
proper brain development. 
 
1.3.8 Tetherin 
Tetherin (also known as bone marrow stromal antigen 2, BST-2) is an 
interferon-inducible restriction factor that causes fully formed virions to be retained 
on the surface of infected cells (Neil et al., 2008).   It is a type II transmembrane 
protein with unusual topology, comprising an N-terminal transmembrane domain 
and a C-terminal glycophosphatidylinositol (GPI) anchor, linked by an extracellular 
coiled-coil motif (Hinz et al., 2010; Schubert et al., 2010).  When a virion buds from 
a producer cell, one of the lipid anchors is incorporated into the viral membrane.  
This results in a physical link between cell and virus that prohibits the latter from 
being disseminated (Neil et al., 2008). 
 
Unsurprisingly, lentiviruses have evolved numerous countermeasures to 
antagonise the activity of tetherin, including HIV-1 Vpu, HIV-2 Env and SIV Nef (Jia 
et al., 2009; Hauser et al., 2010).  In the case of HIV-1 and -2, this involves 
sequestration of tetherin from the plasma membrane to a perinuclear compartment;  
less is known about the mechanism utilised by SIV Nef, although it is clear that the 
process is both clathrin-dependent (Serra-Moreno et al., 2013) and species-specific 
(Zhang et al., 2009). 
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1.4 The TRIM family 
The tripartite motif (TRIM) family has at least 100 representatives in the human 
proteome, with functions as diverse as transcriptional regulation (Cammas et al., 
2012); cell cycle control (Bell et al., 2013); embryonic development (Song et al., 
2011) and apoptosis (Bernardi and Pandolfi, 2003).  The family is defined by its 
tripartite N-terminus, which comprises a RING finger, either one or two B-boxes, 
and a coiled-coil region (otherwise known as the RBCC domain).  These modules 
appear in all family members with conserved order and spacing. 
 
While TRIM proteins are united by their N-terminus, they diverge significantly at the 
C-terminus, where a number of domains and combinations thereof have been 
reported (Ozato et al., 2008).  This has provided the basis for a classification 
system that divides human TRIMs into nine classes (Short and Cox, 2006) (Figure 
1.12).  Interestingly, this system appears to have a phylogenetic basis, indicating 
that the RBCC domain was assembled and fixed prior to the acquisition of 
C-terminal partners. 
 
1.4.1 The RING domain 
The RING domain is a relatively short, cysteine-rich motif that coordinates two zinc 
ions and is found in a range of functionally diverse proteins (Borden and Freemont, 
1996).  It resides at the extreme N-terminus of all TRIM family members, typically 
within 10-20 amino acids of the initiator methionine (Torok and Etkin, 2001); 
(Reymond et al., 2001), and has the canonical sequence 
CX2CX9-39CX1-3HX2-3CX2CX4-48CX2C, where C and H correspond to cysteine and 
histidine, respectively, and X denotes any amino acid.  The RING finger has E3 
ubiquitin ligase activity, mediating the transfer of ubiquitin from an E2 conjugating 
enzyme to a given target substrate and, in doing so, often targeting the substrate 
for destruction by the proteasome (Xu et al., 2003). 
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Figure 1.12: The classification of human TRIMs  
The first nine subgroups were identified by (Short and Cox, 2006), and the 
remaining three described later. R: RING domain; B1: B-box1; B2: B-box2; CC: 
coiled-coil motif; COS: C-terminal subgroup one signature domain; FN-III: 
fibronectin type III domain; B30.2-like: either the full B30.2 domain (PRYSPRY), or 
the PRY or SPRY subdomain in isolation; AR: acid-rich region; PHD-BROMO: plant 
homeodomain and bromodomain; NHL: NHL repeat; MATH: meprin and TRAF 
homology domain; ARF: ADP ribosylation factor-like GTPase; TM: transmembrane 
domain.  Dashed boxes represent domains that are absent in certain members of a 
given subgroup.  Figure is adapted from Meroni (2012). 
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1.4.2 The B-boxes 
Immediately downstream of the RING domain is the B-box, another zinc-binding 
motif that mediates protein-protein interactions.  Given its structural and functional 
similarity to the RING finger, it has been proposed that the two domains diverged 
relatively recently from a common ancestor (Massiah et al., 2007).   
 
B-boxes come in two flavours: type 2 B-boxes (B2), which are found in all TRIM 
proteins, and type 1 (B1), present in fewer than half.  Despite their names, the two 
motifs share little primary sequence identity: the consensus for B1 is 
CX2CX6-17CX2CX4-8CX2-3C/HX3-4HX5-10H[C5(C/H)H2]), while for B2 it is 
CX2_4HX7-10CX1-4D/C4-7CX2CX3-6HX2-5H[CHC(D/C)C2H2], where C, D and H 
correspond to cysteine, aspartic acid and histidine, respectively, and X denotes any 
amino acid. 
 
The structure of B1 from T18 has been solved at high resolution, revealing an 
α-helix, two β-strands and three β-turns, which run from V117 to P164 and adopt a 
ββα topology in the tertiary structure (Figure 1.13A) (Massiah et al., 2006).  Like 
the RING domain, this structure coordinates two Zn2+ atoms: one by a cluster of 
cysteine residues (C119-C122-C142-C145) and the other by a tetrahedral 
arrangement of cysteine and histidine residues (C134-C137-H150-H155).  The 
structure of T18 B2 has also been solved by multidimensional NMR spectroscopy; 
despite the divergence in primary sequence, it exhibited a similar tertiary fold to 
that of B1 (Figure 1.13B) (Massiah et al., 2007).  Crystal structures of B2 are also 
available for the human and rhesus orthologues of T5α (Diaz-Griffero et al., 2009; 
Goldstone et al., 2014b).   
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Figure 1.13: Solution structures of (A) B-box1 and (B) B-box2 from T18 
Zinc atoms are shown in blue. PDB accession codes: 2FFW, 2DQ5, respectively. 
(Massiah et al., 2007, 2006) 
 
 
B2 is the only B-box motif present in T5α, where it serves to mediate the 
higher-order oligomerisation of T5 dimers into a supramolecular assembly (Li and 
Sodroski, 2008).  This is required to increase the avidity of the T5-capsid 
interaction, which itself is imperative for restriction (Perez-Caballero et al., 2005; 
Javanbakht et al., 2005).  Recently, the B-box domain of rhT5α has been 
crystallised in both dimeric and trimeric form (Keown et al., 2016; Keown and 
Goldstone, 2016).  This structure reveals two anti-parallel β-sheets per B-box 
monomer: the first sheet adopting a β1-β2 topology and the second sheet, 
β3-β4-α1-β5.  Again, this motif coordinates two zinc ions in a tetrahedral fashion 
(Figure 1.14).   
 
 
 
Figure 1.14: The B-box and coiled-coil of rhesus T5α 
Zinc atoms are shown in blue. PDB accession code: 5F7T. (Wagner et al., 2016) 
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In the dimeric structure, the interface between monomers involves a salt bridge 
between E120 of one partner and R121 of the opposing one.  This explains the 
former observation that charge-reversing mutations of surface-exposed residues 
(e.g. R121E) attenuate the restriction of HIV-1 by rhT5α, presumably by reducing 
its propensity for self-association (Diaz-Griffero et al., 2009).  Incidentally, the fact 
that the B-box of rhT5α has been observed to form both dimers and trimers in 
solution suggests that this oligomerisation interface is relatively plastic in nature, a 
trait that may lend itself well to recognising the varying curvatures of divergent 
retroviruses (discussed further in Section 1.4.5). 
 
1.4.3 The coiled-coil motif 
The coiled-coil (CC) motif is a highly α-helical region that comprises approximately 
100 amino acids and follows the B-box(es) in all TRIM family members.  Although 
this domain is invariably rich in hydrophobic residues (particularly leucine), the 
primary sequence conservation of CCs from different TRIMs is low. 
 
The CC motif was once believed to consist of several smaller sub-domains 
punctuated by α-helices.  However, more recent data from biochemical and 
crystallographic analyses of T25 have revealed that the domain actually constitutes 
a contiguous supercoil, with heptad and hendecad amino acid repeats that adopt a 
symmetrical 7-7-7-7-11-11-11-11-7-7-7-7 pattern (Sanchez et al., 2014).  The 
supercoil is canonically left-handed at the ends but unwinds towards the middle, 
where it adopts a slightly right-handed topology.  A multiple sequence alignment of 
54 human TRIMs revealed that this arrangement is remarkably well conserved, 
despite limited sequence identity.  Indeed, shortly after the characterisation of the 
T25 coiled-coil, a similar structure was observed in a CC-containing fragment of 
rhT5α (Goldstone et al., 2014b). 
 
CC folding is dependent on short stretches of amino acids known as trigger sites 
(Steinmetz et al., 2007).  These regions spontaneously form α-helices, thereby 
initiating a chain reaction that causes the remainder of the coiled-coil to ‘zip up’ into 
the appropriate conformation.  This progressive supercoiling is often inextricably 
linked to the formation of oligomers (typically dimers or trimers) with other 
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CC-containing proteins.  While all TRIM family members are capable of 
homodimerisation, the requirement for ‘compatible’ trigger sites limits the 
opportunity for heterodimerisation.  Where this does occur, it is usually between 
closely related family members, such as T1 and 18 (Reymond et al., 2001) (see 
Section 1.4.6).  
 
In the case of T5α, the CC motif is both necessary and sufficient for dimerisation 
(Berthoux et al., 2005; Javanbakht et al., 2006).  This is corroborated by the 
observation that restriction-defective T5α mutants act in a dominant-negative 
manner as long as they have an intact CC domain (Stremlau et al., 2004; Perez-
Caballero et al., 2005).  Given the low affinity of the T5-capsid interaction, 
dimerisation is indispensable for restriction (Langelier et al., 2008).  Indeed, 
signatures of positive selection within the CC may reflect the conformational impact 
of dimerisation for restriction specificity (Sawyer et al., 2005). 
 
1.4.4 The B30.2 domain 
Members of the C-I and -IV subgroups of the TRIM family are defined by the 
presence of a C-terminal B30.2 (or PRYSPRY) domain.  In T5α, this region is both 
necessary and sufficient for capsid recognition: substituting the rhT5α B30.2 
domain into the human orthologue endows the latter with a rhesus-like ability to 
restrict HIV-1 (Perez-Caballero et al., 2005; Yap et al., 2005).   
   
Crystal structures of the B30.2 domains from various TRIMs have been solved by a 
number of groups (Weinert et al., 2009; D'Cruz et al., 2013; Weinert et al., 2015).  
According to a model based on these structures, the domain consists of thirteen 
β-strands, with β1-3 residing in the recently acquired PRY domain and β4-13 in the 
ancestral SPRY domain.  These strands form two opposing β-sheets, giving rise to 
a hydrophobic, sandwich-like core.  The domain also contains four flexible loops, 
which protrude from one surface of the core and constitute the capsid-binding 
interface.  These loops are regions of high amino acid variability and are 
correspondingly referred to as the variable regions (VRs).  It is largely the 
species-specific polymorphisms within these regions that determine the panel of 
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retroviruses a given T5 orthologue is able to restrict (Stremlau et al., 2005; Ohkura 
et al., 2006).   
 
A catalogue of data from crystallographic, NMR and in silico simulation studies has 
revealed that the B30.2 domain makes multiple contacts with its viral target.  The 
prevailing model derived from these data positions VR2 and 3 within a single CA 
hexamer, while VR1 extends across the threefold axis to bridge adjacent hexamers 
(Biris et al., 2012, 2013; Kovalskyy and Ivanov, 2014).  Consistent with this notion 
is the structural plasticity of VR1, which may adopt conformations that position the 
same residue up to 30 Å apart in space (Ohkura et al., 2006).  It is likely that such 
flexibility has evolved to facilitate the recognition of divergent retroviral cores, which 
often differ in size, shape and curvature.  Perhaps a further adaptation to this 
pleiomorphy is the fact that T5α need only engage with a minority of capsid 
subunits (~25%) for restriction to ensue (Shi et al., 2013). 
 
Given their need to rapidly evolve with episodes of viral challenge, the VRs are 
hotspots of positive selection.  Interestingly, there is a propensity for charged 
residues to be particularly subject to these selective forces, indicating that the 
interaction between a B30.2 domain and its CA partner is likely electrostatic in 
nature.  For example, the removal of a single positive charge – R332P – in huT5α 
is sufficient to confer it with recognition of HIV-1 (Yap et al., 2005), while the 
analysis of N-MLV escape mutants reveals opposite charge preferences for the 
B30.2 domains of rhesus and human T5α (Ohkura et al., 2011; Ohkura and Stoye, 
2013). 
 
1.4.5 T5α and TCyp 
T5α and -Cyp (collectively referred to as T5 herein) are related proteins derived 
from the T5 gene.  Both molecules restrict retroviral replication prior to reverse 
transcription in a capsid-dependent manner (Stremlau et al., 2004; Sayah et al., 
2004).  However, while T5α orthologues are abundant among mammals and other 
vertebrates (Song et al., 2005a; van der Aa et al., 2009; Pacheco et al., 2010); 
(Fletcher et al., 2010), TCyp is the product of retrotransposition events that 
substituted the B30.2 domain for cyclophilin A (CypA) in a handful of primate 
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lineages (Brennan et al., 2008; Virgen et al., 2008).  This section will describe what 
is known about the nature of the T5-capsid interaction, as well as the mechanisms 
by which restriction is effected.  
 
Capsid recognition 
 
Retroviral cores are pleiomorphic structures that vary in hexamer number, 
pentamer distribution, and overall size and shape (Ganser-Pornillos et al., 2004; 
Benjamin et al., 2005; Heymann et al., 2008).  Indeed, even virions from the same 
quasispecies can exhibit discordant geometries (Welker et al., 2000).  This 
presents a challenge to capsid-binding restriction factors, which must recognise 
divergent retroviral targets with low primary sequence identity (Esteva et al., 2014). 
 
Until recently, much of our understanding of the T5-capsid interaction was based 
on genetic data – particularly the isolation of viral escape mutants (Ohkura et al., 
2011; Ohkura and Stoye, 2013).  Biochemical analyses were hampered by 
technical difficulties in purifying native T5, as well as the need for both interacting 
partners to be present in multimeric form (Diaz-Griffero et al., 2006; Yap et al., 
2007).  Nevertheless, some insight was gleaned thanks to the development of 
various in vitro assays for capsid binding.  These typically involved incubating the 
lysates from restriction factor-expressing cells with core-like assemblies of CA, and 
then detecting binding either through co-immunoprecipitation or electron 
microscopy (Stremlau et al., 2006; Hilditch et al., 2011).  Encouragingly, these 
methods yielded binding data that correlated well with restriction phenotypes. 
 
Since then, there have been numerous efforts to gain deeper structural insight into 
the T5-capsid interaction (Ganser-Pornillos et al., 2011; Goldstone et al., 2014b; 
Sanchez et al., 2014).  Collectively, these studies have given rise to a model in 
which T5 forms elongated, antiparallel dimers that self-associate into a hexameric 
lattice (Figure 1.15A); the resulting structure is geometrically complementary to the 
capsid target.  Regions of electron density within this structure reveal that the 
coiled-coils form the longitudinal axes of each dimer, while the B-box2 domains sit 
at opposing ends, where they can mediate homotypic interactions with 
neighbouring dimers.  The RING domains reside in close proximity to the B-box2 
Chapter 1: Introduction 
 
81 
 
domains, but are thought to face outside the plane of assembly, where they can 
interact with components of the ubiquitination machinery. 
 
In the T5α dimer, a hairpin turn immediately after the coiled-coil causes the 
adjacent linker 2 (L2) region to double back towards the twofold axis of the dimer, 
where it terminates in a four-helix bundle.  This structure firmly anchors the B30.2 
domains at the centre of the dimer (Figure 1.15).  Conversely, in TCyp, CypA is 
attached to the neighbouring L2 region via an unstructured linker.  This confers the 
domain with a greater degree of conformational freedom (Goldstone et al., 2014b).  
It is also noteworthy that while the B-box2 domain is indispensable for 
T5α-mediated restriction (Javanbakht et al., 2005), this is not the case for TCyp, 
indicating that there are probably gross differences in the supramolecular 
structures of these two factors (Diaz-Griffero et al., 2007). 
 
The above model was recently validated by the Sundquist group, who used 
electron microscopy to visualise native T5 proteins in complex with 
disulphide-crosslinked HIV-1 cores (Li et al., 2016c).  Interestingly, this work 
revealed a distinct lack of uniformity within the T5 lattice, with hexamers spanning 
between 15 and 55 nm in diameter.  This phenotype may have evolved to 
accommodate inherent irregularities on the capsid surface arising from different 
chemical microenvironments, in addition to the more overt deformations created by 
pentamers.  A degree of flexibility in the T5 lattice may also be instrumental in 
permitting a single orthologue to adapt to the varying curvatures of distantly related 
viruses.   
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Figure 1.15: Prevailing models for the higher- and lower-order oligomerisation of 
T5α  
(A) The positions of individual domains within the T5α lattice.  The RING and 
B-box2 domains (purple and red) are positioned at the threefold vertices, while the 
coiled-coils (green) extend to form the hexamer edges and the B30.2 domains (red 
and brown) sit at the twofold axes of each edge. (B) Side-view of a single T5α 
dimer interacting with capsid. L2-E: an extended region within linker L2. 
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Mechanisms of restriction 
 
Early models of T5-mediated restriction were largely centred on the RING domain 
and its associated E3 ubiquitin ligase activity.  A number of groups proposed that 
T5 uses this activity to co-opt the proteasome and accelerate capsid uncoating, 
thereby imposing a block to the coupled process of reverse transcription (Perron et 
al., 2007; Kim et al., 2011).  This was based on the observation that particulate 
capsids are converted to soluble capsid proteins more rapidly in cells expressing 
T5α (Diaz-Griffero et al., 2006; Stremlau et al., 2006), and that both mutational 
inactivation of the RING finger (Perez-Caballero et al., 2005) and the use of 
proteasome inhibitors (Butler et al., 2002)  can increase viral titres under usually 
restrictive conditions. 
 
While it was initially believed that CA served as the substrate for ubiquitination, 
later studies have shown that T5 undergoes autoubiquitination of several residues 
once it is bound to the viral core (Yamauchi et al., 2008).  This gave rise to a model 
where translocation of Ub-T5 through the proteasome imparts mechanical stress 
on the attached virion, causing it to disassemble.  Given the recent finding that 
RING domains function as dimers (Yudina et al., 2015), and the trimeric interface of 
RINGs at each vertex of the T5 lattice, it is feasible that this occurs via the mutual 
activation of two RING domains followed by ubiquitination of the third.  This notion 
is supported by the observation that K45 and 50 are preferentially ubiquitinated in 
the rhT5α RING domain (Fletcher et al., 2015). 
 
While proteasome inhibitors relieve the block to reverse transcription, the 
observation that virions accumulate in the cytoplasm of MG132-treated cells – 
coupled with an absence of 2-LTR circles under these conditions – point towards 
an additional pathway that is effected prior to nuclear entry  (Campbell et al., 2008; 
Wu et al., 2006).  This, combined with the recent observation that T5α can mediate 
the autophagic degradation of virions (Mandell et al., 2014a, b), suggests that T5 
orchestrates a number of different restriction pathways, only some of which are 
proteasome-dependent.  
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In addition to the direct restriction of virions, it has been shown that T5 functions as 
an innate immune sensor, thereby contributing to the establishment of an antiviral 
state.  Upon the detection of retroviral cores, T5α works with the E2 
ubiquitin-conjugating enzyme complex, UBC13-UEV1A, to catalyse the synthesis of 
K63-linked polyubiquitin chains.  These molecules activate the TAK1 complex, 
initiating a signalling cascade that culminates in the stimulation of NF-κB and AP1, 
and the resultant transcription of pro-inflammatory genes (Pertel et al., 2011; 
Lascano et al., 2016).   
 
1.4.6 T1 and T18 
T1 and 18 are paralogous members of the C-I subfamily of TRIM proteins (Meroni 
and Diez-Roux, 2005).  Like T5α, both harbour a C-terminal B30.2 domain; 
however, the presence of two additional domains upstream of this region (COS and 
FN-III) makes them almost twice as long. 
T1 and 18 map to mirrored loci on opposing arms on the X chromosome, 
suggesting that one arose from the other following an intrachromosomal duplication 
event (Perry et al., 1998; Buchner et al., 1999).  The two proteins thus share 83% 
amino acid similarity (76% identity) and conserved domain boundaries, while the 
corresponding genes have 71% nucleotide identity and conserved splice sites 
(Perry et al., 1999).   
T1 and 18 form both homo- and heterodimers via their CC motifs, a phenomenon 
that is required for their localisation to microtubules (Short et al., 2002) and is 
indispensable for function (Cainarca et al., 1999).  Both proteins have been 
implicated in stabilising and organising microtubules, as well as anchoring other 
proteins to them (Short et al., 2002; Berti et al., 2004); mutations are thus linked to 
a host of disease phenotypes, including genetic disorders of embryonic midline 
structures (Cox et al., 2000), X-linked intellectual disabilities (Geetha et al., 2014) 
and end-stage breast cancer (Wang et al., 2016). 
Although T1 and 18 are both integral to embryonic development, they have distinct 
spatiotemporal expression profiles (Buchner et al., 1999).  T1 is expressed at a low 
level during early embryogenesis, where it is confined predominantly to the central 
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nervous system and the developing heart (particularly in the ventricle walls and 
septum).  Expression of this protein increases in other organ systems – particularly 
the stomach, thyroid and kidney – later in embryogenesis.  Conversely, T18 is 
ubiquitously expressed among early embryonic tissues, but is not detectable in the 
heart.  Throughout embryogenesis, T18 is typically more abundant than T1. 
Quite apart from these studies, the Stoye group have reported that T1 – but not 
T18 – is able to restrict both wild-type N-MLV and a capsid mutant (N82D) (Yap et 
al., 2004).  This phenotype has since been reported by other groups (Uchil et al., 
2008), but at the time of writing remains poorly characterised. 
 
1.5 Aims of this project 
Although the restriction phenotype of T1 was first described more than a decade 
ago, there have been no attempts to characterise this activity since.  The main 
objectives of this thesis are thus to provide an insight into the basis of T1-mediated 
restriction (Chapter 3) and to draw comparisons between T1 and its distantly 
related cousin, T5α (Chapter 4).  Furthermore, given that these proteins diverge 
significantly in terms of their size, Chapter 5 will explore the impact of 
intramolecular domain spacing on facilitating a productive interaction with capsid.  
Each of these chapters will be prefaced with a brief introduction of their own to 
provide context to the results described therein. 
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2.1 Recombinant DNA 
2.1.1 Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) was used to amplify genes from plasmids, 
produce chimeric DNA and add tags to proteins. 
 
A typical reaction consisted of 50 ng template DNA, 500 nM of each primer (Sigma), 
200 μM dNTPs, and 2.5 U PfuUltra DNA polymerase (Agilent) in the supplied buffer, 
made up to a final volume of 50 μL with dH2O.  Cycling parameters included 
denaturation at 95°C for 2 min, followed by 25 cycles of denaturation (95°C for 
1 min), primer annealing (57°C for 2 min), and extension (72°C for 3 min), before a 
final round of extension at 72°C for 10 min.  The annealing temperature was raised 
to 60°C when using primers with a melting temperature (Tm) exceeding 65°C.   
Thermal cycling was performed using the PTC-100 thermal cycler (MJ Research).  
 
All of the primers used in this project are listed in Appendix 7.1 of this thesis. 
 
2.1.2 Overlapping PCR 
Overlapping PCR is used to stitch together two fragments of DNA to produce a 
chimeric molecule.  Briefly, each fragment is independently amplified from its 
parental construct using primers with cross-complementarity at the ends which are 
to be joined.  The two fragments are then made contiguous in a second round of 
PCR (Figure 2.1).  Standard PCR conditions (Section 2.1.1) were used for these 
reactions. 
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Figure 2.1: Overlapping PCR 
Fragments from two constructs (A and B) are amplified using primer pairs P1-P2 
and P3-P4, respectively.  P2 and P3 have 5’ ends that are complementary to the 
opposing template, enabling the fragments to anneal in the centre following the first 
round of PCR.  Amplification of the resulting product with P1-P4 then yields a 
contiguous chimera. 
 
2.1.3 Site-directed mutagenesis 
Quikchange site-directed mutagenesis (Agilent) was used to introduce point 
mutations, insertions and deletions to a DNA template.  A typical reaction consisted 
of 10 ng of template DNA, 125 ng of each primer (Sigma), 200 μM dNTPs, and 
2.5 U PfuUltra DNA polymerase (Agilent) in the supplied buffer, made up to a final 
volume of 50 μL with dH2O.  Cycling parameters included an initial denaturation 
phase (95°C for 30 s), followed by 18 cycles of denaturation (95°C for 30 sec), 
primer annealing (55°C for 30 sec), and extension (68°C for 1 min per kb DNA).  
The reaction was then chilled at 4°C for 10 min.  Thermal cycling was performed 
using the PTC-100 thermal cycler (MJ Research).   
 
Following mutagenesis, the reaction was incubated with 20 U DpnI (NEB) at 37°C 
for 1.5 h.  DpnI selectively digests methylated DNA, thereby removing any template 
material and leaving the mutant behind.  After DpnI digestion, the remaining DNA 
was concentrated by ethanol precipitation (Section 2.1.10) and transformed into 
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XL10-Gold ultracompetent E. coli (Agilent) that had been pre-treated with 
β-mercaptoethanol (4 μL per 50 μL cells). 
 
2.1.4 Restriction digestion 
DNA was digested with restriction enzymes for the purposes of screening PCR 
clones and providing sticky ends for insert-vector ligation (Section 2.1.12).   
 
A typical 20 μL reaction consisted of up to 1.5 μg DNA and 1 U of restriction 
enzyme in the supplied buffer (NEB; Roche).  If performing a double-digest, then 
0.5 U of each enzyme was used in a buffer compatible with both.  Reactions were 
incubated at 37°C with gentle agitation for 1-3 h.  The digested fragments were 
then resolved by electrophoresis in a 0.8% (w/v) agarose gel (Section 2.1.5).  If 
required for downstream PCR or ligation reactions, the desired bands were excised 
and purified from the gel (Section 2.1.6). 
 
2.1.5 Agarose gel electrophoresis 
DNA fragments were separated by size using agarose gel electrophoresis.  
Agarose gels were made by dissolving 0.8-1.2% (w/v) agarose (Melford) in TBE 
Buffer (0.09 M Tris-HCl, 0.09 M borate, 2 mM EDTA) and adding SYBR Safe DNA 
stain (Invitrogen) at a final concentration of 1:2000.   
 
DNA samples were mixed with 10x loading buffer (0.25% bromophenol blue, 0.25% 
xylene cyanol FF, 30% glycerol) and loaded next to a ladder of DNA size markers 
(SmartLadder, Eurogentec).  Gels were run at 120 V for 30 min and then visualised 
using the Doc-It transilluminator (UVP). 
 
2.1.6 Extraction of DNA from agarose gels 
When DNA fragments were required for overlapping PCR or DNA ligation, they 
were first resolved by agarose gel electrophoresis (Section 2.1.5) and then 
extracted from the gel by placing it on a UV transilluminator and excising the 
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relevant band(s) with a scalpel.  The excised bands were dissolved in Buffer QG 
(Qiagen) at 60°C for 10 min with vigorous shaking.  Agarose and other 
contaminants were then removed using the MinElute Gel Extraction Kit (Qiagen), 
and the DNA was eluted in 10 μL of the supplied elution buffer. 
 
2.1.7 Gateway cloning 
The Gateway cloning system (Life Technologies) is a protocol that dispenses with 
the traditional cut-and-paste method for cloning DNA, instead relying on 
enzyme-directed recombination between proprietary recombination sequences.  In 
this project, the Gateway system was used to clone restriction factor genes into 
various destination vectors.   
 
The LxIY expression vector was the most frequently used (Figure 2.2), where L 
represents the LTR promoter that drives constitutive expression of the insert, x 
represents the insert, I represents the internal ribosome entry site (IRES), and Y 
represents the eYFP reporter gene.  When inducible expression of the restriction 
factor was required, an alternative vector system was used (see Section 2.2.7).  
 
 
Figure 2.2: The LxIY vector used for restriction factor expression 
 
Before putting a PCR product into the appropriate destination vector, it was first 
cloned into an entry vector by either BP recombination or directional TOPO cloning.  
In the former protocol, the PCR product is synthesised using modified primers that 
append attB sites to either end, facilitating enzyme-directed recombination between 
the attB-flanked PCR product and a supplied entry vector (pDONR221).  In the 
latter, the tetranucleotide CACC is appended to the 5’ end of a blunt-end PCR 
product to enable directional recombination into the pENTR-D-TOPO entry vector.  
This tetranucleotide has the additional benefit of embedding the start codon within 
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a Kozak sequence, thereby enhancing the translational efficiency of the gene 
(Kozak, 1987).  In both cases, successful entry clones were identified by selection 
with kanamycin and sequencing with the M13 forward and reverse primers (GATC 
Biotech).  These reactions are depicted graphically in Figure 2.3.  
 
 
Figure 2.3: BP recombination and the TOPO reaction are used to clone PCR 
products into the entry vector 
 
Both of the above reactions embed the PCR product between attL1 and attL2 sites.  
Because destination vectors carry complementary attR1 and attR2 sites, the PCR 
product can then be transferred from entry to destination vector via the LR 
recombination reaction (Figure 2.4).  Prior to LR recombination, the destination 
vector carries a suicide gene (ccdB) flanked by attR sites.  The recombination 
reaction substitutes the desired insert into the destination vector, while transferring 
the suicide gene to the entry vector.  The resulting expression clone can then be 
acquired by selection with ampicillin, while the suicide gene ensures removal of the 
entry clone. 
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Figure 2.4: The LR reaction is used to transfer a PCR product from the entry 
vector to an appropriate destination vector 
 
2.1.8 Transformation 
Transformation was used to propagate plasmid DNA for various downstream 
applications, including screening PCR clones and transfecting mammalian cells.  
The bacteria used for most applications were One Shot TOP10 E. coli (Invitrogen), 
although XL-10 Gold ultracompetent cells (Agilent) were used to transform DNA 
from mutagenesis reactions (Section 2.1.3), and Rosetta 2 DE3 competent cells 
(Novagen) were used to transform DNA for large-scale protein expression and 
purification (Section 2.4.1). 
 
Briefly, cells were defrosted in pre-chilled tubes and DNA was added at a volume 
not exceeding one-tenth that of the cells.  This mixture was left on ice for 30 min, 
heat-shocked at 42°C for 30 s, and then immediately returned to ice for 2 min to 
enable cell recovery.  250 μL SOC media (2% w/v tryptone, 0.5% w/v yeast extract, 
8.55 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM glucose) was added to the cells, 
before incubation at 37°C for 1 h with agitation (225 rpm).  20-100 μL of the 
outgrowth was then plated on LB-agar supplemented with the appropriate 
antibiotic(s) (see Table 2.1), before incubating at 37°C overnight. 
 
Antibiotic(s) Solvent Final concentration  Source 
Ampicillin-
Nafcillin 
Water 50 μg/ml each   Sigma 
Chloramphenicol Ethanol 25 μg/ml  Sigma 
Kanamycin Water 50 μg/ml  Sigma 
Streptomycin Water 50 μg/ml  Sigma 
Table 2.1: List of antibiotics used for the selection of transformants 
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2.1.9 Propagation and purification of plasmid DNA 
Following overnight incubation, a single colony was picked from a plate of 
transformants and added to 3 mL LB (1% tryptone, 0.5% yeast extract, 1% NaCl, 
pH 7) supplemented with the appropriate antibiotic(s), before a second overnight 
incubation at 37°C with agitation (225 rpm).   
 
If screening PCR clones, 2 mL of the overnight culture was pelleted at 13,000xg for 
3 min, and plasmid DNA was purified using the QIAprep Spin Miniprep Kit (Qiagen) 
according to the manufacturer’s instructions.  Clones were then screened by 
restriction digestion and agarose gel electrophoresis of the digested fragments.   
 
For larger scale production of plasmid DNA, 1 mL of the initial outgrowth was 
added to 35 mL LB supplemented with the appropriate antibiotic(s) and grown 
overnight once more at 37°C with agitation (225 rpm).  The cells were then pelleted 
at 4,000xg for 20 min and plasmid DNA was purified using the HiSpeed Plasmid 
Midi Kit (Qiagen). 
 
2.1.10 Concentration of DNA by ethanol precipitation 
DNA was concentrated by adding 0.1 volumes sodium acetate and 2.5 volumes 
100% ethanol and chilling the mixture at -80°C for 30 min.  The cooled mixture was 
then centrifuged at 18,000xg and 4°C for 15 min, and the supernatant replaced with 
500 μL 70% ethanol.  This mixture was centrifuged a second time under the same 
conditions, before removing the supernatant, air-drying the pellet for 5 min, and 
then resuspending it in 5 μL dH2O. Concentrated DNA was either stored at -20°C 
or immediately transformed into bacteria. 
 
2.1.11 Quantitation of DNA by spectrophotometry 
DNA was quantified by absorbance at 260 nm using a NanoDrop 2000 UV 
spectrophotometer. 
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2.1.12 DNA ligation 
Large-scale protein expression required the ligation of DNA into an appropriate 
expression vector, pET-47b (Novagen).  To achieve this, both insert and vector 
were digested with HindIII and XhoI in the appropriate reaction buffer.  The 
digested fragments were then resolved by electrophoresis on a 1% (w/v) agarose 
gel, and the relevant bands excised and purified (Section 2.1.6).  The volumes of 
insert and vector to use in the ligation reaction were calculated using the equation 
below, ensuring a minimum of 40 ng vector and an insert-to-vector ratio of ~8-10: 
 
 
 
The appropriate volumes of insert and vector were incubated with 1 μL T4 DNA 
ligase (NEB) in the supplied reaction buffer for 3 h at room temperature.  The entire 
reaction was then transformed into One Shot TOP10 E. coli cells (Invitrogen), and 
the transformants plated on LB-agar supplemented with kanamycin.  All ligation 
products were sequence-verified using the T7 forward and reverse sequencing 
primers (GATC Biotech). 
 
2.1.13 DNA sequencing 
DNA samples were shipped to GATC Biotech for overnight single-pass sequencing.  
All samples were diluted to 100 ng/μL in dH2O before shipping, and sequencing 
primers supplied at 10 μM.  The resulting chromatograms were analysed on 
SeqMan Pro (Lasergene) for sequence verification. 
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2.2 Cell culture & the restriction assay 
2.2.1 Maintenance of cell lines 
Human embryonic kidney (293T) cells and Mus dunni tail fibroblasts (MDTF) were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies) 
supplemented with 10% foetal calf serum (FCS), 100 U/mL penicillin and 
100 μg/mL streptomycin.  Cells were maintained at 37°C under conditions of 95% 
humidity and 5% CO2, and passaged at a ratio of 1:10 every 3-4 days by adding 
1 mL trypsin-versene (0.05% w/v trypsin and 0.53 mM EDTA in PBS) to the 
monolayer and resuspending the detached cells in 9 mL fresh DMEM.  
 
2.2.2 Overview of the restriction assay 
Restriction was measured using an established two-colour flow cytometry assay 
(Bock et al., 2000).  Briefly, a vector carrying a restriction factor construct and an 
eYFP reporter was co-transfected into 293T cells with plasmids encoding the viral 
Gag, Pol and Env genes (Section 2.2.3).  This yielded ‘delivery viruses’ which could 
be used to transduce MDTF cells (Section 2.2.5).   
 
In parallel, ‘tester viruses’ – those viruses whose restriction was being measured – 
were generated by co-transfecting the appropriate gag, pol and env genes with an 
eGFP reporter construct.  These viruses were used to infect MDTF cells 48 h after 
transduction with the restriction factor construct (Section 2.2.6).  Restriction of the 
tester virus by the transduced construct was then measured 48 h post-infection by 
flow cytometry (Section 2.3.3).  This entire process is depicted graphically in Figure 
2.5. 
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Figure 2.5: The two-colour restriction assay 
 
2.2.3 Virus production by transient transfection 
293T cells in the log phase of growth were seeded in 6 cm dishes (Nunc) at a 
density of 2 x 106 cells per dish and left overnight to adhere.  The media was then 
replaced with 5.5 mL fresh DMEM, and the cells returned to incubation for at least 
4 h prior to transfection.  DNA was introduced to the cells by lipofection using 
TurboFect (Stratagene), according to the manufacturers’ instructions.  Briefly, equal 
masses of three plasmids (6 μg total DNA; see Section 2.2.4 for a description of the 
transfected constructs) were incubated with 600 μL serum-free DMEM and 12 μL 
TurboFect at room temperature for 20 min.  The mixes were than added to the cells 
dropwise, and the cells returned to incubation overnight. 
 
Approximately 15 h post-transfection, cells were stimulated with 5 mL fresh DMEM 
containing 10 mM sodium butyrate.  Sodium butyrate enhances transcription by 
acting as a histone deacetylase inhibitor (Candido et al., 1978), thereby increasing 
viral titres.  After 6 h, the media was replaced with 2.5 mL regular DMEM and the 
cells left to grow overnight.  The next morning, viruses were harvested by drawing 
off the media with a 5 mL syringe (BD Plastipak) and passing it through a 0.45 
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micron filter (Sartorius) to remove cells and debris.  The filtrate was divided into 
250 μL aliquots, frozen at -80°C for at least 2 h, and then titrated on MDTF cells to 
determine the volume of virus required to give an MOI ≈ 0.7. 
 
2.2.4 Plasmids used for virus production by transient transfection 
As described in Section 2.2.3, viruses were produced by transiently co-transfecting 
a total of 6 μg DNA.  This was split equally between three plasmids when producing 
MLVs and lentiviruses, and between two plasmids when producing foamy viruses.  
Table 2.2 shows a list of the plasmids used to produce each type of virus.  Note 
that all MLVs and lentiviruses were pseudotyped with VSVg Env.  This both 
broadens the viral tropism, thereby permitting infection of any cell type, and 
standardises viral entry so that any restriction data obtained can be attributed 
purely to post-entry events.  All foamy viruses were pseudotyped with SFV Env. 
 
 
 
Plasmid function 
 Gag-Pol Env Reporter 
Tester 
viruses 
G
a
m
m
a
 B-MLV pCIG3 B pVSVg pIRES2-EGFP 
N-MLV pCIG3 N pVSVg pIRES2-EGFP 
NB-MLV pHit60 pVSVg pIRES2-EGFP 
L
e
n
ti
 
HIV-1 p8.91 pVSVg pCSGW 
HIV-2 pHIV2GagPol pVSVg pHIV2gfp 
FIV pFP93 pVSVg pGiNWF 
F
o
a
m
y
 
PFV POO1 
pciSFV-
1Envwt 
eGFP reporter is 
present in the Gag-
Pol vector 
SFV SOO1 
pciSFV-
1Envwt 
FFV FOO3 
pciSFV-
1Envwt 
 
Delivery viruses 
 
pHit60 
 
pVSVg 
Expression vector 
with RF and eYFP 
reporter 
Table 2.2: Plasmids used in the transient transfection of 293T cells to produce 
retroviruses 
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2.2.5 Transduction of MDTF cells 
MDTF cells were seeded in 12-well plates (Corning) at a density of 5 x 104 
cells/well and left to adhere overnight.  Approximately 24 h after seeding, the cells 
were transduced with delivery virus at an MOI ≈ 0.7 and returned to incubation for 
48 h.   
 
2.2.6 Infection of transduced MDTF cells 
48 h post-transduction, MDTF cells were re-seeded in multiple wells at a density of 
5 x 104 cells/well, and then infected in duplicate with the appropriate tester virus 
(MOI ≈ 0.7).  After a further 48 h, the cells were harvested, pelleted and fixed for 
analysis by flow cytometry.  A full description of the preparation of samples for flow 
cytometry, and the acquisition and analysis of flow cytometry data, can be found in 
Section 2.3. 
 
2.2.7 Regulation of restriction factor expression by doxycycline induction 
To measure the relationship between the expression level of a restriction factor and 
the potency of restriction, C-terminally HA-tagged constructs were cloned into 
expression vectors with doxycycline-inducible promoters.   
 
2.2.7.1 Development of a doxycycline-inducible vector system 
Tet-On 3G is the third generation in a series of expression systems with 
doxycycline-inducible transcription.  In contrast to the former Tet-On and Tet-On 
Advanced systems, Tet-On 3G uses the PTRE3G promoter, which has a lower basal 
level of transcription (Loew, 2009), and the rtTA3 trans-activator, which has 
increased sensitivity to doxycycline (Zhou et al., 2006).  These two features 
combine to minimise transcriptional leakiness while maximising the level of 
induction. 
 
A former student in the Stoye lab generated an MDTF cell line constitutively 
expressing rtTA3 by stable transfection (‘R18 cells’ herein).  Retroviral vectors were 
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also produced, carrying both the PTRE3G promoter and attR sequences for Gateway 
cloning of restriction factor genes from their entry vectors (Section 2.1.7).   
 
Only two dox-inducible vectors were used in this project, denoted CS14 and CS15.  
In both vectors, the eYFP gene is placed furthest upstream in order to maximise 
reporter expression via cap-dependent translation.  The restriction factor construct 
was then placed downstream, either following an IRES (CS14), or directly after 
eYFP without any intervening IRES (CS15).  In the latter case, restriction factor 
translation can only occur via leaky ribosome scanning; thus CS15 provides a 
lower range of expression than does CS14.  The structure of both inducible vectors, 
as well as the non-inducible vector used in all other restriction experiments (Bock et 
al., 2000), is shown in Figure 2.6.  A more thorough account of the design and 
generation of these vectors can be found in Li et al. (2016b).  All of the protocols 
described herein are adapted from that work. 
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Figure 2.6:  The non-inducible and doxycycline-inducible vectors used for 
restriction factor expression  
The non-inducible vector LxIY was used to express restriction factor (RF) 
constructs in the vast majority of experiments described in this thesis.  In this 
vector, transcription is initiated from the U3 promoter, and the upstream position of 
the RF construct relative to eYFP ensures its overexpression.  However, when it 
was necessary to control the amount of restriction factor present in the cell, a CS14 
or CS15 vector was used instead: in these vectors, the U3 promoter is deleted to 
permit transcription from a TRE3G element, and the RF construct is placed 
downstream of the reporter in order to limit its expression. 
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2.2.7.2 Measuring restriction by restriction factors under doxycycline-
inducible expression 
R18 cells were seeded in 12-well plates (Corning) at a density of 5 x 104 cells/well 
and left overnight to adhere.  24 h after seeding, the cells were transduced with 
delivery virus (MOI ≈ 0.7) carrying a restriction factor construct in either a non- or 
dox-inducible vector.   
 
At least 48 h post-transduction, the cells were reseeded into 24-well plates 
(Corning) at a density of 2.5 x 104 cells/well.  Those cells transduced with a 
non-inducible construct were reseeded in regular DMEM, while those transduced 
with a dox-inducible construct were re-seeded in DMEM containing the appropriate 
concentration of doxycycline.  Approximately 24 h after re-seeding, the cells were 
infected with a tester virus (MOI ≈ 0.7) and, after a further 24 h, 5 μg doxycycline 
was added to boost reporter expression.  Cells were harvested for flow cytometry 
between 24 and 48 h after the second exposure to doxycycline. 
 
Restriction factor expression was quantified in parallel to the restriction assay by 
performing a western blot using a primary antibody against the C-terminal HA tag 
of the protein (Section 2.4.10). 
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2.3 Flow cytometry 
2.3.1 Preparation of samples for flow cytometry 
Confluent MDTF cells were detached by adding 1 mL trypsin-versene and 
incubating at 37°C for 10 min.  Once detached, the cells were fixed by 
resuspending in 3 mL 2% formaldehyde-PBS that had been pre-aliquoted into 5 mL 
round-bottom tubes (Corning).  The cells were then pelleted at 400xg for 10 min 
and the pellet resuspended in 150 μL regular PBS, before filtering through a 35 μm 
nylon mesh (Corning) to remove clumped cells and debris. 
 
2.3.2 Acquisition of data by flow cytometry 
All flow cytometry was performed using the FACSVerse flow cytometer and 
associated software (BD Biosciences).  Live cells were gated according to their 
forward-scatter versus side-scatter profile.  Untransduced and single-colour 
controls were then used to gate GFP-YFP-, GFP+YFP-, GFP-YFP+ and GFP+YFP+ 
populations within the live cell population.  Because GFP and YFP have 
overlapping emission spectra, a compensation matrix was employed to account for 
detection spillover.  10,000 cells were acquired for each experimental sample and 
the data outputted to FlowJo (Tree Star) for post-acquisition analysis. 
 
2.3.3 Calculation of restriction from flow cytometry data 
FlowJo was used to count the number of cells in each of the four live-cell 
populations: GFP-YFP-, GFP+YFP-, GFP-YFP+ and GFP+YFP+.  These numbers 
were then exported to Microsoft Excel and plugged into the formula below to 
calculate the restriction ratio: 
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This formula represents a ratio of the percentage of infected (GFP+) cells in 
populations expressing restriction factor (YFP+) versus those not (YFP-). 
 
Values ≤0.3 were taken as restriction, ≥0.7 as absence of restriction, and 
intermediate values as partial restriction. 
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2.4 Protein expression, purification and analysis 
2.4.1 Expression and harvesting of protein from E. coli  
One colony was picked from the plate of transformants and grown in 100 mL terrific 
broth (12 g tryptone, 24 g yeast extract, 4 mL glycerol, 100 mL 0.17 M KH2PO4 plus 
0.72 M K2HPO4) supplemented with kanamycin and chloramphenicol.  The 
following day, large-scale cultures were made by transferring 7.5 mL of overnight 
culture to 750 mL fresh TB with kanamycin and chloramphenicol.  These cultures 
were grown in 2 L flasks at 37°C with moderate agitation (180 rpm), until they 
reached an average optical density (OD) of 0.6.  At this point, the temperature was 
reduced to 20°C, and 1 mM IPTG added to induce protein expression.  The 
cultures were then left to grow overnight. 
 
The following morning, the bacteria were pelleted at 4000xg (4°C for 30 min).  The 
supernatant was decanted and the pellet weighed and resuspended in 7 mL lysis 
buffer (50 mM Tris pH8, 750 mM NaCl, 20 mM imidazole, 5 mM MgCl2, 5 mM ATP, 
0.5 mM TCEP, 0.2% v/v Triton) per gram of cells, by stirring at 4°C until 
homogenised.  The lysate was sonicated for 10 min (power output 4, duty cycle 
40%), and then pelleted at 56,000xg and 4°C for 1 hour.  The supernatant was then 
filtered in preparation for affinity purification. 
 
2.4.2 Protein purification by affinity to a nickel column 
Following filtration, bacterial lysate was placed on a nickel (Ni2+) column for affinity 
purification via the N-terminal His6 tag.  100 column volumes were loaded to enable 
binding, and then the column was washed in an equivalent volume of Buffer A 
(50 mM Tris pH8.0, 500 mM NaCl, 20 mM imidazole, 0.5 mM TCEP) in order to 
remove unbound species.  Upon completing the wash step, Buffer B (Buffer A + 
300 mM imidazole) was used to elute the bound protein. The increased 
concentration of imidazole in Buffer B outcompetes His6 for binding to the column, 
enabling any nickel-bound species to be displaced and eluted. 
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2.4.3 Protein purification by ion exchange chromatography 
To remove any contaminating species after affinity purification, the eluate from the 
nickel column was subjected to a second round of purification by ion exchange 
chromatography.   
 
Briefly, the concentration of salt in the eluate from the nickel column was reduced 
to 50 mM NaCl by diluting with Buffer C (50 mM Tris pH8.0, 0.5 mM TCEP), before 
loading onto a 55 mL Source Q anion exchange column which had been 
equilibrated in Buffer D (Buffer C + 50 mM NaCl).  A linear gradient was used from 
50 mM to 1 M NaCl over 10 column volumes, and the eluate collected in 10 mL 
fractions. 
 
2.4.4 Protein purification by size exclusion chromatography 
Following ion exchange chromatography, a final round of purification was 
performed by pooling and concentrating the relevant fractions, and then loading 
them onto an S200 16/60 size-exclusion column (GE Life Sciences) for gel filtration.  
The column was run with a flow rate of 0.3 mL min-1 and the protein collected in 
elution buffer (20 mM Tris pH8.0, 150 mM NaCl, 0.5 mM TCEP).   
 
2.4.5 Expression and harvesting of protein from mammalian cells 
To determine the protein expression levels for various restriction factor constructs, 
either MDTF cells (for non-inducible vectors) or R18 cells (for inducible vectors) 
were seeded at 5 x 104 cells/well in a 12-well plate.  A delivery virus containing the 
relevant construct was then used to transduce the cells with an MOI ≈ 0.7.  The 
transduced were left to grow for 48 h, before reseeding in T20 flasks (Thermo 
Scientific) at 1:5 dilution.  After a further 48 h, the cells were transferred to a T80 
flask and left to grow for a further 24 h. 
 
Upon reaching approximately 70% confluence, the cells were trypsinised, 
resuspended in DMEM and centrifuged at 300xg for 15 min to obtain a cell pellet.  
The pellet was resuspended in 1 mL PBS and centrifuged again at 300xg for 5 min.  
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The supernatant was then aspirated, and the pellet resuspended in RIPA buffer 
(150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 
50 mM Tris, pH 8.0; Sigma) with 1 protease inhibitor tablet added per 10 mL buffer. 
  
The resuspension was incubated at 4°C for >30 min to allow complete lysis of the 
cells.  The lysates were then centrifuged at 18,000xg for 10 min to separate the 
protein-containing supernatant from the cell debris.  Finally, the supernatant was 
removed and diluted in RIPA buffer (1:5) ready for quantitation by the BCA assay 
(Section 2.4.7).   
 
2.4.6 Quantitation of total protein by spectrophotometry 
Protein was quantified by absorbance at 280 nm using a NanoDrop 2000 UV 
spectrophotometer. 
 
2.4.7 Quantitation of total protein using the BCA assay 
Given the presence of detergent in RIPA buffer, total protein concentration in cell 
lysates was determined using the bicinchoninic acid (BCA) assay rather than the 
Bradford assay.  Briefly, 5 μL of each lysate sample (diluted 1:5) was added to 
separate wells of a 96-well plate (BD Falcon) alongside standards of known 
concentration (2000, 1000, 500, 250, 125, 62.5, 31.25 and 0 μg/mL).  200 μL of 
prepared BCA reagent (Thermo Fisher) was then added to all of the wells, before 
shaking for 30 s and incubating at 37°C for 30 min.  Following incubation, 
absorbance at 562 nm was measured using the Synergy 2 plate reader and 
associated software (Gen5).  A curve of standards was produced, and total protein 
concentration in the lysates was interpolated from the curve. 
 
2.4.8 Separation of proteins by SDS-PAGE 
Proteins were separated by size using a 4-20% Mini-Protean TGX Precast Gel 
(Bio-Rad).  Briefly, samples were mixed with dH2O and 5x SDS loading buffer 
(250 mM Tris-HCl pH6.8, 10% SDS, 12.5% β-mercaptoethanol, 0.1% w/v 
Chapter 2: Materials and Methods 
 
107 
 
bromophenol blue, 50% glycerol) to achieve a final concentration of 1 mg/mL. The 
samples were then boiled at 95°C for 5 min to remove any higher-order structures 
that might interfere with migration through the gel.  Approximately 10-30 μg of cell 
lysate or 10-100 ng of purified protein was loaded in each well, alongside a 
pre-stained protein ladder (PageRuler, Thermo Scientific).  Gels were run at 100 V 
for 50-70 min, depending on the size of the target protein, and then either stained 
with Coomassie Brilliant Blue (Sigma) for immediate visualisation, or transferred to 
a PVDF membrane for western blotting (Section 2.4.9). 
 
2.4.9 Electro-transfer to a PVDF membrane 
If using an SDS gel for western blotting, the proteins were first transferred to an 
Immobilon-FL PVDF membrane (Thermo Scientific) in SDS-free transfer buffer 
(5.8 g Tris, 2.9 g glycine, 200 mL methanol, 800 mL ddH2O) at 20 V for 90 min.  
The membrane was then blocked in 1:1 PBS and Odyssey blocking buffer 
(LI-COR) for either 1 h at room temperature, or overnight at 4°C. 
 
2.4.10 Western blotting by infrared detection 
To enable the precise quantitation of a protein band, an infrared detection system 
was used in place of chemiluminescence. 
 
Briefly, a blocked membrane was incubated with primary antibody diluted in 
Odyssey blocking buffer (LI-COR) supplemented with 0.2% Tween-20 for 1-3 h at 
room temperature, or overnight at 4°C.  The membrane was then washed in PBS 
supplemented with 0.1% tween (PBS-T) for 4 rounds of 5 min with gentle agitation.  
Next, the membrane was incubated for 1 h at room temperature with the 
appropriate secondary antibody, diluted in the same buffer as the primary but with 
the addition of 0.01% SDS to reduce non-specific binding.  The membrane was 
then washed 4 times in PBS-T as before.  A list of primary and secondary 
antibodies used in this project can be found in Table 2.3: List of antibodies used for 
western blots 
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Antibody Source Company Dilution 
Anti-HA Rabbit polyclonal Santa Cruz, Y-11, sc805 1:200 
Anti-GAPDH Rabbit monoclonal Cell Signalling, 14C10, #2118 1:2000 
Anti-rabbit-800 
Goat polyclonal 
IRDye 800CW 
conjugated 
LI-COR, #926-32211 1:10,000 
Table 2.3: List of antibodies used for western blots 
 
Because the secondary antibody used in this system is conjugated to an infrared 
dye, the membrane can be visualised using the 700 and 800 nm channels of a 
high-resolution infrared scanner (LI-COR).  This method achieves more accurate 
quantitation than chemiluminescent detection because of its greater sensitivity and 
the improved linearity between signal intensity and amount of protein.  Quantitation 
was performed by normalisation to a loading control using the Image Studio Lite 
software (LI-COR). 
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T5α has been extensively characterised since its first identification as a restriction 
factor, more than ten years ago (Stremlau et al., 2004).  However, this molecule is 
far from the only TRIM family member to exhibit such a phenotype.  In fact, at least 
19 others have been shown to restrict divergent retroviruses at distinct stages in 
their lifecycles (Uchil et al., 2008). 
 
T1 is one such factor.  Its ability to inhibit N-MLV replication was first identified by 
the Stoye group (Yap et al., 2004, 2005), but this observation has not been 
characterised since.  The aim of this chapter is thus to offer an in-depth analysis of 
the T1 restriction phenotype.  
 
3.1 Murine T1 restricts N-MLV comparably to its primate 
orthologues 
Previous work has shown that both human (hu) and African green monkey (agm) 
T1 are able to restrict N-MLV  (Yap et al., 2004; 2005).  However, prior to this work, 
it was not known whether this phenotype is shared by T1 orthologues of 
non-primate origin. To investigate this possibility, a cDNA expressing murine (m) 
T1 (Source Bioscience) was cloned into the LxIY expression vector and its 
restriction activity measured via the two-colour assay.  When challenged with 
B- and N-MLV, mT1 restricted the latter but not the former (Figure 3.1).  This 
phenotype is reminiscent of that already described for the primate variants, 
confirming that the restriction activity of T1 indeed extends to other mammals. 
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Figure 3.1: Restriction of N-MLV by the African green monkey (agm), human and 
murine orthologues of T1 
Graph shows the mean and SEM from three independent experiments (n = 6). 
 
 
3.2 T1 restricts a limited panel of retroviruses 
It is well established that T5α contains signatures of positive selection, and is 
correspondingly able to restrict divergent retroviruses (Sawyer et al., 2005; 
Johnson and Sawyer, 2009). To investigate whether T1 has a similarly broad target 
range, the restriction of a panel of lentiviruses (Figure 3.2) and foamy viruses 
(Figure 3.3) by two isoforms of agmT1 (T1L and T1S) was examined via the 
two-colour assay.  However, none of these viruses were restricted by either isoform, 
limiting the panel of known targets for T1 to N-MLV alone. 
 
One explanation for this limited target range might be the integral role that T1 plays 
in the development of embryonic midline structures.  Given the biologically 
fundamental nature of this process, it’s highly likely that the T1 gene has been 
subjected to negative selection over the course of its evolution.  This would 
promote sequence conservation at the protein level, in stark contrast to the 
extensive diversification seen among T5α orthologues. 
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Figure 3.2: T1 is unable to restrict a panel of lentiviruses 
Graphs show the restriction ratios obtained by challenging T1L and S from the 
African green monkey (Chlorocebus aethiops) with three lentiviruses: HIV-1, HIV-2 
and FIV.  N-MLV is included as a positive control (top left), and rhesus T5α (rhT5a), 
brown capuchin T5α (bcT5a) and cotton top tamarin T5α (cttT5a) are included as 
restriction factor controls.  Red bars denote full restriction (ratio < 0.3), grey bars, 
partial restriction (ratio 0.3-0.7) and black bars, absence of restriction (ratio > 0.7).  
Graph for N-MLV shows the mean and SEM from four (rhT5a, T1L, T1S) or three 
(bcT5a, cttT5a) independent experiments (n = 8 and 6, respectively). Graphs for 
the lentiviruses show the mean and SEM from three (rhT5a, T1L, T1S) or two 
(bcT5a, cttT5a) independent experiments (n = 6 and 4, respectively). 
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Figure 3.3: T1 is unable to restrict a panel of foamy viruses 
Graphs show the restriction ratios obtained by challenging T1L and S from the 
African green monkey (Chlorocebus aethiops) with three foamy viruses: PFV, SFV 
and FFV.  N-MLV is included as a positive control (top left), and rhesus T5α 
(rhT5a), brown capuchin T5α (bcT5a) and cotton top tamarin T5α (cttT5a) are 
included as restriction factor controls.  Red bars denote full restriction (ratio < 0.3), 
grey bars, partial restriction (ratio 0.3-0.7) and black bars, absence of restriction 
(ratio > 0.7).  Graph for N-MLV shows the mean and SEM from four (rhT5a, T1L, 
T1S) or three (bcT5a, cttT5a) independent experiments (n = 8 and 6, respectively). 
Graphs for the foamy viruses show the mean and SEM from four (PFV) or three 
(SFV, FFV) independent experiments (n = 8 and 7, respectively). 
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To determine whether T1 is indeed constrained by negative selection, an alignment 
of T1 cDNAs from a host of mammals (Table 3.1) was generated using PAML 4.8 
(Yang, 2007) (Error! Reference source not found.). To avoid false positives, a 90 
bp region present in certain splice variants was omitted from this analysis. 
 
Primates 
Human 
Chimpanzee 
Gorilla 
Orangutan 
Gibbon 
Rhesus macaque 
Baboon 
African green monkey 
Rodents 
Mouse  
Rat 
Kangaroo rat 
Guinea pig 
Squirrel 
Table 3.1: T1 orthologues used to construct a phylogenetic tree 
 
The selective pressures acting on a gene can be measured by calculating values 
for ω across all the sites in its DNA sequence, where ω equals the ratio of 
non-synonymous to synonymous substitutions at a particular site (dN/dS).  ω ≤ 1 is 
indicative of negative selection, while ω > 1 indicates positive selection.  Codeml 
was used to conduct this analysis, with the help of Dr George Young (Figure 3.5).  
 
Briefly, ω values were calculated and then pairs of models – one allowing and the 
other disallowing positive selection – were applied to the values obtained.  The 
models’ relative fits, as likelihood ratio tests, were then compared using a χ2 test 
(degrees of freedom = 2).  The model pairs M2a vs M1a and M8 vs M7 were 
compared in this way, and each comparison performed using two methods of 
codon frequency calculation (F3x4 and F61).  None of the alternative models 
provided a better fit to the data than the null hypothesis (p ≥ 0.584 across all tests), 
confirming that T1 is indeed highly conserved at the protein level. This might 
explain the limited ability of the molecule to recognise divergent retroviruses.   
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Figure 3.4: Phylogenetic tree of T1 DNA sequences 
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Figure 3.5: Workflow for measuring positive selection in T1 
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3.3 The short isoform of T1 restricts N-MLV more potently than 
the long 
The T1 gene undergoes alternative splicing to produce several transcripts, two of 
which encode proteins with a B30.2 domain.  Due to an alternative splice donor site 
in the middle of exon 7, these isoforms differ exclusively in the length of their FN-III 
domains, with the longer one (T1L) possessing 30 amino acids in the centre of the 
domain (residues 430-459) that are lacking in the short (T1S) (Figure 3.6).  T18 
also undergoes alternative splicing, although its longest isoform has an FN-III 
domain of equivalent length to that of T1S.  
 
 
 
Figure 3.6: The intron-exon structures of agmT1L/S  
 
 
At the start of this project, cDNAs for both agm isoforms were available in the lab, 
but only the short cDNAs were available for the human and mouse variants.  Thus, 
long isoforms were produced for each of these orthologues by overlapping PCR, 
using the short cDNAs as templates, and a pair of internal primers with portions of 
the missing sequence appended to their 5’ ends. 
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All six constructs were then cloned into the LxIY expression vector and their 
restriction activity measured via the two-colour assay.  Figure 3.7 shows the FACS 
plots from a typical experiment.  The plots clearly depict a more potent restriction of 
N-MLV by the short isoform than the long in all three cases.  This observation was 
highly reproducible, reaching statistical significance for each orthologue tested 
(Figure 3.8A).  Again, B-MLV was not restricted in any case and served as a 
negative control in these experiments (Figure 3.8B).  
 
The FN-III domain is a protein-protein interaction module of about 100 amino acids 
(in T1S).  It possesses a hydrophobic β-sandwich core, with flexible loops that 
protrude from either side to form the interaction surfaces.  The domain is present in 
a range of animal proteins and shows remarkable evolutionary conservation at the 
structural level (Marino-Buslje et al., 1998).  Since protein-protein interactions are 
pivotal for a number of biochemical phenomena, there are numerous mechanisms 
that might explain the relationship between the length of the FN-III domain and 
restriction activity. 
 
To investigate whether this phenotype is the result of differences in protein 
expression, a C-terminal HA tag was appended to each of the agm isoforms to 
enable their detection and quantitation by western blotting.  The tagged proteins 
restricted N-MLV comparably to their native counterparts (Figure 3.9A). 
 
The tagged constructs were transduced into MDTF cells to yield approximately 
20-40% YFP+ cells (Figure 3.9B), and the cells grown to about 70% confluency, 
before harvesting total protein for a western blot.  As Figure 3.9C shows, a slightly 
darker band was present for T1S-HA than T1L-HA; normalisation of these bands 
indicates that expression of the former is almost double that of the latter.  
Collectively, these data imply a correlation between protein concentration and 
restriction potency, which is underpinned by determinants in the FN-III domain. 
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Figure 3.7: Typical FACS plots obtained when challenging the agm, human and 
murine orthologues of T1L/S with N-MLV 
Values indicate the percentage of live cells that are present in each gate.  The 
proportion of double-positive cells (i.e. T1+ cells infected with N-MLV) is highlighted 
in red to emphasise the difference in potency between the two isoforms. 
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Figure 3.8: Restriction profiles of agm, human and murine T1L/S 
Graph shows the mean and SEM from (A) at least five or (B) three independent 
experiments (n ≥ 10 and n = 6, respectively).  Statistical significance was 
established using an unpaired t-test: **** P ≤ 10-4 and *** P ≤ 10-3. 
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Figure 3.9: Quantitation of T1L/S protein expression 
(A) HA-tagged T1L/S restrict N-MLV comparably to their native counterparts. 
Graph shows the mean and SEM from three independent exp’ts (n = 10). (B) FACS 
plots of the cell populations harvested for western blotting. (C) Representative 
western blot of T1L/S-HA, using GAPDH as a loading control. (D) Quantitation of 
bands obtained by western blotting. Graph shows the mean and SEM from three 
independent exp’ts (n = 3). In all cases, statistical significance was established 
using an unpaired t-test: **** P ≤ 10-4, * P ≤ 0.05 and ns = not significant.   
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3.4 The majority of the T1 B30.2 domain can be functionally 
replaced with equivalent components from T18 
It has long been known that T5α interacts with capsid via surface-exposed loops 
known as variable regions, which reside within the C-terminal B30.2 domain 
(Ohkura et al., 2006).  Before this work, however, very little was known regarding 
the interaction between T1 and capsid.  Previously, reciprocal chimeras of T1S and 
its non-restricting paralogue, T18, had been made at position 314 (Yap et al, 2004).  
Restriction data from these constructs revealed that the determinants for capsid 
recognition lie in the C-terminal half of the protein; however, given that the B30.2 
domain is over 150 residues downstream of 314 (see Figure 3.10), this work lacked 
sufficient resolution to identify the specific regions that confer this property. 
 
Thus, an early aim of this project was to narrow down the regions within T1 that 
enable capsid recognition. To this end, reciprocal swaps were made between T1 
and 18 again, but this time at the start of the B30.2 domain, and the restriction 
phenotypes of the resulting chimeras were measured.  As expected, the T1 B30.2 
domain was sufficient to confer T18 with activity, while the reciprocal construct was 
inactive (Figure 3.11).  This rules out any contribution of the COS and FN-III 
domains to capsid recognition. 
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Figure 3.10: An alignment of the T1 and 18 protein sequences 
The short isoform of T1 (T1S) was used for this alignment; both sequences are 
from the agm orthologues.  Boundaries for the RBCC and B30.2 domains were 
established using the UniProt proteomics database, while those for the COS and 
FN-III domains were taken from Short and Cox (2006) and Li et al. (2016a), 
respectively.  The positions at which the 314 and B30.2 chimeras were made are 
indicated in red. 
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Figure 3.11: Restriction activities of B30.2-swapped chimeras of T1S and T18 
Restriction of N-MLV by T1S, T18 and chimeras where the B30.2 domain is 
exchanged between these proteins. Graph shows the mean and SEM from five 
independent experiments (n = 10).  Red bars denote full restriction (ratio < 0.3) and 
black bars, absence of restriction (ratio > 0.7).   
 
 
Having confirmed that capsid recognition is indeed mediated by the B30.2 domain, 
the next goal was to assess the contribution of the variable regions (‘VRs’ herein) 
to this process. In order to do this, the boundaries of each VR were established 
using a published alignment of TRIM sequences (James et al, 2007) (Figure 3.12).  
The T1 VRs were then individually substituted into 1-18B30.2 in an attempt to rescue 
restriction (Figure 3.13, Constructs A-D).  Interestingly, however, none of these 
components were individually sufficient to confer capsid recognition.  Following this 
observation, various combinations of T1 VRs were then substituted into 1-18B30.2 in 
the following manner:  VR1 and 2 (E); 2 and 3 (F); 1, 2 and 3 (G); and 1, 2, 3 and 4 
(H).  Surprisingly, however, these constructs were also inactive (Figure 3.13). 
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Figure 3.12: An alignment of the T1 and 18 B30.2 domains 
VR boundaries were established by comparing the T1 sequence with a published 
alignment of TRIM proteins, including T5α and T18, in which the topology of the 
B30.2 domains had been established (James et al., 2007).   
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Figure 3.13: Single and combinatorial substitutions of the T1 VRs into 1-18B30.2 
(A) The structures of Constructs A-H (Section 3.4). (B) Restriction of N-MLV by 
Constructs A-H. Graph shows the mean and SEM from five (T1S, 1-18B30.2), three 
(A-G) or two (H) independent experiments (n = 10, 6 and 4, respectively).  Red 
bars denote full restriction (ratio < 0.3) and black bars, absence of restriction 
(ratio > 0.7).   
Chapter 3: Characterising retroviral restriction by T1 
 
127 
 
In addition to the VR sequences, the T1 and 18 B30.2 domains diverge at the 
C-terminus: T1 possesses an 18-residue C-terminal tail (CT) that is absent in T18.  
To investigate the possibility that the CT is required for restriction, the relevant 
sequence was removed from T1S and 18-1B30.2, and appended to T18.  However, 
the former two molecules remained restriction-competent without the tail, and the 
latter remained inactive despite it (Figure 3.14).  This indicates that the CT is 
neither necessary nor sufficient for capsid recognition. 
 
 
Figure 3.14: The C-terminal tail (CT) bears no impact on restriction  
Graph shows the mean and SEM from three independent experiments (n = 6). 
 
 
To account for the possibility that regions outside of the VRs and CT contribute to 
capsid recognition, a panel of chimeras were generated where bulk regions of T1 
B30.2 were substituted into 1-18B30.2 (Figure 3.15, Constructs I-Q).  Surprisingly, 
only three of these molecules – N, P and Q – acquired restriction activity.  
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Figure 3.15: Bulk substitutions of the T1 B30.2 domain into 1-18B30.2 
(A) The structures of Constructs I-Q (Section 3.4). (B) Restriction of N-MLV by 
Constructs I-Q. Graph shows the mean and SEM from four (T1S, Q), three (N-P) or 
two (I-M) independent experiments (n = 8, 6 and 4, respectively).  Red bars denote 
full restriction (ratio < 0.3) and black bars, absence of restriction (ratio > 0.7).  
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In parallel to the above experiments, the T18 VRs were substituted into the 
18-1B30.2 chimera (Figure 3.16, Constructs R-U).  Interestingly, the presence of VR1, 
3 or 4 from T18 had no effect on N-MLV restriction by this molecule, although this 
phenotype was attenuated by T18 VR2 (Construct S).  This latter observation is 
given more attention in Section 3.5. 
 
Collectively, these data indicate that the majority of the T1 B30.2 domain can be 
functionally replaced with the equivalent regions from T18, with the exception of the 
region flanked by VRs 2 and 3 (Table 3.2).  The only other region that might 
contribute to this phenotype is the one between VRs 3 and 4.  Unfortunately, it was 
not possible to examine this region within the timeframe of this project; however, a 
suitable construct has been synthesised at the time of writing and is currently being 
tested in the Stoye lab.  However, since all of the constructs that lacked this portion 
of T1 were inactive, it is highly likely that this component is also necessary for 
capsid recognition. 
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Figure 3.16: Single substitutions of the T18 VRs into 18-1B30.2 
(A) The structures of Constructs R-U (Section 3.4). (B) Restriction of N-MLV by 
Constructs R-U. Graph shows the mean and SEM from five (T1S, 18-1B30.2) or two 
(R-U) independent experiments (n = 10 and 4, respectively).  Red bars denote full 
restriction (ratio < 0.3) and grey bars, partial restriction (ratio 0.3-0.7).   
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Region in 
T1 B30.2 
Does equivalent 
region from T18 
preserve function? 
Construct(s) that 
demonstrate this 
Cross-
reference 
Pre-VR1 Yes N, P and Q Figure 3.15 
VR1 Yes R Figure 3.16 
VR1-2 Yes N Figure 3.15 
VR2  Partially S  Figure 3.16 
VR2-3 No O  Figure 3.15 
VR3 Yes T Figure 3.16 
VR3-4 Unknown – – 
VR4 Yes U Figure 3.16 
VR4-CT Yes P Figure 3.15 
CT Yes 
T1S and 18-1B30.2 ΔCT; 
N, P and Q 
Figure 3.14 
and Figure 
3.15 
Table 3.2: The majority of the T1 B30.2 domain can be functionally replaced with 
equivalent regions from T18 
CT = C-terminal tail. 
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3.5 T1 residue 595 is an important determinant of N-MLV 
capsid recognition 
The data presented in Section 3.4 showed that T18 VR2 can attenuate restriction in 
the context of a T18-1B30.2 chimera (Figure 3.16, Construct S).  Interestingly, the 
VR2 sequences of T1 and 18 differ by only a single amino acid: an asparagine in 
the former (T1L N595, T1S N565) is replaced by a histidine at the corresponding 
position in the latter (T18 H565).   
 
To determine whether this phenotype is unique to the 18-1B30.2 chimera, a single 
amino acid substitution was made in each of the wild-type T1 isoforms to produce 
T1L N595H and T1S N565H.  Curiously, this modification yielded an even more 
dramatic phenotype: N-MLV restriction was lost in both cases, albeit to a greater 
extent for T1L (Figure 3.17).  As expected, the reciprocal construct (T18 H565N) 
did not acquire restriction activity.  
 
 
Figure 3.17: H595 (T1L), 565 (T1S) is sufficient to inhibit the restriction of N-MLV 
Graph shows the mean and SEM from three (T1L/S constructs) or two (T18 
constructs) independent experiments (n = 6 and 4, respectively). Red bars denote 
full restriction (ratio < 0.3); grey bars, partial restriction (ratio 0.3-0.7) and black 
bars, absence of restriction (ratio > 0.7).  
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Collectively, these data suggest that a histidine at this position weakens capsid 
recognition, and that this attenuation is partly relieved by the N-terminus of T18 (the 
latter phenomenon is discussed further in Section 3.6). 
 
To verify whether this effect is unique to histidine, a panel of mutants were 
generated where each of the remaining 18 standard amino acids were introduced 
at position 595 in T1L, and the effect on restriction measured.  Interestingly, T1L 
was highly sensitive to these substitutions, with the vast majority completely 
inhibiting restriction activity (Figure 3.18).  In fact, only the acidic residues, D and E 
permitted restriction of N-MLV to a degree approaching that of wild-type. 
 
 
Figure 3.18: Restriction of N-MLV by T1L N595 mutants 
Graph shows the mean and SEM from three independent experiments (n = 6). 
Grey bars denote partial restriction (ratio 0.3-0.7) and black bars, absence of 
restriction (ratio > 0.7). 
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3.6 The restriction of N-MLV by T1 is affected by N-terminal 
components 
In Section 3.4, the inhibitory effect of H595/565 in T1L/S was shown to be partially 
rescued by the T18 N-terminus.  This phenomenon is corroborated by a previous 
observation by Yap et al. (2005), where a chimera of T18 and T1S made at position 
314 (18-1314) was shown to restrict N-MLV more potently than wild-type T1S.  
Given that this swap excludes the COS and FN-III domains, the only T18-derived 
regions that could possibly contribute to this phenotype are the RING, B-box and/or 
coiled-coil domains. 
 
To identify which of these regions is responsible for the enhanced restriction 
potency of 18-1314, the RING, B-box and coiled-coil domains of T1 were substituted 
into this molecule, first individually (Figure 3.19, Constructs A-C), then in 
combination (D-G), and finally as a single unit (H).  The majority of these molecules 
saw a return to the weaker phenotype of wild-type T1S – with the exception of 
those that retained the T18 B-boxes (A, C and E), indicating that this region is 
responsible for the enhanced potency of 18-1314.   
 
To verify this observation, the T18 B-boxes were introduced into full-length T1L 
and -S by overlapping PCR to produce T1L-B18 and T1S-B18.  As expected, 
restriction was augmented in both cases, especially for T1L (Figure 3.19C).  This 
confirms that the T18 B-boxes, when paired with a T1 B30.2 domain, yield a 
molecule with a restrictive potential similar to that of T5α.  
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Figure 3.19: The T18 B-boxes augment N-MLV restriction by T1 
(A) The structures of Constructs A-H (Section 3.6). (B) Restriction of N-MLV by 
Constructs A-H. Graph shows the mean and SEM from five (T1S, 18-1314, A-C) or 
four (D-H) independent experiments (n = 10 and 8, respectively). Where 
significance is shown, this is relative to T1S. (C) Restriction of N-MLV by T1L/S 
with and without the T18 B-boxes (B18). Graph shows the mean and SEM for three 
independent experiments (n = 6). In all cases, statistical significance was 
established using an unpaired t-test: *** P ≤ 10-3, ** P ≤ 10-2, * P ≤ 0.05 and 
ns = not significant.   
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3.7 The restriction phenotypes of T1, 18-1314 and T5α are 
probably not artefacts of overexpression 
All of the experiments described so far were performed using the LxIY vector, 
which is optimised for constitutive expression in mammalian cells.  One limitation of 
this approach is the potential for artefactual restriction phenotypes resulting from 
protein overexpression. 
 
To preclude the possibility that N-MLV restriction is a consequence of restriction 
factor overexpression, six constructs (huT5α, rhT5α, a chimera of the huT5α RBCC 
and rhT5α B30.2 domains [hurhT5α], agmT1L, agmT1S and 18-1314) were fused to 
a C-terminal HA tag and cloned into the CS14 and 15 vectors previously described 
(Section 2.2.7). These vectors differ from LxIY in two important respects: (1) the 
CMV promoter is replaced with PTRE3G, permitting transcription only in the presence 
of doxycycline, and (2) the restriction factor gene is placed downstream of the 
eYFP reporter, thereby attenuating its recognition by the ribosome. CS15 provides 
the lower range of expression levels, while CS14 provides a level intermediate 
between that of CS15 and LxIY. 
 
In a preliminary experiment, N-MLV restriction by each of the six constructs was 
tested in five conditions of increasing protein expression: (1) CS15 without dox; (2) 
CS14 without dox; (3) CS15 with dox; (4) CS14 with dox and (5) LxIY.  Western 
blots were performed in parallel to quantify the relative amount of protein under 
each condition.   
 
Conditions 1, 2 and 3 invariably yielded no detectable protein (Figure 3.20) and a 
corresponding absence of N-MLV restriction (Figure 3.21).  However, the results of 
condition 4 varied with different constructs. RhT5α expression fell just within the 
limits of detection and restricted N-MLV only weakly at this concentration.  In stark 
contrast, huT5α and hurhT5α were both more abundantly expressed and exhibited 
full restriction of N-MLV (albeit not quite as potently as when overexpressed in 
condition 5).  All three of the T1-derived constructs were detectable under condition 
4 and exhibited partial restriction phenotypes, with 18-1314 approaching the 
threshold for full restriction. 
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To investigate whether these observations are unique to N-MLV restriction, the 
same experiment was performed using HIV-1.  Given their inability to restrict the 
lentiviruses, all of the T1-derived constructs were excluded from this assay.  
Although huT5α is also inactive against HIV-1, this construct was included as a 
negative control here.  As expected, the restriction data obtained were similar to 
those for N-MLV: conditions 1, 2 and 3 yielded no activity against HIV-1, while in 
condition 4 a modest restriction phenotype manifested, albeit not quite to the levels 
seen in 5 (Figure 3.21C). 
 
These initial experiments confirmed that inhibition of both N-MLV and HIV-1 can 
occur at modest levels of T1 and 5α expression, albeit not as potently as when 
these factors are overexpressed.  However, this work used only a single 
concentration of doxycycline (1000 ng/mL), and therefore lacked sufficient 
resolution to determine a precise correlative relationship between protein 
expression level and restriction activity.   
 
In order to fine-tune these data, CS14 vectors bearing either T1L or 18-1314 were 
transduced into R18 cells and then exposed to eight concentrations of doxycycline 
ranging from 10 to 2000 ng/mL.  The lower limit for this experiment was chosen 
based on the previous observation that Fv1b exhibits a restriction phenotype that 
closely mirrors its endogenous counterpart when induced with 10 ng/mL 
doxycycline (Li et al., 2016b).  Cells grown in dox-free media were included as a 
negative control, and cells transduced with the LxIY vector as a positive. 
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Figure 3.20: Expression of six restriction factor constructs under five conditions 
The expression level of each construct was quantified by western blotting using an 
antibody against the C-terminal HA tag.  Untransduced R18 cells were used as the 
negative control.  The loading control is an extraneous band of unidentified origin 
that is detectable in all samples when αHA is used to probe R18 cell lysate. Where 
dox is present, it is added at a final concentration of 1000 ng/mL. REL: relative 
expression level (normalised to the loading control); AU: arbitrary units. 
Chapter 3: Characterising retroviral restriction by T1 
 
139 
 
 
Figure 3.21: Restriction phenotypes of six constructs when expressed in 
inducible and non-inducible vector systems 
Graph shows the mean values from a preliminary experiment (n = 2). (n = 1 for 
rhT5α in the CS15 Dox negative condition). 
Chapter 3: Characterising retroviral restriction by T1 
 
140 
 
As Figure 3.22 shows, T1L became partially active at 50 ng/mL [Dox] and 
maintained this phenotype up to the maximum concentration used in this 
experiment (2000 ng/mL).  The corresponding western blot shows that T1L protein 
became detectable at 50 ng/mL, and that this level of expression was roughly 
maintained at higher drug concentrations (with the exception of 1000 ng/mL); this 
aligns well with the restriction data.  Protein levels were about sevenfold greater 
when T1L was overexpressed. 
 
18-1314 was active at a slightly lower concentration of drug (20 ng/mL) and reached 
the threshold for full restriction at 100 ng/mL, before plateauing in a similar manner 
to T1L.  However, the corresponding western blot did not yield values that marry 
well with these data.  For example, the quantities of protein present following 
induction with 20 and 100 ng/mL [Dox] were roughly equivalent, despite the former 
yielding a partial restriction phenotype and the latter, full.  Conversely, 100 and 
2000 ng/mL [Dox] resulted in drastically different protein quantities, despite similar 
values for restriction.  Moreover, there appeared to be greater expression in the 
presence of 2000 ng/mL [Dox] than from the LxIY vector, which is also discordant 
with the restriction data.  It is possible that these discrepancies are due to technical 
issues with performing and/or quantifying the western blot; however, given that the 
blot for T1L was run in parallel, using an identical protocol, this seems unlikely.  
Unfortunately, time constraints prohibited further investigation into this issue. 
 
Given the data presented in Section 3.6, it is noteworthy that 18-1314 appeared to 
be more abundantly expressed than T1L in these experiments.  To confirm that this 
is the case, both factors were probed on the same membrane to enable a direct 
comparison of protein quantity (Figure 3.23A).  Under the four conditions tested (20, 
50 and 100 ng/mL doxycycline, plus overexpression), 18-1314 was visibly more 
abundantly expressed than T1L.  Given that LxIY was used in the experiments 
described in Section 3.6, the relative expression levels of each factor in this vector 
were quantified and compared (Figure 3.23B).  Indeed, 18-1314 was about twice as 
abundant as T1L when expressed from the LxIY vector.  However, given that T1S 
expression is also about twice that of T1L under this condition (Section 3.3), and 
that 18-1314 restricts N-MLV to a greater degree than T1S (Section 3.6), this is 
unlikely to be the sole reason for the enhanced restriction potency of this chimera.    
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Figure 3.22: Restriction of N-MLV by T1L and 18-1314 under titrated doxycycline 
(A) Restriction ratios are plotted for T1L and 18-1314 at nine concentrations of 
doxycycline (0, 10, 20, 50, 100, 500, 1000, 1500 and 2000 ng/mL). Restriction 
values obtained from overexpression are included as a positive control. Dotted 
lines mark the thresholds for partial (ratio 0.3-0.7) and full restriction (ratio < 0.3). 
Graph shows the mean and SEM from two independent experiments (n = 4). (B, C) 
Quantitative western blots of T1L (B) and 18-1314 (C) under eight conditions of 
expression.  Relative amounts of protein (in arbitrary units) were calculated by 
normalisation to GAPDH. 
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Figure 3.23: Comparative quantitation of T1L and 18-1314 
Each restriction factor was expressed under four conditions: three levels of Dox 
induction, plus overexpression. All eight samples were then run on the same gel 
and probed on the same membrane to enable a direct comparison of protein 
quantities. (A) Blots of T1L-HA and 18-1314-HA, using GAPDH as a loading control. 
(B) Comparative quantitation of T1L-HA and 18-1314-HA expressed from the LxIY 
vector. Values were obtained by normalisation to GAPDH.  
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3.8 Discussion 
The ability of T1 to inhibit N-MLV replication was first described more than a 
decade ago (Yap et al., 2004); however, at the start of this project, there had been 
no further attempts to characterise this phenotype.  The aim of this chapter was 
thus to offer a more detailed description of T1-mediated restriction.  Each of the key 
findings arising from this work will now be addressed in turn. 
 
T1 is constrained by negative selection 
 
T5α contains numerous signatures of positive selection, and is correspondingly 
able to restrict divergent retroviruses (Song et al., 2005b; Yap et al., 2008; Fletcher 
et al., 2010).  In order to verify whether T1 shares these properties, three 
orthologues of this protein were challenged with a panel of lenti- and foamy viruses.  
Unlike T5α, however, T1 was permissive to all of these viruses.  In support of these 
data, our phylogenetic analysis of the T1 gene reveals that it has been constrained 
by negative selective pressures over the course of its evolution. 
 
These observations are perhaps unsurprising given that T1 participates in the 
development of embryonic midline structures (Cox et al., 2000), a biologically 
fundamental process that necessitates strict functional conservation.  While T5α is 
free to diversify with successive rounds of viral challenge, the T1 protein sequence 
is constrained by its primary function.  Indeed, it could be argued that the 
T1-mediated restriction of N-MLV is merely an incidental phenomenon: a 
by-product of the domain architecture and microtubular localisation of this protein. 
 
The majority of the T1 B30.2 domain can be functionally replaced with the 
equivalent regions from T18 
 
The species-specific restriction profiles of T5α orthologues have been mapped to 
surface-exposed loops in the C-terminal B30.2 domain, known as variable regions 
(VRs) (Ohkura et al., 2006; Yap et al., 2008; Kono et al., 2009).  However, while 
the restriction activity of T1 had previously been mapped to the C-terminal half of 
the protein (Yap et al., 2005), the relative contribution of elements within this region 
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remained elusive.  We therefore sought to gain further insight by making C-terminal 
chimeras of T1 and its non-restricting paralogue, T18. 
 
Unsurprisingly, this work revealed that T1 also recognises capsid via the B30.2 
domain.  However, an extensive panel of chimeras generated within this region 
revealed that only a small fraction of T1-derived sequence is required for this 
phenotype, including VR2 and the sequences flanked by VRs 2-3 and 3-4.  This 
stands in stark contrast to T5α, where VRs 1, 2 and 3 and numerous inter-loop 
regions have been reported to contribute to restriction specificity in different 
orthologues (Song et al., 2005b; Ohkura et al., 2006). 
 
The requirement for T1 VR2 is particularly striking, given that this region differs by 
only a single amino acid between T1 and 18: an asparagine in the former (N595) is 
replaced by a histidine at the corresponding position in the latter (H565).  To 
determine whether this effect is unique to histidine, the remaining 18 amino acids 
were substituted at position 595 of T1L.  Interestingly, the results revealed a 
remarkably low mutational robustness of this region, with 17 out of 20 amino acids 
completely ablating restriction activity.  In fact, the only residues that maintained 
restriction competence, besides the wild-type asparagine, were aspartic and 
glutamic acid, both of which are negatively charged at physiological pH.  
Surprisingly, even glutamine, which shares biochemical properties with both 
asparagine and glutamic acid, appeared to have an inhibitory effect on capsid 
recognition at this position.  While there are no clear biochemical explanations for 
these patterns, it is hoped that the eventual structural characterisation of the T1 
B30.2 domain (see Section 4.3) will shed light on the molecular basis for these 
observations. 
 
There are number of caveats to the above data.  Firstly, in the absence of western 
blots for each mutant, we cannot be certain that the inactive constructs were 
adequately expressed. Moreover, even if they were, their inactivity could be 
attributed to a host of phenotypes that are unrelated to capsid binding, such as a 
change in localisation, or failure to initiate an effector pathway. While the genetic 
data in this chapter provide a good starting point for further investigation, they 
should be interpreted with caution until they are biochemically verified. 
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T1 protein concentration correlates with restriction potency 
 
T1 is alternatively spliced to produce multiple RNA species, two of which encode 
proteins with a B30.2 domain.  Interestingly, the shorter isoform (T1S) appears to 
restrict N-MLV with 2-3 fold greater potency than the long (T1L).  While this is 
certainly a modest difference, it was highly reproducible; we therefore sought to 
identify the biological property that underpins it.   
 
T1L and S differ in the length of their fibronectin type III (FN-III) domains by 30 
residues.  Since this domain is a protein-protein interaction module, and such 
interactions often regulate biochemical phenomena such as protein stability (Paci 
et al., 2012; Dar et al., 2014), the expression level of each isoform was quantified 
by western blotting.  As expected, T1S was expressed at a level approximately 
double that of T1L, suggesting that a shorter FN-III domain favours increased 
protein concentration.  This would endow the short isoform with a greater capacity 
to handle the incoming viral load.  However, the possibility that other variables 
contribute to this phenomenon cannot be excluded.  For example, determinants 
within the FN-III domain may influence the propensity for each isoform to associate 
with microtubules, which would in turn affect their abilities to intercept virions as 
they translocate towards the nucleus. 
 
However, the FN-III domain is not the only determinant that appears to have dual 
effects on expression level and restriction potency.  When generating the B30.2 
domain chimeras, we found that the VR2 loop of T18 was more inhibitory in T1L/S 
than in an 18-1B30.2 chimera, implying that determinant(s) in the T18 N-terminus can 
augment restriction.  This observation aligns well with a previous finding by Yap et 
al. (2005), where a chimera made between T18 and T1S at position 314 restricted 
N-MLV more potently than wildtype T1S.  By generating a panel of chimeras where 
N-terminal portions of T1 were substituted into 18-1314, we identified the B-boxes as 
the determinant responsible for this enhanced potency.  Subsequent western 
blotting revealed that, like T1S, 18-1314 is more abundantly expressed than T1L.  
Indeed, these data are in agreement with the observation that T18 expression 
typically exceeds that of T1 in the developing mouse embryo (Buchner et al., 1999). 
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Collectively, these data indicate that both the B-boxes and the FN-III domain can 
increase restriction potency by boosting protein expression levels.  The fact that 
18-1314 restricts N-MLV more potently than T1S suggests that these effects are 
additive, although it is difficult to conclusively establish this without a comparative 
blot of the two proteins.  Furthermore, given that the relative difference between 
T1L and S is only slightly less than that between T1L and 18-1314, it is likely that the 
T18 B-boxes also potentiate restriction in a concentration-independent manner.  
For example, it is conceivable that differences in the T1 and 18 B-box sequences 
(corresponding to 21% of residues) permit the latter to multimerise more efficiently 
than the former, thereby enhancing capsid binding through avidity effects. 
 
The T1 restriction phenotype is probably not an artefact of overexpression 
 
One limitation of the restriction assay developed by Bock et al. (2000), and used in 
the majority of experiments described in this chapter, is that it involves 
overexpression of the restriction factor in the transduced cell.  This raises the 
possibility that the restriction profiles described thus far do not accurately reflect 
endogenous phenotypes.  To assuage this concern, T1L, T1S and 18-1314 were 
each cloned into two separate, doxycycline-inducible vector systems: CS15 for 
low-level expression, and CS14 for intermediate.  Both vectors have previously 
been used to correlate expression level and restriction specificity for the murine 
restriction factor, Fv1 (Li et al., 2016b).   
 
Interestingly, while Fv1 exhibits modest restriction of MLV in the CS15 vector (Li et 
al., 2016b), the three constructs tested in this project were inactive under this 
condition.  Nevertheless, all three acquired partial activity when expressed from the 
CS14 vector.  While this provisional finding was interesting, it was derived using 
only a single concentration of doxycycline (1000 ng/mL).  Previous work has shown 
that a small fraction of this dose (10 ng/mL) is required to yield an endogenous-like 
restriction phenotype for Fv1 (Li et al., 2016b).  The restriction activities of T1L and 
18-1314 were therefore tested at eight concentrations of doxycycline, taking 
10 ng/mL as the lower limit. 
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T1L became partially active at 50 ng/mL doxycycline and maintained this level of 
activity up to 2000 ng/mL.  In agreement with these data, T1L protein levels were 
roughly equivalent at these concentrations.  18-1314 showed a similar trend, 
although it became active at a slightly lower concentration of drug (20 ng/mL) and, 
as expected, restricted N-MLV more potently than T1L at all higher concentrations.  
Unfortunately, however, the corresponding western blot did not align well with 
these data, and time constraints prohibited further investigation of this issue.   
 
It is important to be conscious of various limitations arising from the above 
experiments.  While technical issues may be partly to blame for the poor quality of 
the quantitative data, it is also possible that western blotting is simply a less 
sensitive measure of protein concentration than the restriction assay.  Furthermore, 
the apparent ‘plateaus’ in restriction activity observed upon induction with 
≥50 ng/mL [Dox] probably reflect the upper limit for transcriptional induction in this 
system, since a more potent phenotype is achievable when the restriction factors 
are overexpressed from the LxIY vector. 
 
Nevertheless, these experiments confirm the restriction-competence of T1 at lower 
concentrations of protein.  However, assessing the biological relevance of these 
findings will necessitate a precise quantitation of the endogenous levels of T1. 
  
148 
 
Chapter 4 Searching for parallels 
between T1 and T5α  
Chapter 4: Searching for parallels between T1 and T5α 
 
149 
 
Given its limited target range and lack of positive selection, it seems unlikely that 
T1 plays a key role in the cellular defence against retroviruses.  Instead, the utility 
of this protein lies in what it can teach us about the more prominent restriction 
factors – particularly T5α – by comparing what unites these proteins and what sets 
them apart. 
 
The T1 and 5α protein sequences are highly divergent: the former is almost double 
the length of the latter due to two additional domains between the RBCC and B30.2 
compartments (Figure 4.1A).  Furthermore, in Chapter 3, it became apparent that 
while the variable regions are critical for capsid recognition in T5α (Ohkura et al., 
2006; Anderson and Akkina, 2008), they are functionally replaceable in T1.  
Despite these differences, however, both factors are able to restrict N-MLV to 
comparable degrees.  This suggests that either there are common features that 
unite the two proteins, or that evolution has devised two distinct mechanisms for 
recognising and/or restricting N-MLV.  The focus of this chapter is thus to compare 
and contrast T1 and 5α in order to verify whether or not such parallels exist.   
 
4.1 T1 and 5α can be fused to produce a molecule with 
restriction activity 
Given that T1 and 5α each contain effector and capsid-binding domains, we 
reasoned that it might be possible to fuse them to generate a restriction-competent 
chimera.  To explore this possibility, reciprocal chimeras were made between 
agmT1S and rhT5α at two positions – one immediately following the coiled-coil and 
the other at the start of the B30.2 domain (Figure 4.1B).  Their restriction activities 
were then measured using the two-colour assay (Figure 4.2).   
 
As expected, neither of the chimeras with a T1 B30.2 domain were able to restrict 
the lentiviruses.  Surprisingly, however, their reciprocal counterparts were equally 
permissive to lentiviral replication.  Of the four chimeras, one (5-1B30.2) restricted 
N-MLV to a degree comparable to that of T1S.  Collectively, these data indicate 
that it is possible to produce a restriction-competent chimera of T1 and 5α, 
although the position at which the swap is made has an impact on this phenotype. 
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Figure 4.1: T1 compared with T5α  
(A) Schematic comparison of T1 and T5α. (B) Positions at which the T1-5α 
reciprocal chimeras were made.  Domain boundaries were established using the 
UniProt database (for T1) and Sastri et al. (2014) (for T5α).  
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Figure 4.2: Restriction profiles for the T1-5α reciprocal chimeras 
Graphs show the restriction activities of T5α (from the rhesus macaque), T1S (from 
the African green monkey), and reciprocal chimeras thereof.  Red bars denote full 
restriction (ratio < 0.3) and black bars, absence of restriction (ratio > 0.7).  Graphs 
show the mean and SEM from three independent experiments (n = 6). 
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4.2 A panel of N-MLV capsid mutants escape restriction by 
both T5α and T1 
Having established that T1 and 5α are sufficiently similar in their overall design to 
produce a functional chimera (Section 4.1), we next wanted to establish whether 
these proteins bind to similar epitopes on the N-MLV capsid. 
 
Prior to the start of this project, the Stoye group identified a number of mutations in 
N-MLV CA that confer escape from restriction by rhT5α (Ohkura et al., 2011).  This 
work revealed an extensive T5-binding interface, including residues in the formerly 
established Fv1-binding pocket (N82D, E92K, A95D), and in a cluster on the 
N-terminal side of this pocket (L4S, G8D, L10W).  A subsequent study revealed 
that some of these mutations facilitated the acquisition of compensatory mutations 
that confer escape from huT5α (L10W/E100K and N82D/N113K) (Ohkura et al, 
2013).  Collectively, these findings indicated that the T5-binding interface spans a 
much broader surface on the N-MLV capsid than had previously been thought 
(Stevens et al., 2004). 
 
To determine whether T1 recognises similar epitopes, we selected five mutants 
from the above experiments and measured their abilities to escape restriction by 
T1L, T1S and the 18-1314 chimera.  In all cases, viral titres were adjusted to 
account for relative differences in infectivity.  As Figure 4.3 shows, there was 
considerable variability in the degree of escape that each mutant accomplished.  
While N7K was able to escape restriction by T1L entirely, it retained some 
sensitivity to T1S and 18-1314, albeit to a lesser extent than wild-type in both cases.  
A similar phenotype was observed for L10W.  E92K was the most sensitive virus in 
the panel, retaining a degree of sensitivity to all three T1 constructs. Conversely, 
the double mutants were fully resistant to restriction.  In many cases, these 
phenotypes were distinct from those previously described for T5α (discussed in 
Section 4.4).   
 
Collectively, these data indicate that T1 and 5α engage with distinct epitopes on the 
N-MLV capsid surface, although it is possible that certain residues and motifs 
contribute to both binding interfaces.   
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Figure 4.3: Sensitivity of N-MLV capsid mutants to restriction 
Sensitivity of wild-type (WT) N-MLV and five capsid mutants to restriction by T1L, 
T1S and 18-1314. Graph shows the mean and SEM from four (T1L) or three (T1S, 
18-1314) independent experiments (n = 8 and 6, respectively). Statistical 
significance was established using an unpaired t-test: * P ≤ 0.05. Where 
significance is shown for T1S, this is relative to T1L, and for 18-1314, relative to 
T1S.  
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4.3 Expression and purification of a recombinant T1 B30.2 
domain  
The fact that T1 and 5α bind to N-MLV through distinct sets of interactions (Section 
4.2) implies that the B30.2 domains of these proteins diverge at the structural level.  
Unfortunately, while crystal structures exist for several B30.2 domains, including 
that of T5α (Yang et al., 2012), T25 (D'Cruz et al., 2013), and T72 (Park et al., 
2010), no such structure is currently available for T1.  We therefore set out to 
express and purify a recombinant T1 B30.2 domain for crystallisation trials.  
 
4.3.1 Expression of MBP-B30.2 in E. coli 
To express sufficient amounts of the T1 B30.2 domain, the corresponding region 
was amplified from the agmT1 gene using primers with inbuilt restriction sites 
(Table 4.1). The PCR product was then digested and ligated into an expression 
vector (pET47) that includes N-terminal His6 and MBP tags, to aid in protein 
purification and solubility, respectively. 
 
Forward 5’- CGTAGAAAGCTTACCCGACTAAAAACAAACAGCC  
Reverse 5’- GTTCGACTCGAGTTAATGACAGGTTTTCATCCC  
Table 4.1: Primers used to amplify the B30.2-encoding region of agmT1 
Emboldened sequences correspond to the restriction sites used to generate sticky 
ends for ligation: HindIII in the forward primer, and XhoI in the reverse. Bases 
upstream of these sites were selected at random. 
 
 
The resulting construct (MBP-B30.2 herein) was then sequence-verified and 
transformed into Rosetta 2 (DE3) cells (Novagen). This strain of E. coli is 
engineered to enhance the translation of eukaryotic proteins, thus circumventing 
the need for codon optimisation.  A full description of the protocol used for protein 
expression and harvesting can be found in Section 2.4.1 of this thesis. 
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4.3.2 Purification of MBP-B30.2  
Bacterial lysate was passed through a nickel column according to the protocol 
outlined in Section 2.4.2.  The trace obtained from the column is shown in Figure 
4.4: a clear peak of elution is visible soon after the imidazole concentration is 
increased.  The load, flowthrough and eluate were then run in parallel on an SDS 
gel (Figure 4.7A).  A band of the expected size (67.1 kDa) was observed, 
consistent with the successful expression and purification of MBP-B30.2.  However, 
the presence of multiple contaminating species warranted further purification by ion 
exchange chromatography (Figure 4.5).  Given the acidic isoelectric point of 
MBP-B30.2 (pI = 6.18), a Source Q anion exchange column was used for this 
purpose.  A full description of this protocol can be found in Section 2.4.3.   
 
Given that a peak of elution from the anion exchange column was visible between 
fractions A8 and A12, an aliquot from each of these fractions was loaded on an 
SDS gel in order to verify protein yield and purity (Figure 4.7A).  The relevant 
fractions were then pooled and further purified by size exclusion chromatography.  
This final step was taken to minimise the presence of extraneous contaminants that 
might interfere with the crystallisation process.  Figure 4.6 shows the trace obtained 
from the size exclusion column, with the peak of elution falling between fractions 23 
and 29.  These fractions were once again pooled, concentrated to 7.4 mg mL-1, and 
then run on a gel to check protein yield and purity (Figure 4.7B).  Although lower 
molecular weight bands were visible upon staining, MBP-B30.2 was visibly the 
predominant species, with an estimated purity of >95%. 
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Figure 4.4: Trace from the affinity purification of MBP-B30.2 
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Figure 4.5: Trace from the ion exchange chromatography of MBP-B30.2 
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Figure 4.6: Trace from the size exclusion chromatography of MBP-B30.2 
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Figure 4.7: MBP-B30.2 after various stages of purification 
MBP-B30.2 following (A) affinity purification (left) and ion exchange 
chromatography (right), and (B) size exclusion chromatography (sec) 
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4.3.3 Verification of MBP-B30.2 identity by mass spectrometry 
To confirm the identity of the purified protein, an aliquot of eluate from the size 
exclusion column was sent for analysis by mass spectrometry.  As Figure 4.8 
shows, a large peak was observed at 67,140.9 Da.  This value appears consistent 
with the theoretical mass of MBP-B30.2 following removal of the N-terminal 
methionine (67,131.5 Da), a common post-translational modification in bacteria 
(Giglione et al., 2004). 
 
Possible explanations for the slight discrepancy between the observed and 
theoretical masses include oxidation of methionine residues within the protein, as 
well as the intrinsic error associated with mass spectrometry of high molecular 
weight proteins. Nevertheless, the presence of a large peak within 9 Da of the 
theoretical mass was taken as evidence that the correct protein had been purified. 
 
A number of smaller peaks at both lower and higher molecular weights were also 
observed on the mass spectrum.  Those at a lower MW probably correspond to 
species that have lost their N-terminal His6 tag, but were able to co-purify with their 
full-length counterparts through homodimeric associations between MBP.  
Meanwhile, those at a higher MW likely represent proteins with gluconoylated or 
phosphogluconoylated His6 tags.  Such modifications are well-documented in E. 
coli expression systems (Geoghegan et al., 1999; Matthies et al., 2005). 
 
4.3.4 Crystallisation trials of MBP-B30.2 
To grow crystals of MBP-B30.2, neat (7.4 mg mL-1) and diluted (1.85 mg mL-1) 
samples were incubated in sparse matrix and systematic screens using the sitting 
drop method (Roksana Ogrodowicz, the Francis Crick Institute).  The latter 
concentration was chosen given its reported effectiveness in growing crystals of the 
T5α B30.2 domain (Yang et al., 2012).  The ratio of clear to precipitated drops 
obtained under these conditions indicated that both concentrations were 
favourable; however, no crystals grew within the timeframe of this project.  A list of 
screens used in these trials can be found in Appendix 7.2. 
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Figure 4.8: The mass spectrum deconvolution report for MBP-B30.2  
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4.4 Discussion 
Although T1 and 5α are divergent proteins, they are united in their ability to restrict 
N-MLV.  The aim of this chapter was to identify parallels between these factors that 
endow them with this common phenotype.  Each of the key findings arising from 
this work will now be discussed in turn. 
 
T1 and 5α can be fused to produce a restriction-competent chimera 
 
Given that T1 and 5α have common capsid-binding and effector domains, we 
reasoned that it might be possible to fuse them to generate a restriction-competent 
chimera.  To this end, reciprocal swaps were made between T1 and 5α, both 
immediately after the coiled-coil (1-5CC and 5-1CC) and at the start of the B30.2 
domain (1-5B30.2 and 5-1B30.2).  Although these chimeras were inactive against the 
lentiviruses, one of them (5-1B30.2) did restrict N-MLV to a degree approaching that 
of wildtype T1S.  This suggests that it is possible to generate a T5α-1 fusion with 
restriction activity, although the position at which the two molecules are joined has 
an impact on this phenotype.   
 
One explanation for these data is the contribution of the region immediately 
preceding the B30.2 domain to capsid recognition.  In T5α, this is known as Linker 
2 (L2), a predominantly α-helical region that serves to align the neighbouring B30.2 
domain with viral epitopes.  The analogous region in T1 is much longer, owing to 
the presence of two intervening domains (COS and FN-III) between the coiled-coil 
and B30.2 domain.  It is conceivable that capsid recognition by T5α B30.2 is 
contingent on the upstream L2 region, while T1 B30.2 can function adequately with 
either partner.  In other words, while T5α is sensitive to the spacing between 
capsid-binding and effector domains, T1 is relatively flexible in this regard (this 
notion is covered in depth in Chapter 5).  This hypothesis would explain the ability 
of 5-1B30.2 to restrict N-MLV, while the reciprocal construct is inactive. 
 
However, this hypothesis does not provide a satisfactory explanation for the 
inactivity of 1-5CC and 5-1CC, both of which contain B30.2 domains that are paired 
with their native N-terminal neighbours.  It has previously been shown through 
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molecular modelling that contacts between L2 and the preceding coiled-coil are 
required to maintain the integrity of the T5α dimer, thereby ensuring a productive 
interaction with capsid (Sastri et al., 2014).  If this is the case, then one explanation 
for the loss-of-function for 1-5CC and 5-1CC might be the lack of complementarity 
between the L2 region (in the former), or the analogous region from T1 (in the 
latter), and the coiled-coil to which it is attached.  This would prohibit the relevant 
region from docking onto the coiled-coil in the dimer, in turn preventing the B30.2 
domains from efficiently engaging with their target.  However, in the absence of 
structural data for these chimeras, it is difficult to conclusively establish the nature 
of the secondary and tertiary structures that they (fail to) form. 
 
Nevertheless, the fact that one of these molecules was restriction-competent 
indicates that T1 and 5α share a common overall design.  Both proteins are 
endowed with effector and capsid-binding domains, and these components appear 
to be at least somewhat cross-compatible, contingent on the position at which the 
two molecules are fused. 
 
T1 and 5α recognise distinct epitopes on the N-MLV capsid surface 
 
Having established that T1 and 5α can complement one another in a contiguous 
molecule, we next wanted to explore whether the two proteins recognise similar 
epitopes on the N-MLV capsid.  
 
Work from the Stoye group has already begun to define regions on the N-MLV 
capsid that are recognised by T5α.  This was accomplished by serial passage of 
virions in T5-expressing cells, and the subsequent isolation and characterisation of 
mutants that escape restriction (Ohkura et al., 2011; Ohkura and Stoye, 2013).  
These experiments revealed an extensive T5α-binding interface, spanning most of 
the capsid’s outer surface and incorporating residues positioned up to 29 Å apart.  
In order to establish whether the T1 B30.2 domain binds a similar set of epitopes, 
five escape mutants were selected from the above experiments (N7K, L10W, 
E92K, L10W/E100K and N82D/N113K), and tested for their ability to escape 
restriction from T1L, T1S, and the 18-1314 chimera described previously.  As shown 
in Table 4.2, these data varied considerably between mutants.  
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N-MLV capsid mutant 
 
 
 
N7K 
 
L10W E92K L10W/E100K N82D/N113K 
huT5α Escape 
 
Restriction 
 
Escape Escape Escape 
rhT5α Escape 
 
Escape 
 
 
Escape 
 
Escape Escape 
agmT1L Escape 
 
Escape 
 
 
Partial 
escape 
 
Escape Escape 
agmT1S 
Partial 
escape 
 
Partial 
escape 
 
Partial 
escape 
Escape Escape 
18-1314 
Partial 
escape 
 
Partial 
escape 
 
Partial 
escape 
Escape Escape 
Table 4.2: Restriction phenotypes of five N-MLV capsid mutants 
See Figure 4.3 for quantitative restriction data. 
 
 
N7K falls outside of the formerly established Fv1-binding pocket (Mortuza et al., 
2008); specifically, it resides in the apical loop of the conserved N-terminal 
β-hairpin (Mortuza et al., 2008).  Given that this mutation has a destabilising effect 
on the viral core (and a corresponding impact on viral fitness), it has been 
postulated that escape from restriction is conferred by rapid transition of the virion 
through a TRIM-sensitive state (Ohkura and Stoye, 2013).  While this model 
satisfactorily explains the loss of restriction by T5α and T1L, a question mark 
remains over the abilities of T1S and 18-1314 to partially overcome this effect.  In 
the latter case, it is conceivable that the T18 B-boxes endow a greater avidity effect 
than their counterparts in T1.  This might enable restriction to be effected before 
N7K has sufficient time to disassemble.  The case for T1S is less clear, however.  
While it’s feasible that the increased expression of T1S over L (see Section 3.3) 
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provides greater opportunity for restriction to occur within the timeframe of core 
integrity, this hypothesis hinges on T1S expression superseding that of T5α, which 
is also unable to restrict N7K prior to disassembly.  Parallel quantitation of the two 
proteins will be necessary to confirm whether or not this is the case. 
 
L10W maps to a shallow channel between the β-hairpin and helix α6 (the β-α6 
channel herein) of MLV CA (Figure 4.9).  In the wildtype structure, the aliphatic 
sidechain of leucine forms the base of this channel; substitution for the bulkier 
tryptophan elevates the base by ~2.3 Å.  Interestingly, this mutation inhibits 
restriction by rhesus, but not human, T5α (Ohkura et al., 2011), indicating that 
different T5 orthologues interact with distinct structures on the MLV capsid surface.  
Although T1L was unable to inhibit L10W, the fact that both T1S and 18-1314 
remained restriction-competent confirms that this is not due to elements within the 
T1 B30.2 domain.  Collectively, these data give rise to the rather bizarre notion that 
changes in the β-α6 channel can discriminate between the closely related rhesus 
and human T5αs, but not between the highly divergent B30.2 domains of huT5α 
and agmT1.  This discrepancy is even more startling in light of the fact that L10W 
has been shown to evade restriction by a broad panel of primate T5αs, including 
variants from the New World monkeys (Ohkura et al., 2011).  It is not immediately 
clear what sets the L10W-restricting factors apart from their inactive counterparts, 
especially given that members of the former group often have greater sequence 
identity with members of the latter than they do with each other. 
 
As was the case with the N7K mutant, E92K has a substantial impact on viral 
fitness, although it does not have appear to have a corresponding effect on core 
stability (Ohkura and Stoye, 2013).  This loss of fitness correlates with escape from 
restriction by both rhesus and human T5α.  Interestingly, this effect appears to be 
charge-dependent: a basic residue at position 92 causes escape from T5α with a 
concomitant loss of fitness, while acidic residues confer the inverse phenotype 
(Ohkura and Stoye, 2013).  Strangely, however, T1 appears to be relatively 
unhindered by this modification: in fact, E92K was the only mutant in the panel to 
retain sensitivity to all three T1 constructs.  This observation implies that the T1 
B30.2 domain is relatively insensitive to changes in charge, at least at this position 
in N-MLV CA. 
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Figure 4.9: The impact of L10W on the structure of N-MLV CA 
(A) Structural superimposition of wild-type N-MLV CA (grey) and the L10W mutant 
(blue). (B) The β-α6 channel in wild-type CA, with residue L10 indicated. (C) In the 
L10W mutant, the bulky side-chain of W10 obscures the base of this channel. 
Figure is taken from Ohkura et al. (2011), and reproduced here under the terms of 
the Creative Commons Attribution Licence.   
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The double mutants, L10W/E100K and N82D/N113K, were the only viruses in this 
panel to fully escape restriction by all five restriction factor constructs.  While the 
molecular basis for these data is unclear, work from Ohkura & Stoye (2013) 
demonstrated the importance of charge for the escape of a similar mutant 
(N82D/E100K).  Specifically, it was shown that removing arginine residues from the 
VR1 loop of huT5α (or introducing them at the corresponding positions in rhT5α) 
can restore restriction of this virus.  While it is not clear whether charge-reversing 
mutations would have a similar impact on the restriction of L10W/E100K and 
N82D/N113K, it is noteworthy that the VR1 loop of T1 B30.2 contains 8 charged 
residues (3 acidic and 5 basic), providing ample opportunity to explore this 
possibility in the future. 
 
Collectively, these data indicate that T1 and 5α engage with distinct epitopes on the 
N-MLV capsid surface, although it is likely that certain residues and motifs 
contribute to both binding interfaces.  This probably reflects underlying structural 
differences in the B30.2 domains of the two factors.  In order to confirm this 
hypothesis, we have successfully expressed and purified a recombinant form of the 
T1 B30.2 domain for crystallisation trials.  Although no crystals were grown within 
the timeframe of this project, the high quality of protein obtained from the 
purification has provided ample raw material for further work in this area.  Future 
attempts may benefit from using MBP as a seed to nucleate crystal formation, or 
perhaps introducing a cleavage site upstream of the B30.2 domain to enable 
removal of the tags after purification. 
 
Collectively, the data presented in this chapter indicate that, despite their 
divergence, T1 and 5α share a common overall design that enables them to 
complement one another in a contiguous molecule.  However, there are important 
differences that set these proteins apart, including their mechanisms of capsid 
recognition and their intramolecular requirements for effecting restriction.  The latter 
point will be the central focus of the next chapter. 
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Chapter 4 outlined efforts to produce a restriction-competent chimera of T1 and 5α.  
Given that all of the constructs described had intact capsid-binding and effector 
domains, it is curious that only one of them retained the ability to restrict N-MLV.  
This observation led us to consider the notion that it is not only the presence of 
certain domains that is important for restriction, but also the relative spacing 
between them. 
 
Linker 2 (L2) is a 64 amino acid region that runs between the coiled-coil and B30.2 
domain of T5α (Figure 5.1A).  L2 has been under extensive scrutiny in recent years, 
and a wealth of information is now available regarding its structure and contribution 
to the T5α dimer (Goldstone et al., 2014a; Sanchez et al., 2014). The N-terminal 
portion consists of two α-helices, α3 and α4, which are followed by an extended 
and largely unstructured region known as L2-E.  L2-E runs for 24 residues before 
terminating in a final helix, α5, which forms the C-terminal connection with the 
B30.2 domain.  In the T5α dimer, α3 and α4 interact with the B-boxes of the 
opposing monomer at either end of the dimer.  L2-E then doubles back along the 
coiled-coil and runs towards the twofold axis of the dimer, thereby positioning α5 at 
the centre, where it serves to align the B30.2 domains with complementary 
epitopes on the capsid surface (Figure 5.1B).   
 
The equivalent region in T1 is about three times as long (195 residues), and 
includes a COS domain (60 aa) for microtubule binding and an FN-III domain 
(100 aa) for mediating protein-protein interactions.  No structural information about 
the T1 dimer is currently available (nor, indeed, is it known whether T1 dimerisation 
is required for restriction at all), but it is likely that it differs substantially from T5α in 
this respect.  This may go some way towards explaining the relative difficulty in 
producing a functional chimera of the two proteins.   
 
The aim of the studies described in this chapter is to explore the impact of domain 
spacing on facilitating a productive interaction between TRIM and capsid.  The 
main focus of these studies will be the L2 region of T5α, since this is shorter and 
better characterised than its counterpart in T1.  For the purpose of this work, a 
productive interaction is defined as one that results in restriction of the virus 
concerned. 
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Figure 5.1: The T5α L2 region  
(A) Position of L2 within the rhT5α protein sequence. (B) Side-view of a T5α dimer 
interacting with the capsid surface.   
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5.1 Rhesus T5α is largely intolerant of deletions in L2 
To investigate the importance of L2 length for permitting a productive interaction 
between T5 and capsid, a panel of deletions were made in this region of rhT5α.  
The rhesus orthologue was chosen because it potently restricts a number of 
retroviruses, thereby providing a suitable baseline from which to compare any 
mutant phenotypes.   
 
In an initial experiment, the entirety of L2-E and the N-terminus of α5 (L2-α5 herein) 
were deleted from rhT5α to yield Construct A (Table 5.1; Figure 5.2).  Structural 
modelling of this mutation predicts repositioning of the B30.2 domains to either end 
of the dimer (Figure 5.3).  Unsurprisingly, this construct was inactive against all four 
of the viruses tested.  Following this observation, three smaller deletions were 
made in L2-α5, each containing progressively larger amounts of L2-E, but all still 
lacking the N-terminus of α5 (B-D).  However, these constructs were also largely 
inactive.  In fact, only D – which retains all but two residues of L2-E – yielded a 
protein with any restriction activity at all: a partial phenotype against FIV.   
 
To verify whether the inactivity of B and C was attributable to the missing 
N-terminus of α5, two more constructs were made with equivalent deletions in L2-E, 
but this time retaining helix α5 in its entirety (H and I).  However, as Table 5.1 
shows, the presence of α5 was insufficient to rescue restriction by these constructs, 
indicating that the portions of L2-E removed in B and C are necessary, either in 
size or sequence, for a productive capsid interaction. 
 
To further investigate the partially restrictive phenotype of D, the region concerned 
(residues 282-290) was split into two halves, and deletions made of each, yielding 
E (Δ282-285) and F (Δ286-290).  In silico modelling predicted similar structural 
manifestations for both mutations: the central position of the B30.2 domains is 
roughly maintained, but with a ~90° rotation relative to the axis of the coiled-coil 
(Figure 5.3).  Interestingly, E and F regained full activity against the lentiviruses, but 
were unable to restrict N-MLV.   
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To establish whether this phenotype is unique to the regions deleted in E and F, or 
simply a general consequence of shortening helix α5, a similarly sized deletion was 
made in the C-terminal half of α5 to produce G.  However, G was entirely inactive, 
indicating that the ability of E and F to recognise the lentiviral capsids is attributable 
to dispensable residues in the N-terminus of α5, rather than a general tolerance of 
α5 shortening. 
 
Table 5.1: Restriction phenotypes of the rhT5α deletion constructs  
Data show the mean and SEM (2 dp) from three independent experiments (n = 6).  
Black boxes represent full restriction; grey, partial, and white, absence of restriction 
 
 
 
Figure 5.2: Positions of the removed portions in the rhT5α deletion constructs 
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Figure 5.3: A structural model of wild-type and mutant T5α dimers  
(A) Wild-type; (B) Δ259-290 (Construct A); (C) Δ282-285/286-290 (Constructs E 
and F).  Models were constructed using the Pymol software.  Credit to Dr Neil Ball 
at the Francis Crick Institute, Mill Hill Laboratory. 
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5.2 Rhesus T5α tolerates small extensions in α5 
Having deleted portions of L2-α5, we next wanted to examine the consequences of 
extending it.  To this end, three sequences were inserted roughly in the middle of 
the α5 helix, specifically between residues 289 and 290 (see Table 5.2).  These 
sequences were designed specifically to lengthen the helix while preserving its 
secondary structure.     
 
 
Table 5.2: Sequences inserted into the centre of helix α5 in rhT5α  
The conformational effects of each insertion on the T5α dimer are shown in the 
right hand columns. Credit to David Goldstone (former Division of Molecular 
Structure, NIMR) for the design of these mutants. 
 
 
Figure 5.4 shows the predicted effect of the largest insertion, FRELFRL, on the 
structure of the T5α dimer: the B30.2 domains are pushed apart in opposite 
directions and swivelled with respect to the axis of the dimer.  Strikingly, the 
restriction data for these constructs were reminiscent of those seen with Constructs 
E and F in Section 5.1: in all three cases, lentiviral recognition was unperturbed, 
while N-MLV recognition was lost (Table 5.3). 
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Table 5.3: Restriction phenotypes of wild-type rhT5α and a panel of constructs 
with extended α5 helixes 
Data show the mean and SEM (correct to 2 dp) from three independent 
experiments (n = 6).  Black boxes represent full restriction; grey, partial restriction, 
and white, absence of restriction. 
 
 
Figure 5.4: A structural model of wild-type and mutant T5α dimers  
(A) Wild-type; (B) 289-FRELFRL-290. Models were constructed using the Pymol 
software.  Credit to Dr Neil Ball at the Francis Crick Institute, Mill Hill Laboratory. 
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5.3 Disrupting the secondary structure of α5 has variable 
effects on restriction by rhesus and human T5α 
Having altered the length of L2-α5, we next sought to examine the consequences 
of disrupting its secondary structure.  To this end, an alignment of the α5 
sequences from multiple primate T5αs was performed using an online protein 
alignment tool (Table 5.4).  This analysis revealed two highly conserved leucine 
residues that are likely to contribute to helix formation in this region.  Thus, each of 
these residues was mutated to proline – which has a propensity to disrupt α-helices 
– and the effect on restriction measured. 
 
 
Table 5.4: An alignment of α5 sequences from ten primate orthologues of T5α  
Conserved leucine residues are highlighted in red.  Alignment was performed using 
the Clustal Omega multiple sequence alignment tool (EMBL-EBI). 
 
 
As Table 5.5: shows, the effects of proline substitution on restriction were highly 
variable between constructs.  In rhT5α, L287P resulted in a rather dramatic 
phenotype: HIV-2 restriction was lost entirely, while HIV-1 and FIV restriction were 
both attenuated.  L293P was much better tolerated, with no discernible effect on 
lentiviral restriction. Recognition of N-MLV, however, was lost in both cases.  In 
huT5α, the equivalent mutations had an even more profound effect, with 
substitution of either residue completely ablating restriction of this panel of viruses. 
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Table 5.5: Restriction phenotypes of wild-type rhesus and human T5α and a 
panel of constructs with leucine-to-proline substitutions in helix α5 
Data show the mean and SEM (correct to 2 dp) from two (N-MLV) or three (HIV-1, 
HIV-2, FIV) independent experiments (n = 4 and 6, respectively).  Black boxes 
represent full restriction; grey, partial restriction, and white, absence of restriction. 
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5.4 CypA tolerates L2 deletions more readily than the B30.2 
domain 
Section 5.1 described the impact of L2 deletions on the restriction phenotype of 
rhT5α.  To determine whether these observations are unique to restriction factors 
containing a B30.2 domain, we synthesised a chimera comprising the N-terminus 
of rhT5α (residues 1-300) fused to the CypA domain of owl monkey TCyp (Yap, 
unpublished work).  This construct was designed specifically to incorporate the L2 
region of rhT5α in its entirety, thereby enabling a comparison of the two 
capsid-binding domains in the same N-terminal background.  The resulting 
molecule (T5α-Cyp herein) was restriction-competent (Table 5.6, Construct A).   
 
A number of deletions were then made in the L2 region of this construct by 
site-directed mutagenesis (Constructs B-F).  As the data show, these modifications 
were far better tolerated than their equivalents in rhT5α.  For all but the largest 
deletion (F), HIV-1 and FIV restriction were fully preserved.  The pattern for HIV-2 
restriction was a little less clear: interestingly, B restricted this virus more potently 
than the parental A, while C-F were permissive.  This phenomenon is discussed in 
greater detail in Section 5.5. 
 
 
Table 5.6: Restriction phenotypes of an artificial T5α-Cyp chimera and a panel of 
daughter constructs with L2 deletions 
Data show the mean and SEM (correct to 2 dp) from two independent experiments 
(n = 4).  Black boxes represent full restriction; grey, partial restriction, and white, 
absence of restriction. 
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5.5 The restriction specificity of TCyp is governed by multiple 
determinants 
It is curious that removing just 9 amino acids from T5α-Cyp boosts HIV-2 restriction 
by more than tenfold, whilst having no concomitant effect on the inhibition of HIV-1 
or FIV (Table 5.6, Constructs A and B).  This observation prompted us to conduct 
further enquiries into the determinants that govern restriction specificity in TCyp 
restriction factors.  This section is thus divided into three parts, each one exploring 
a separate determinant. 
 
5.5.1 Exon 7 
The 9 amino acid difference between Constructs A and B falls within the C-terminal 
half of helix α5, and is encoded by exon 7 (e7) of the T5 gene.  TCyp fusions have 
independently arisen in several primate lineages, but due to differences in the site 
of CypA retrotransposition, the owl monkey variant (omTCyp) retains e7, while the 
rhesus macaque orthologue (rhTCyp) does not.  These molecules also differ in 
their restriction profiles: the former potently restricts HIV-1, while the latter does not.   
 
To establish whether this difference can be attributed to the presence or not of e7, 
this region was deleted from omTCyp and the restriction activity of the resulting 
molecule measured (Figure 5.5). Curiously, we observed restriction of HIV-2 in 
these experiments, which is at odds with the restriction profile reported elsewhere 
(Wilson et al., 2008).  Nevertheless, the inhibition of HIV-1 and FIV is consistent 
with the literature, and neither of these activities were affected by the removal of e7, 
indicating that this region is inconsequential for restriction by omTCyp.  This stands 
in marked contrast to the situation with T5α-Cyp, where the presence of e7 appears 
to be inhibitory (Section 5.4, Constructs A and B) and in rhT5α, where it is essential 
(Section 5.1, Construct G).   
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Figure 5.5: Restriction phenotypes of wild-type and e7-deficient omTCyp 
Graph shows the mean and SEM from two independent experiments (n = 4). 
 
 
Collectively, these data suggest that the impact of e7 on TRIM-mediated restriction 
is highly context-dependent, with influences from both the downstream 
capsid-binding domain and the target virus concerned.  It is thus difficult to make 
any broad generalisations about its function on the basis of these data.    
 
5.5.2 Residues in the active site of CypA 
Modern rhTCyp has a strong affinity for the HIV-2 capsid, while the parental CypA 
molecule from which it is derived has a strong affinity for HIV-1 and only a weak 
one for HIV-2.  One group has suggested that this affinity switch can be attributed 
to two mutations in the active site of the CypA domain (Price et al., 2009).  The first 
of these (R69H) broadened specificity from HIV-1 to both viruses, while the second 
(D66N) enhanced HIV-2 restriction while ablating HIV-1 restriction entirely.  
 
To test this model in T5α-Cyp and its derivatives, the D66N mutation was 
introduced to each of Constructs A-F (Table 5.6), yielding A1-F1 (Table 5.7).  The 
expectation was that this would reverse the phenotypes described in Section 5.4: 
thus, in C1-F1, HIV-1 restriction would be lost and HIV-2 restriction gained.  
Chapter 5: The requirements for a productive TRIM-capsid interaction 
 
181 
 
Consistent with the findings of Price et al. (2009), this modification inhibited HIV-1 
restriction; surprisingly, however, there was no concomitant gain-of-function against 
HIV-2.  FIV restriction was much less affected by this change. 
 
 
 
Table 5.7: Restriction phenotypes of T5α-Cyp and its derivatives with the D66N 
active site mutation in CypA 
Data show the mean and SEM (correct to 2 dp) from two independent experiments 
(n = 4).  Black boxes represent full restriction; grey, partial restriction, and white, 
absence of restriction. 
 
 
Next, the R69H mutation was introduced to A and B, yielding A2 and B2 (Figure 
5.6).  This modification caused A to completely lose its limited ability to restrict 
HIV-2, although HIV-1 restriction was unaffected.  B underwent a very slight 
attenuation of HIV-2 restriction – again, with no impact on the restriction of HIV-1.  
Finally, the two mutations were introduced to A and B in combination to produce 
A3 and B3.  Both resulting constructs lost activity against HIV-1.  A3 also lost the 
ability to restrict HIV-2, while for B3 this function was merely attenuated. 
 
Collectively, these data suggest that while R69H and D66N might have converted 
the restriction specificity of rhesus CypA from HIV-1 to -2, this is not the case for 
owl monkey CypA, at least in the context of this artificial chimera.   
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5.5.3 Leader sequence 
In the splicing of T5 and CypA to produce a TCyp fusion, the splice acceptor site 
lies slightly upstream of the CypA coding region.  The resulting protein thus 
contains a short stretch of amino acids immediately N-terminal to the CypA domain 
known as the leader sequence.  This sequence differs slightly between the owl 
monkey and rhesus orthologues (Table 5.8). 
 
 
Table 5.8: The leader sequences of owl monkey and rhesus macaque TCyp 
 
To investigate the impact of this region on restriction specificity, the owl monkey 
leader in Constructs A and B (Table 5.6), was substituted for that of the rhesus 
macaque to produce A4 and B4 (Figure 5.6).  This modification had no effect on B; 
however, interestingly, it rescued the attenuated restriction of HIV-2 by A.  This 
suggests that the inhibitory effect of e7 in this context can be reversed by simply 
substituting the downstream leader sequence. 
 
Next, the impact of leader sequence substitution in the context of the mutations 
described in Section 5.5.2 was investigated.  To this end, the rhesus leader was 
again introduced to A and B, but this time in combination with either D66N, R69H, 
or both (Figure 5.6).   
 
In the case of A, the rhesus leader lost the ability to rescue the inhibitory effect of 
e7 on HIV-2 restriction when either D66N or R69H was also present (compare A4 
with A5 and A6, respectively).  Curiously, though, when the rhesus leader was 
paired with the double mutant (A7), HIV-2 restriction was restored.  Conversely, in 
the case of B, the rhesus leader rescued the attenuating effects of both D66N and 
R69H on HIV-2 restriction (compare B5 with B1, and B6 with B2, respectively).  
Interestingly, the double mutant (B7) restricted HIV-2 to a comparable degree as 
the one lacking either mutation (B4), despite the fact that each of these mutations 
attenuated HIV-2 restriction when present in isolation. 
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It is noteworthy that a strong inhibition of FIV was preserved for every construct 
described in this section.  This served as a useful internal control, indicating that all 
of the constructs were expressed and active, albeit with modified restriction profiles. 
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Data show the mean and SEM (correct to 2 dp) from two independent experiments 
(n = 4).  Black boxes represent full restriction; grey, partial restriction, and white, 
absence of restriction. 
Figure 5.6: Restriction phenotypes of Constructs A (e7-proficient) and B 
(e7-deficient) and their derivatives. 
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5.6 Discussion 
While T1 and 5α share common capsid-binding and effector modules, they differ 
substantially in how these regions are linked to one another.  In T5α, the coiled-coil 
and B30.2 domain are bridged by a 64-residue, highly α-helical Linker 2 (L2) 
region.  However, the analogous region in T1 is approximately three times as long 
and comprises two additional domains.  
 
Interestingly, while the T1 B30.2 domain is still able to interact with N-MLV when 
partnered with the L2 region of T5α, the reciprocal chimera (T5α B30.2 partnered 
with the equivalent portion of T1) is inactive (Section 4.1).  This implies that the 
relative position of the domains in T5α has been finely tuned over the course of 
evolution.  The aim of this chapter was thus to characterise the impact of 
intramolecular domain spacing on the T5-capsid interaction.  Each of the key 
findings arising from this work will now be discussed in turn. 
 
Modifications to the L2 region have variable effects on restriction by rhT5α  
 
To investigate the impact of L2 length on restriction by rhT5α, we deleted various 
portions within this region and measured the effect on restriction.  These 
modifications were broadly deleterious, with the vast majority yielding proteins with 
no restriction activity.  While the immediate implication of this observation is that 
the length of L2 influences capsid recognition, work published by the Campbell 
group identified two stretches of amino acids within this region (266-268 and 
275-277) that are required for both cytoplasmic body localisation and retroviral 
restriction (Sastri et al., 2010).  It is therefore possible that the loss-of-function 
exhibited by the mutants in this project is not related to changes in L2 length, but 
rather a direct consequence of removing these critical motifs.  
 
While it is not possible to formally exclude this possibility, the fact that the removal 
of residues 282-290 (which excludes both of these motifs) also impedes restriction 
suggests that the modulation of L2 length alone has an impact on restriction activity.  
Indeed, this is unsurprising in the context of a T5α dimer, where substantial losses 
in L2 would cause a dramatic reorientation of the B30.2 domains relative to the 
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capsid surface, and the potential loss of important contacts between restriction 
factor and virus.  Nevertheless, constructs with very small deletions (~ 4 aa) at the 
L2-E/α5 boundary, and in the N-terminus of α5 itself, retained restriction activity 
against the lentiviruses. 
 
Having considered the impact of shortening the L2 region, we next turned our 
attention to lengthening it: specifically, by extending the α5 helix.  To this end, three 
mutations (FRE, FREL and FRELFRL) were added to the centre of the helix in 
order to extend it by 1-2 additional turns.  In silico modelling of the longest insertion 
in the context of the dimer revealed that this change not only separates the B30.2 
domains by 22 Å, but also causes their rotation relative to the underlying coiled-coil.  
Despite these substantial conformational changes, however, all three mutants 
remained restriction-competent against the lentiviruses (although, again, N-MLV 
restriction was lost). 
 
It has previously been reported that the α-helical content of L2 is critical for 
restriction by rhT5α, perhaps by enabling it to dock on the coiled-coil and thus 
orient the B30.2 domains appropriately (Sastri et al., 2010; 2014).  However, this 
analysis focused on short stretches of amino acids within L2-E.  We therefore 
sought to examine the effect of secondary structural modifications on the 
downstream α5 helix.   
 
To do this, we identified two conserved leucine residues within α5 and substituted 
each for proline in both rhesus and human T5α.  While leucine has a high 
propensity to form α-helices, the side-chain of proline imposes a steric barrier to 
helix formation.  Surprisingly, the phenotypes arising from these mutations differed 
considerably depending on which position was mutated.  While L287P completely 
inhibited restriction of HIV-2 by rhT5α (and attenuated that of HIV-1 and FIV), 
L293P bore no effect on lentiviral restriction.  The impact of L287P is particularly 
surprising, given that deletion of the region including residue 287 (Δ286-290) bears 
no impact on lentiviral restriction.  Yet again, anti-N-MLV activity was lost in both 
cases.   
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The equivalent mutations in huT5α had even more profound consequences: 
mutating either residue to proline ablated activity against both the lentiviruses and 
N-MLV.  It is unclear whether the discrepant effects of proline mutagenesis on 
rhesus and human T5α are due to divergence in the surrounding sequences, or 
fundamental differences in the mechanism by which each orthologue binds to its 
target.  In any case, further characterisation of these mutants in order to confirm 
the predicted changes in their secondary structures (perhaps by circular dichroism 
or NMR), alongside a western blot to confirm their expression, will be necessary 
before any meaningful conclusions can be drawn.  
 
N-MLV restriction is highly sensitive to L2 modifications 
 
An interesting phenotype exhibited by a number of the L2 mutants described in this 
chapter was a complete loss of N-MLV restriction, even when lentiviral restriction 
was preserved.  This is particularly striking given the relatively conservative nature 
of these mutations: the deletion of just four amino acids at the L2-E/α5 boundary, 
for example.   
 
This observation may reflect the fact that lentiviruses possess conical cores, while 
for N-MLV and other gammaretroviruses, this structure is spherical.  In the absence 
of high-resolution structural data, it is hard to envisage precisely why a spherical 
core would place such tight restrictions on the T5α dimer, but it is possible that the 
higher degree of curvature on the capsid surface would position the viral epitopes 
in such a way as to constrain the conformational freedom of the B30.2 domains.  
Validating this hypothesis will require pairing the L2 mutants constructed in this 
project with other lenti- and gammaretroviruses, and perhaps members of other 
retroviral genera as well. 
 
CypA tolerates L2 modifications more readily than the B30.2 domain 
 
While the B30.2 domain consists of four variable loops – at least three of which 
make critical contacts with the capsid target (Ohkura et al., 2006) – the 
capsid-binding domain of TCyp need only interact with a single viral epitope: the 
Cyp-binding loop (Yoo et al., 1997).  This endows the latter with the freedom to 
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sample multiple monomers within a CA hexamer while still maintaining a productive 
interaction.  We therefore expected that modifications to the L2 region of TCyp 
might have a less severe impact on restriction than was the case for rhT5α.   
 
To examine this possibility, we generated a chimera consisting of the N-terminal 
portion of rhT5α (up to and including helix α5) fused to the CypA domain of owl 
monkey TCyp (T5α-Cyp).  In stark contrast to the data obtained from the rhT5α 
mutants, T5α-Cyp retained the ability to restrict HIV-1 and FIV even upon the 
removal of helix α5 and the majority of L2-E.  However, HIV-2 restriction was lost in 
almost every case.  Nevertheless, these data confirm that capsid recognition by 
CypA is relatively immune to modifications in the preceding L2 region, particularly 
when compared to the B30.2 domain. 
 
The restriction specificity of TCyp is governed by multiple determinants 
 
An interesting observation arising from the above experiments is that the removal 
of exon 7 (e7) from T5α-Cyp, which corresponds to just 9 amino acids, results in a 
>10-fold increase in the inhibition of HIV-2.  This led us to consider the role of e7 in 
restriction.   
 
To this end, we deleted the relevant region from wildtype omTCyp.  Interestingly, 
we observed restriction of HIV-2 by both wildtype and e7-deficient omTCyp, which 
is discordant with the phenotype described by other groups (Wilson et al., 2008).  
The reasons for this discrepancy are unclear; however, the fact that HIV-1 and FIV 
restriction were also unaffected by the removal of e7 indicates that this region is 
dispensable for restriction by omTCyp.  This is in marked contrast to the case for 
T5α-Cyp, where e7 has an inhibitory effect, and in rhT5α, where it appears to be at 
least partly required for restriction.  
 
Collectively, these data paint a rather convoluted picture of the role of e7 in 
restriction.  Recent work from the Zheng lab showed that e7 deficiency is 
associated with an inability to localise to cytoplasmic bodies and a reduced 
propensity for multimerisation (Liu et al., 2015).  While this certainly explains the 
dependence of rhT5α on e7, it is not clear whether these functions are simply 
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dispensable in the case of omTCyp, or whether other regions compensate for the 
loss of e7 in this protein.  It is also unclear why this region would inhibit HIV-2 
restriction by the T5α-Cyp chimera.  Further investigation into the role of e7 in a 
broader range of TRIM molecules is warranted before any meaningful conclusions 
can be drawn about its function.  
 
It is interesting to note that while the majority of T5α-Cyp deletion constructs 
retained the ability to restrict HIV-1, most of them were inactive against HIV-2.  The 
capsid structures of HIV-1 and -2 are broadly similar, although they differ in the 
conformation of the Cyp-binding loop due to the deletion of residue CA-88 in the 
latter.  One group has proposed that rhTCyp acquired the ability to restrict HIV-2 at 
the expense of HIV-1 by acquiring two mutations in the active site of CypA 
(R69H/D66N) (Price et al., 2009).  In particular, D66N is believed to have facilitated 
this interaction by inducing structural rearrangements within the active site that 
enabled it to accommodate the displaced Cyp-binding loop of HIV-2.   
 
Although these analyses were based on the rhesus orthologue, we reasoned that 
the same mutations might have a similar effect in owl monkey CypA.  We therefore 
introduced the D66N mutation to T5α-Cyp and each of its daughter constructs.  
Consistent with the findings of Price et al. (2009), D66N inhibited HIV-1 activity in 
all of these mutants; however, unlike the case for rhesus CypA, there was no 
concomitant gain-of-function against HIV-2. 
 
Collectively, these observations indicate that the recognition of capsid by TCyp 
involves the cooperation of multiple components: both e7 and D66N yield different 
restriction phenotypes depending on their context.  This prompted a more detailed 
enquiry into how the various determinants within TCyp interact to permit a 
productive capsid interaction.  To this end, a panel of modifications were made to 
both T5α-Cyp and its e7-deficient counterpart.  These included the D66N and 
R69H active site mutations, either alone or in combination; substitution of the owl 
monkey leader sequence for that of the rhesus macaque, and pairwise 
combinations thereof.  This analysis yielded a number of apparently conflicting 
phenotypes that are difficult to reconcile. 
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In the case of full-length T5α-Cyp, HIV-1 restriction was ablated by D66N, but 
unaffected by R69H or substitution of the leader sequence.  Strikingly, the 
attenuation of HIV-2 restriction imparted by e7 was rescued upon substitution of the 
owl monkey leader sequence for that of the rhesus macaque.  The leader 
sequence is a short stretch of amino acids found just N-terminal to the CypA 
domain due to the presence of a splice acceptor site upstream of the CypA coding 
region.  The owl monkey and rhesus leader sequences vary quite substantially; 
however, it is not immediately clear why the latter would rescue the attenuating 
effect of e7 on HIV-2 restriction while the former cannot. 
 
When the same modifications were made to the e7-deficient form of T5α-Cyp, the 
resultant phenotypes were markedly different from the above.  Again, HIV-1 
restriction was intolerant of D66N, but resilient to both R69H and substitution of the 
upstream leader sequence.  As expected, HIV-2 restriction was better preserved in 
the absence of e7; however, D66N ablated this phenotype, and both R69H and the 
D66N/R69H double mutant attenuated it.  Nevertheless, pairing any of these 
mutants with a rhesus leader sequence restored HIV-2 restriction.   
 
Given the lack of any obvious patterns in the above data, it is difficult to disentangle 
the contribution of each determinant to restriction.  This issue is further 
compounded by the fact that FIV restriction was unaffected by the vast majority of 
modifications described in this chapter.  This is particularly striking given that, like 
HIV-1, FIV interacts with CypA via a central proline residue (P90) in the 
Cyp-binding loop (Lin and Emerman, 2006).  However, it is possible that 
divergence elsewhere in the loop contributes to the discrepant phenotypes 
observed for HIV and FIV in this chapter.  Indeed, the Hatziioannou group have 
previously observed that FIV restriction is relatively unhindered by the addition of 
CsA, a competitive inhibitor of CypA, indicating that FIV might have an inherently 
higher affinity for CypA than its lentiviral cousins (Virgen et al., 2008).  If this is the 
case, then it is perhaps unsurprising that FIV restriction is robust in the face of 
TCyp modifications. 
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To summarise, this chapter has provided insight into several intramolecular 
requirements for facilitating a productive interaction between TRIM and capsid.  
While it appears that these are most stringent for restriction factors with a B30.2 
domain, there are also determinants immediately preceding the CypA domain that 
may affect restriction specificity.  However, defining the precise contribution of each 
of these determinants is difficult in the absence of structural data. 
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Chapter 6 Conclusions 
Chapter 6: Conclusions 
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The focus of this thesis has been on retroviral restriction by TRIM proteins, with a 
particular emphasis on T1, T18, T5α and TCyp.  Although these factors have many 
distinct characteristics, they are nevertheless united by a few common themes.  
 
One idea that has cropped up repeatedly throughout this work is the notion that 
TRIM proteins share a common overall design.  This is epitomised by the ability of 
the T1 B30.2 domain to function adequately with components from both T5α and 
T18 (Chapter 3 and Chapter 4), and the generation of a restriction-competent 
chimera between rhesus T5α and owl monkey TCyp (Chapter 5). 
 
Nevertheless, each of these factors has undoubtedly been shaped by unique 
evolutionary forces, and this has resulted in certain distinct requirements, 
particularly in terms of how the modules are positioned relative to one another.  
This likely reflects the need for TRIM molecules to complement regularly spaced 
epitopes on the capsid surface, while simultaneously engaging components of the 
ubiquitination and innate immune signalling pathways.  Each factor has 
accomplished this in a slightly different way; as a result, introducing foreign 
components without consideration of the surrounding context may not always 
garner favourable results. 
 
Another issue arising from this work surrounds the definition of the term restriction 
factor itself.  While T5α is a prototypic member of this class of proteins, the antiviral 
activity of T1 is rarely considered.  Indeed, most of the recent literature concerning 
T1 (or MID2 as it is more commonly known) focuses on its role in non-infectious 
diseases, such as X-linked developmental disorders and advanced-stage breast 
cancer (Li et al., 2016a; Wang et al., 2016).  Thus, the restriction activity of T1 may 
be a phenotype of circumstance: a mere by-product of the subcellular localisation 
and domain complement of this protein.  Perhaps it would then be inaccurate to 
label it as a restriction factor per se, but rather a protein with an existing cellular 
function that happens to also have restriction activity.  Indeed, it could be argued 
that the likes of T28, SAMHD1 and SERINC3/5 also fall into this camp. 
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While this might seem like a semantic issue, these definitions could inform future 
searches for proteins with restriction activity – some of which may have clinical 
potential.  Currently, restriction factor candidates are identified using reverse 
genetic techniques, often in the form of RNAi screens.  However, such techniques 
may result in a number of candidates being overlooked, either because their 
knockdown has unrelated effects on cell viability, or because they are 
compensated for by more dedicated restriction factors.  Widening our definition will 
pave the way for novel approaches in the search for host-derived factors with 
antiviral activity.   
 
In many ways, the findings discussed in this work can be related to what is already 
known for the murine restriction factor, Fv1.  Much like the TRIM family members, 
Fv1 comprises both capsid-binding and multimerisation domains, although the 
precise mechanism by which restriction is effected remains elusive.  The modularity 
of Fv1 has previously been demonstrated by generating a C-terminal fusion with 
the owl monkey CypA domain; the resulting molecule acquired restriction activity 
against both HIV and FIV (Yap et al., 2007; Schaller et al., 2007).   
 
This restriction factor ‘reprogramming’ is mirrored in the case of T5α, where 
specificity can often be exchanged between primate orthologues (Stremlau et al., 
2005; Yap et al., 2005; Anderson and Akkina, 2008), and replacement of the B30.2 
domain with CypA has yielded novel factors with potent antiviral activity on several 
occasions (Sayah et al., 2004; Dietrich et al., 2010).  Similarly, the work presented 
in this thesis demonstrates that the T1 B30.2 domain can function adequately when 
paired with the N-terminus of either T5α or T18, and in fact restriction is even 
augmented in the latter case.  Moreover, previous work in the Stoye lab has shown 
that both T1 and T18 are restriction-competent when appended with a CypA 
domain (Yap et al., 2006). 
 
Collectively, these data reinforce the notion that capsid-binding restriction factors 
are comprised of interchangeable units that promote capsid association and 
multimerisation (Yap et al., 2007).  This opens the door to generating artificial 
restriction factors with tailored specificities and enhanced effector functions – some 
of which may have therapeutic potential. 
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7.1 Primer directory 
7.1.1 Primers used in Chapter 3 
To make the long isoform of murine T1 (Section 3.3) 
 
Name Template Sequence (5’-3’) 
mT1L P1 mT1S 
GGGGACAAGTTTGTACAAAAAAGCAGGCTACCATGGAAAC
ACTGGAGTCAG 
mT1L P2 mT1S 
TACTGCTTCCTTACATTTCCTTATCTCTGGCCACAGGCCC
CAACTACACCATGACTTACTGATGAAGTTAGCCTGGC 
mT1L P3 mT1S 
AAGGAAATGTAAGGAAGCAGTAAGCTGCTCAAGATTGGCC
GGTGCGCCACGAGGCAAGTACAATTCAGTGGATAGCTGG 
mT1L P4 mT1S 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTAATGGCAAG
CTTTCATCC 
 
 
To make the long isoform of human T1 (Section 3.3) 
 
Name Template Sequence (5’-3’) 
huT1L P1 huT1S 
GGGGACAAGTTTGTACAAAAAAGCAGGCTACCATGGGTGA
AAGCCCAGCCTC 
huT1L P2 huT1S 
CTGCTTCCTTACATTTCCTTATCTCTGGCCACAGGCCCCA
ACTACACCATGACTTACTGATGAAGTTAGCCTGGCC 
huT1L P3 huT1S 
AAGGAAATGTAAGGAAGCAGTAAGCTGCTCAAGATTGGCC
GGGGCGCCACGAGGCCTGTATAATTCAGTAGACAG 
huT1L P4 huT1S 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTAATGACAGG
TTTTCATCC 
 
 
To exchange the B30.2 domains of T1 and 18 (Section 3.4) 
 
Name Template Sequence (5’-3’) 
1-18B30.2 
P1 
agmT1S 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCACCATGGAAA
CACTGGAGTCTG 
1-18B30.2 
P2 
agmT1S GTTGGCTGTTTGTTTTTAGTCGGGTAGGTTC 
1-18B30.2 
P3 
agmT18 ACTAAAAACAAACAGCCAACCATTTAAACTG 
1-18B30.2 
P4 
agmT18 
GGGGACCACTTTGTACAAGAAAGCTGGGTTCACGGCAGCT
GCTCTGTGCAGTCC 
18-1B30.2 
P1 
agmT18 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCACCATGGAAA
CACTGGAGTCAG 
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18-1B30.2 
P2 
agmT18 GTTGGCTGTTTGTCTTCAACTTCCCAGGCTC 
18-1B30.2 
P3 
agmT1S GTTGAAGACAAACAGCCAACCCTTTAAATTG 
18-1B30.2 
P4 
agmT1S 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTAATGACAGG
TTTTCATCCCAG 
 
 
To exchange the variable regions of T1 and 18 (Section 3.4) 
 
Name Template Sequence (5’-3’) 
T1 VR1 
FWD 
1-18B30.2* 
CTTGACAGTAGAAAAGGATGAAAGCTCTCTCTAAAGAAGA
GCCATACCCCAGAGAGGTTTAGTGGCACAGGGTGCTATGG
GGTAGCTGGAAATG 
T1 VR1 
REV 
1-18B30.2* 
CATTTCCAGCTACCCCATAGCACCCTGTGCCACTAAACCT
CTCTGGGGTATGGCTCTTCTTTAGAGAGCTTTCATCCTTT
TCTACTGTCAAG 
T1 VR2 
FWD 
1-18B30.2* 
CTATTGGTCTTGCTTACAAATCAGCTCCAAAGAATGAATG
GATTGGCAAGAACTCTGCTTC 
T1 VR2 
REV 
1-18B30.2* 
GAAGCAGAGTTCTTGCCAATCCATTCATTCTTTGGAGCTG
ATTTGTAAGCAAGACCAATAG 
T1 VR3 
FWD 
1-18B30.2* 
GCGCTCTGCCGCTGCAATAGTAACTTCGTGGTGAGACATA
ACAACAAGGAAATGCTGGTGGATGTGCCCCCACAGCTCCG
GCGCGTG 
T1 VR3 
REV 
1-18B30.2* 
CACGCGCCGGAGCTGTGGGGGCACATCCACCAGCATTTCC
TTGTTGTTATGTCTCACCACGAAGTTACTATTGCAGCGGC
AGAGCGC 
T1 VR4 
FWD 
1-18B30.2* 
CCCACCTTCACGGTGTGGAACAAATCCCTAATGATCTTGT
CTGGCTTGCCTATCCCAGACCATTTG 
T1 VR4 
REV 
1-18B30.2* 
CAAATGGTCTGGGATAGGCAAGCCAGACAAGATCATTAGG
GATTTGTTCCACACCGTGAAGGTGGG 
T18 VR1 
FWD 
18-1B30.2** 
GATTGCAGATGGAGCGTGATGAATCATCATCTAAGAAGAG
TCACACGCCTGAACGCTTCACCAGCCAGGGGAGCTATGGA
GCAGCAGGAAATATATTC 
T18 VR1 
REV 
18-1B30.2** 
GAATATATTTCCTGCTGCTCCATAGCTCCCCTGGCTGGTG
AAGCGTTCAGGCGTGTGACTCTTCTTAGATGATGATTCAT
CACGCTCCATCTGCAATC 
T18 VR2 
FWD 
18-1B30.2** 
CAATTGGCATTGCCTATAAATCAGCCCCGAAGCATGAATG
GATTGGGAAGAATGCCTCC 
T18 VR2 
REV 
18-1B30.2** 
GGAGGCATTCTTCCCAATCCATTCATGCTTCGGGGCTGAT
TTATAGGCAATGCCAATTG 
T18 VR3 
FWD 
18-1B30.2** 
GTCTTCTCTCGCTGCAACAATAACTGGGTGGTGAGACACA
ATAGCAAGGAAATCCCCATTGAGCCTGCTCCCCACCTGAA
GCGTCTG 
T18 VR3 
REV 
18-1B30.2** 
CAGACGCTTCAGGTGGGGAGCAGGCTCAATGGGGATTTCC
TTGCTATTGTGTCTCACCACCCAGTTATTGTTGCAGCGAG
AGAAGAC 
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T18 VR4 
FWD 
18-1B30.2** 
CCAACATTTACAATCTGGAACAAGTGTCTGACGATTATCA
CTGGGCTTCCTGCCCCAGATTTTATTG 
T18 VR4 
REV 
18-1B30.2** 
CAATAAAATCTGGGGCAGGAAGCCCAGTGATAATCGTCAG
ACACTTGTTCCAGATTGTAAATGTTGG 
* Construct A, Section 3.4 
** Construct S, Section 3.4  
 
 
To remove (or add) the C-terminal tail (Section 3.4) 
 
Name Template Sequence (5’-3’) 
+CT FWD agmT18 
CAGAGCAGCTGCCGTGCAACTGCAGGCCTCAAGAATCCCC
TTATGTTTCTGGGATGAAAACCTGTCATTGAACCCAGCTT
TC 
+CT REV agmT18 
GAAAGCTGGGTTCAATGACAGGTTTTCATCCCAGAAACAT
AAGGGGATTCTTGAGGCCTGCAGTTGCACGGCAGCTGCTC
TG 
ΔCT FWD 
agmT1S, 
18-1B30.2* 
CCTGAGCGGCAGGAATAAACCCAGCTTTC 
ΔCT REV 
agmT1S, 
18-1B30.2* 
GAAAGCTGGGTTTATTCCTGCCGCTCAGG 
* Construct S, Section 3.4  
 
 
To substitute position 595 in T1L (or 565 in T18) (Section 3.5) 
 
Name Template Sequence (5’-3’) 
T1L N595n 
FWD 
agmT1L, 
agmT1S 
CAAATCAGCTCCAAAG(NNN)GAATGGATTGGCAAG 
T1L N595n 
REV 
agmT1L, 
agmT1S 
CTTGCCAATCCATTC(NNN)CTTTGGAGCTGATTTG 
T18 
H565N 
FWD 
agmT18 
CTTATAAATCAGCCCCGAAGAATGAATGGATTGGGAAGAA
C 
T18 
H565N 
REV 
agmT18 
GTTCTTCCCAATCCATTCATTCTTCGGGGCTGATTTATAA
G 
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To substitute the T18 RBCC domains for those of T1 (Section 3.6) 
 
Name Template Sequence (5’-3’) 
18-1314 R1 
P1 
18-1314* GGGGACAAGTTTGTACAAAAAAGCAGGCTACCATGGAAAC
ACTGGAGTCAGAACTGACCTGTCCAATCTGCCTAGAG 
18-1314 R1 
P2 
agmT1S 
TGATGACATGCCTGCAGGTAGGACACTG 
18-1314 R1 
P3 
agmT1S 
TACCTGCAGGCATGTCATCACCCTCAGC 
18-1314 R1 
P4 
18-1314* 
TTAATGACAGGTTTTCATCCC 
18-1314 B1 
P1 
18-1314* 
CACCATGGAAACACTGGAGTCAG 
18-1314 B1 
P2 
18-1314* 
CAATTCGCTCGGCGGAGGTCATGGTGTTGG 
18-1314 B1 
P3 
agmT1S 
GACCTCCGCCGAGCGAATTGCTTGCCAATTC 
18-1314 B1 
P4 
agmT1S 
GATGATCGCGGTGACGACCCACCAGTTTGC 
18-1314 B1 
P5 
18-1314* 
GGGTCGTCACCGCGATCATCAGGTGGCAGC 
18-1314 B1 
P6 
18-1314* 
TTAATGACAGGTTTTCATCCC 
18-1314 
CC1 P1 
18-1314* 
CACCATGGAAACACTGGAGTCAG 
18-1314 
CC1 P2 
18-1314* 
GATGGTCTCGGTGCCGCCCAACCAGTTTAC 
18-1314 
CC1 P3 
agmT1S 
GTTGGGCGGCACCGAGACCATCAGGTCGCATC 
18-1314 
CC1 P4 
agmT1S 
CATCACCTTCCCCTCTTTGATTTTGACAGCG 
18-1314 
CC1 P5 
18-1314* 
CAAAATCAAAGAGGGGAAGGTGATGAGGCTTCGC 
18-1314 
CC1 P6 
18-1314* 
TTAATGACAGGTTTTCATCCC 
* Construct  A, Section 3.6 
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To put the T18 B-boxes into T1 (Section 3.6) 
 
Name Template Sequence (5’-3’) 
T1-B18 P1 agmT1L, 
agmT1S 
CACCATGGAAACACTGGAGTCTG 
T1-B18 P2 agmT1L, 
agmT1S 
GGACCTTCTCACTAGACATGGCGGTGTTGG 
T1-B18 P3 agmT18 CATGTCTAGTGAGAAGGTCCTCTGCCAG 
T1-B18 P4 agmT18 GATGGTCTCGGTGCCGCCCAACCAGTTTAC 
T1-B18 P5 agmT1L, 
agmT1S 
TGGGCGGCACCGAGACCATCAGGTCGCATC 
T1-B18 P6 agmT1L, 
agmT1S 
TTAATGACAGGTTTTCATCC 
 
 
To add C-terminal HA tags to T1L, T1S and 18-1314 (Section 3.7) 
 
Name Template Sequence (5’-3’) 
T1-HA 
FWD 
agmT1L, 
agmT1S 
CACCATGGAAACACTGGAGTCTG 
18-1314-HA 
FWD 
18-1314* 
CACCATGGAAACACTGGAGTCAG 
HA REV 
agmT1L, 
agmT1S,
18-1314* 
CTAAGCGTAATCTGGAACATCGTATGGGTAATGACAGGTT
TTCATC 
* Construct  A, Section 3.6 
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7.1.2 Primers used in Chapter 4 
To make reciprocal chimeras of agmT1S and rhT5α (Section 4.1) 
 
Name Template Sequence (5’-3’) 
1-5CC P1 agmT1S 
GGGGACAAGTTTGTACAAAAAAGCAGGCTATGGAAACACT
GGAGTCTG 
1-5CC P2 agmT1S GATGCTCCAGCTCTTTGATTTTGACAGCG 
1-5CC P3 rhT5α  AATCAAAGAGCTGGAGCATCGGTTGCAGGG 
1-5CC P4 rhT5α 
GGGGACCACTTTGTACAAGAAAGCTGGGTTCAAGAGCTTG
GTGAGCAC 
5-1CC P1 rhT5α 
GGGGACAAGTTTGTACAAAAAAGCAGGCTATGGCTTCTGG
AATCCTGC 
5-1CC P2 rhT5α  TAACCTTTGTTTCTGAGATGAGCTCTCTC 
5-1CC P3 agmT1S CATCTCAGAAACAAAGGTTATGAAACTGAG 
5-1CC P4 agmT1S 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTAATGACAGG
TTTTCATCC 
1-5B30.2 P1 agmT1S 
GGGGACAAGTTTGTACAAAAAAGCAGGCTATGGAAACACT
GGAGTCTG 
1-5B30.2 P2 agmT1S TCACATCAACTGTTTTTAGTCGGGTAGGTTC 
1-5B30.2 P3 rhT5α ACTAAAAACAGTTGATGTGACACTGGCTAC 
1-5B30.2 P4 rhT5α 
GGGGACCACTTTGTACAAGAAAGCTGGGTTCAAGAGCTTG
GTGAGCAC 
5-1B30.2 P1 rhT5α 
GGGGACAAGTTTGTACAAAAAAGCAGGCTATGGCTTCTGG
AATCCTGC 
5-1B30.2 P2 rhT5α GTTGGCTGTTCCAGTAGCGTCGGGCATCTG 
5-1B30.2 P3 agmT1S ACGCTACTGGAACAGCCAACCCTTTAAATTGG 
5-1B30.2 P4 agmT1S 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTAATGACAGG
TTTTCATCC 
 
To amplify the B30.2 domain for expression in E. coli (Section 4.3) 
 
Name Template Sequence (5’-3’) 
MBP-
B30.2 
FWD 
agmT1S CGTAGAAAGCTTACCCGACTAAAAACAAACAGCC 
MBP-
B30.2 REV 
agmT1S GTTCGACTCGAGTTAATGACAGGTTTTCATCCC 
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7.1.3 Primers used in Chapter 5 
To make deletions in rhT5α (Section 5.1) 
 
Name Template Sequence (5’-3’) 
Δ 259-290 
FWD 
rhT5α GGCATCATTAAAAGGAGAGAGCTAACAG 
Δ 259-290 
REV 
rhT5α CTGTTAGCTCTCTCCTTTTAATGATGCC 
Δ 263-290 
FWD 
rhT5α GGATTGAGAACATGAGAGAGCTAACAG 
Δ 263-290 
REV 
rhT5α CTGTTAGCTCTCTCATGTTCTCAATCC 
Δ 272-290 
FWD 
rhT5α CCAAAAACTTTTCACAGAGAGCTAACAG 
Δ 272-290 
REV 
rhT5α CTGTTAGCTCTCTGTGAAAAGTTTTTGG 
Δ 282-290 
FWD 
rhT5α GTGTTTCGAGCTCCTAGAGAGCTAACAG 
Δ 282-290 
REV 
rhT5α CTGTTAGCTCTCTAGGAGCTCGAAACAC 
Δ 282-285 
FWD 
rhT5α GTGTTTCGAGCTCCTATGCTAGACATG 
Δ 282-285 
REV 
rhT5α CATGTCTAGCATAGGAGCTCGAAACAC 
Δ 286-290 
FWD 
rhT5α CCTGATCTGAAAGGAAGAGAGCTAACAG 
Δ 286-290 
REV 
rhT5α CTGTTAGCTCTCTTCCTTTCAGATCAGG 
Δ 291-295 
FWD 
rhT5α GCTAGACATGTTTGCCCGACGCTACTGG 
Δ 291-295 
REV 
rhT5α CCAGTAGCGTCGGGCAAACATGTCTAGC 
Δ 263-280 
FWD 
rhT5α GGATTGAGAACATGCCTGATCTGAAAGG 
Δ 263-280 
REV 
rhT5α CCTTTCAGATCAGGCATGTTCTCAATCC 
Δ 272-280 
FWD 
rhT5α CCAAAAACTTTTCACCCTGATCTGAAAGG 
Δ 272-280 
REV 
rhT5α CCTTTCAGATCAGGGTGAAAAGTTTTTGG 
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To make insertions in rhT5α (Section 5.2) 
 
Name Template Sequence (5’-3’) 
FRE FWD rhT5α GGAATGCTAGACATGTTTAGAGAGTTTAGAGAGCTAAC 
FRE REV rhT5α GTTAGCTCTCTAAACTCTCTAAACATGTCTAGCATTCC 
FREL 
FWD 
rhT5α 
GGAATGCTAGACATGTTTAGAGAGCTATTTAGAGAGCTAA
C 
FREL REV rhT5α 
GTTAGCTCTCTAAATAGCTCTCTAAACATGTCTAGCATTC
C 
FRELFRL 
FWD 
rhT5α 
GGAATGCTAGACATGTTTAGAGAGCTATTTAGACTATTTA
GAGAGCTAAC 
FRELFRL 
REV 
rhT5α 
GTTAGCTCTCTAAATAGTCTAAATAGCTCTCTAAACATGT
CTAGCATTCC 
 
 
To disrupt helix α5 in T5α (Section 5.3) 
 
Name Template Sequence (5’-3’) 
rhT5α 
L287P 
FWD 
rhT5α GATCTGAAAGGAATGCCAGACATGTTTAGAGAG 
rhT5α 
L287P 
REV 
rhT5α CTCTCTAAACATGTCTGGCATTCCTTTCAGATC 
rhT5α 
L293P 
FWD 
rhT5α GACATGTTTAGAGAGCCAACAGATGCCCGACGC 
rhT5α 
L293P 
REV 
rhT5α GCGTCGGGCATCTGTTGGCTCTCTAAACATGTC 
huT5α 
L285P 
FWD 
huT5α GATCTGAAAGGAATGCCAGAAGTGTTTAGAGAG 
huT5α 
L285P 
REV 
huT5α CTCTCTAAACACTTCTGGCATTCCTTTCAGATC 
huT5α 
L291P 
FWD 
huT5α GAAGTGTTTAGAGAGCCGACAGATGTCCGACGC 
huT5α 
L291P 
REV 
huT5α GCGTCGGACATCTGTCGGCTCTCTAAACACTTC 
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To remove exon 7 (Section 5.5) 
 
Name Template Sequence (5’-3’) 
omTCyp 
Δe7 FWD 
omTCyp CTACAAGTGTTTAAAGACGCCGCCGCCTGG 
omTCyp 
Δe7 REV 
omTCyp CCAGGCGGCGGCGTCTTTAAACACTTGTAG 
rhT5α Δe7 
FWD 
rhT5α GACATGTTTAGAGTTGATGTGACACTGG 
rhT5α Δe7 
REV 
rhT5α CCAGTGTCACATCAACTCTAAACATGTC 
 
 
To mutate residues in the active site of CypA (Section 5.5) 
 
Name Template Sequence (5’-3’) 
CypA 
D66N 
FWD 
T5αCyp* GTGTCAGGGTGGTAACTTCACACGCCATAATG 
CypA 
D66N REV 
T5αCyp* CATTATGGCGTGTGAAGTTACCACCCTGACAC 
CypA 
R69H 
FWD 
T5αCyp* GGTGGTGACTTCACACACCATAATGGCACTGG 
CypA 
R69H REV 
T5αCyp* CCAGTGCCATTATGGTGTGTGAAGTCACCACC 
* An artificial chimera consisting of rhT5α fused to CypA from owl monkey TCyp 
(see Section 5.4) 
 
 
To put the rhesus leader sequence into owl monkey CypA (Section 5.5) 
 
Name Template Sequence (5’-3’) 
Rhesus 
leader 
FWD 
T5αCyp* 
GACGCCGCCGCCGAAGAATCACCAGTACTTCTTGCCATGG
TCAATCC 
Rhesus 
leader 
REV 
T5αCyp* 
GGATTGACCATGGCAAGAAGTACTGGTGATTCTTCGGCGG
CGGCGTC 
* An artificial chimera consisting of rhT5α fused to CypA from owl monkey TCyp 
(see Section 5.4) 
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7.2 Screens used for crystallisation trials 
Below is a list of screens used for crystallisation trials of the T1 B30.2 domain 
(Section 4.3.4).    
 
Screen Company External link 
Anions Qiagen 
https://www.qiagen.com/products/protein/crystal
lization/compositiontables/pdf/1054288_ps_xtal
_anions-suite.pdf  
Classics Qiagen 
https://www.qiagen.com/products/protein/crystal
lization/compositiontables/pdf/1054292_ps_xtal
_classics-suite.pdf  
JCSG Core I Qiagen 
https://www.cicbiogune.es/services/userfiles/JC
SG-Core-I-Suite.pdf  
JCSG Core II Qiagen 
https://www.cicbiogune.es/services/userfiles/JC
SG-Core-II-Suite.pdf  
JCSG Core III Qiagen 
https://www.cicbiogune.es/services/userfiles/JC
SG-Core-III-Suite.pdf  
JCSG Core IV Qiagen 
http://services.mbi.ucla.edu/Crystallization/xtals
creens/docs/JCSGcoreIV_comp.pdf  
PACT Qiagen 
https://www.qiagen.com/products/protein/crystal
lization/compositiontables/pdf/1057791_ps_xtal
_pact-suite_update_160609_lowres.pdf  
Proplex 
Molecular 
dimensions 
http://www.moleculardimensions.com/applicatio
ns/upload/MD1-42%20ProPlex%20HT-96.pdf  
Wizard I  Rigaku 
http://www.rigakureagents.com/UploadDocume
nts/wiz1_rigaku_15.pdf  
Wizard II Rigaku 
http://www.rigakureagents.com/UploadDocume
nts/wiz2_rigaku_15.pdf  
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